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Abstract 
 
Background  
Preterm labour and post-partum haemorrhage are leading causes of pregnancy 
morbidity and mortality. Previous work identified potassium channels expressed 
in myometrium and  hypothesized modulation of channels with greater 
expression in MSMC than VSMC will influence contractility and avoid 
cardiovascular effects. By combining calcium channel blockers with potassium 
channel openers an enhanced tocolytic effect is anticipated.  VU590 inhibits Kir 
7.1 and it was  hypothesised would elicit a contractile effect with therapeutic 
potential for post-partum haemorrhage. 
 
Aim 
To determine the effect of select potassium channel openers and a specific 
potassium channel blocker in myometrial contractility.  
 
Methods 
Human and murine myometrial strips were used in contractility organ bath 
experiments. Select combined doses were tested in myometrial small arteries 
using wire myography. Western blotting was carried out to determine the 
gestational and labour-state expression of potassium channels in human 
myometrium and myometrial small arteries. 
 
Results  
Pinacidil demonstrated a relaxatory effect on both myometrial and vascular 
smooth muscle. Riluzole reduced contractility alone and greater inhibition in 
combination with nifedipine than nifedipine alone. Riluzole appeared to have a 
mild effect on myometrial arteries.  
Kir 7.1 showed a trend of diminished expression by gestation and was down-
regulated in term and preterm labour states.  
VU590 elicited a significant increase contractility characterised by a prolonged 
contraction phase of up to 6.7±1.9 hrs (VU590 10 µM). A gestational-dependent 
effect was seen on murine myometrium. 
 
Conclusion 
The combination of nifedipine with potassium channel openers has a more 
potent effect on reducing contractility than either compound alone. Riluzole 
combined with nifedipine warrants further investigation for potential tocolytic 
therapy. 
VU590 augments spontaneous contractions profoundly in human myometrium 
in vitro and could have potential therapeutic benefits in the treatment of post-
partum haemorrhage.  
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1. Introduction 
 
1.1  The problem of preterm labour 
Preterm birth continues to be a national and global problem (Figure 1.1). 
Complications of pre-term birth continue to be the largest direct cause of 
neonatal deaths and deaths of children under five,  globally (Blencowe et al 
2013). Recent data published by the World Health Organisation from 65 
countries shows that in all but three countries, the rates of preterm birth are 
increasing (Blencowe et al 2012). The global average preterm birth rate for 2010 
was 11.1% with a global increase of 14.7% from 1990 to 2010 (Blencowe et al 
2012). There continues to be a disparity in preterm birth rates from high-income 
(9% average) to low-income countries (12% average) (WHO 2015) (Figure 1.2) . 
This disparity continues when looking at the trends over the past 25 years. There 
was a 19.4% increase in preterm birth rates in Developing regions from 1990 to 
2010, an increase of 9.1% in Latin America, and an increase of 25.8% in the 
Caribbean for the same time period (Blencowe et al 2012). Although the increase 
in the Developed regions may seem disproportionately high, it is worth bearing 
in mind that in developed regions, deaths resulting from prematurity are 
reducing significantly (Blencowe et al 2012). Increased antenatal care and 
improved antenatal ultrasound surveillance leads to more iatrogenic preterm 
birth in high-income countries, largely to the benefit of both maternal and child 
health; supported by access to high quality and specialist neonatal care 
(Blencowe et al 2013). Aetiology of preterm birth differs from high income to 
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low-income countries, with assisted reproduction and higher multiple pregnancy 
rates contributing to the increase in preterm birth rates seen in high-income 
countries from 1990 to 2010 (Blencowe et al 2013). More than 90% preterm 
infants in low income countries die where as less than 10% die in high income 
settings (WHO 2015). In recognition of the significant medical, social, and 
economic impact that infant and pregnancy loss, or significant disability resulting 
from preterm birth has on worldwide communities; The United Nations focused 
on the reduction of childhood mortality as part of their Millennium Development 
Goal programme (UN 2015). From 1990 to 2015, Goal 4; to reduce child 
mortality recognised the significance of the number of worldwide neonatal 
deaths caused by preterm birth complications (35%) (UN 2015). This continues to 
be a priority in the new UN Sustainable Development Goals that are initiated in 
January 2016 with the aim of ending preventable deaths of newborns and 
children under 5 by 2030 (UN 2016). All countries are encouraged to aim to 
reduce neonatal mortality by < 12/1000 live births, and deaths of under fives to 
<25/1000 (UN 2016). Deaths by complications of immaturity represent 43% of all 
infant deaths in England and Wales (Figure 1.3). In both low-income and high-
income settings, there are simple cost-effective and high-impact interventions 
that could improve survival and reduce morbidity (UN 2015). These include 
increased access to antenatal health care, better social support for pregnant 
women, and simple treatments and technique that could support the preterm 
newborn such as kangaroo care and oxygen support (UN 2015). As 84% of 
preterm births in low-income countries are moderate to late preterm births, a 
significant number could potentially survive, or have lessened  disability with 
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minimal intervention and this remains a priority of intervention strategies 
(Blencowe et al 2012).  
Although this data is insightful, and encourages national and global 
improvements in care to prevent preterm birth; issues with data quality must be 
considered. Access to antenatal ultrasound for pregnancy dating differs from 
country to country, and this affects accuracy of gestation-at-delivery data. 
Reporting systems and accuracy of birth outcome data from hospitals and 
medical centres vary country to country with a lack of consistency in 
classification, live birth and stillbirth reporting and birth and death registration 
requirements (Lawn et al 2010). In recognition of this, recommendations to 
improve data quality includes; using more household and survey data on birth 
outcome, using standardised definitions and reporting tools; and having more 
standardised death registration and certification systems (Lawn et al 2010). This 
will assist in monitoring whether the desired reduction in neonatal and infant 
mortality as a result of the complications of prematurity are being achieved.  
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Figure 1.1  Key facts from World Health Organisation Factsheet on Preterm birth 
(2015) 
 
 
 
Figure 1.2: The 10 countries with the highest global preterm birth rates per 100 
live births (blue), against the rate for the USA and England and Wales. All data 
from WHO (2012) other than data for England and Wales from ONS (2014). 
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World Health Organisation November 2015 
Preterm Birth Factsheet No. 363 
Key facts: 
 15 million babies born preterm (before 37 completed weeks) 
 This number is rising 
 Preterm birth complications are a leading cause of death among 
children under 5 years old 
 Preterm birth is responsible for nearly 1 million deaths in 2013 
 3/4 of babies of babies lost could be saved with current cost-
effective interventions 
 Across 184 countries, preterm birth rates range from 5-18 % of 
babies 
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Figure 1.3: The percentage of total infant deaths, England and Wales (2012) by 
classification. (ONS 2014) 
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preterm birth or mid-trimester loss is the biggest single indicator of risk of 
subsequent preterm birth, women reporting a history are offered screening in 
the antenatal period (Mercer et al 1996, Mazaki-Tovi et al 2007).  
Clinical trials of both prophylactic progesterone and of cervical cerclage have 
shown that administration to women at risk of preterm birth may reduce the risk 
of subsequent preterm birth although further trial data is awaited (Meis et al 
2003, Norman et al 2012, Deshpande et al 2013, Winer, 2015).  
Prophylactic progesterone and prophylactic cervical cerclage is offered to 
women with a history of spontaneous preterm birth or mid-trimester loss 
between 16 and 34 weeks of pregnancy and in those in whom a cervical length of 
less than 25 mm has been identified (NICE 2015). Prophylactic vaginal 
progesterone is offered to women with no history of spontaneous preterm birth 
but cervical length of less than 25 mm (NICE 2015); and prophylactic cervical 
cerclage for women in whom cervical length of less than 25 mm has been 
identified and who have had preterm pre-rupture labour of the membranes in a 
previous pregnancy, or a history of cervical length (NICE 2015). Intra-uterine 
infection must always be suspected where threatened preterm birth presents. 
Antibiotic use has previously been used in obstetric practice in an attempt to 
prevent preterm birth. Findings of the ORACLE II study found an increased 
cerebral palsy rates in babies born in the arm of the trial where antibiotics were 
administered when fetal membranes were intact (Kenyon et al 2008). This 
highlights the importance of due vigilance when introducing new treatment 
strategies, and of long-term follow-up in trial outcome design. The OPPTIMUM 
study for prophylactic vaginal progesterone to prevent preterm birth in those 
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with a history of preterm birth, is currently ongoing and has a 3 to 5 year follow-
up on infant development scores as part of the trial design (Norman et al 2012). 
This will inform practice as to whether prophylactic treatment such as this 
increases the primary outcome of birth at term, but will also inform any potential 
benefits or harms to ongoing child development. Previous trial findings in the 
success of cervical cerclage for prevention of subsequent preterm birth have 
varied in terms of timing, techniques used, and outcomes (Burghella 2011, Suhag 
2015). As such, although guidelines instruct on when not to offer 'rescue' cervical 
cerclage; whether to undertake 'rescue' cerclage if symptoms of threatened 
preterm birth present in the absence of infection bleeding or active contractions, 
is currently left to physician judgement (NICE 2015). When a woman presents in 
active suspected preterm labour, then fetal fibronectin testing can be a useful 
diagnostic test to determine the likelihood of birth within 48 hours (Deshpande 
et al 2013, Abbott 2015). This can assist the obstetrician considering access to 
the level of neonatal care that may be required and is locally available, and in 
considering administrating feto-protective agents (Table 1.2). The decision on 
when or whether to administer tocolysis may depend on presenting symptoms 
and the time needed to achieve care provision and treatments to improve 
neonatal outcome.  
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Category Risk Factor Source 
Reproductive/ Gynaecological 
history 
History of Pre-term 
Labour 
Mercer et al (1996), 
Mazaki-Tovi et al (2007) 
Multiple pregnancy Bloom et al (2001), ONS 
(2014) 
Assisted reproduction Dunietz et al (2015) 
Uterine abnormalities Woefler et al (2001) 
Short cervix Mercer et al (1996), Odibo 
et al (2003), Hughes et al 
(2015), Souka et al (2015) 
Short pregnancy interval Smith et al (2003) 
Placenta praevia Zlatnik et al (2007) 
Bacterial vaginosis Leitch et al (2003) 
Medical history Diabetes (Gestational 
and exisiting) 
Köck et al (2010) 
Social and demographics Ethnicity Lu and Halfon (2003) 
Age (younger or older) ONS (2014) 
Lifestyle Copper et al (1996) 
No antenatal care Hollowell et al (2009) 
Smoking Kyrklund-Blomberg and 
Cnattingius (1998) 
Alcohol use (4-7 or over 
7 drinks a week) 
Albersten et al (2004) 
Domestic violence Neggers et al (2004) 
Poor social support Hollowell et al (2009) 
Stress Cooper et al (1996) 
Long working hours van Melick et al (2014) 
Table 1.1: Reproductive, medical, lifestyle and social risk factors associated with 
spontaneous preterm birth. 
 
1.1.2 Definition 
Pre-term birth is defined as birth before 37 completed weeks of pregnancy with 
significantly higher morbidity and mortality in births occurring before 34 weeks.  
In the UK the age of viability was reduced from 28 completed weeks of gestation 
to 24 weeks in 1992 reflecting advances in neonatal support (Tucker & McGuire, 
2004).   
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1.1.3 Cause 
Williamson et al (2008) describe preterm birth as “a multi-factorial disease 
caused by genetic, social and environmental factors that most likely interact to 
increase risk”. Iatrogenic causes of preterm birth account for approx 30% of all 
cases and this rate has recently increased due to assisted reproductive 
technologies with its associated rise in multiple births. Improvements in 
ultrasound technology have also led to recognition of intrauterine growth 
restriction and fetal compromise (Danielian & Hall, 2005). Other causes include 
maternal factors such as cervical incompetence, general medical conditions, 
history of previous preterm birth and infection. Exposure to stress may lead to 
immunosuppression and infection and many commentators have highlighted the 
association of poor socioeconomic status with preterm birth (Williamson et al, 
2008).  Lifestyle factors such as poor diet, obesity, smoking, economic and 
educational status have all been associated with preterm birth (Tucker & 
McGuire, 2004).  The multifactorial causes and manifestations of preterm birth 
make it difficult to study.  The label of preterm birth covers a variety of 
underlying physical conditions, some well understood and some not.  Without 
further, in depth, understanding of the variance in the different causes of 
preterm birth, combined with appropriate diagnostic techniques to reliably 
differentiate between them, the treatment of preterm birth will remain 
problematic. 
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1.2. Tocolysis 
The term tocolysis is derived from the Greek toco for contractions or birth and 
lysis to untie or destroy.  The term was first used with regard to a therapeutic 
intervention in 1964.  The primary aim of tocolysis is to delay delivery long 
enough to allow for the administration of antenatal steroids and/or in utero 
transfer.  Antenatal steroids significantly reduce the occurrence of respiratory 
distress syndrome, neonatal death, intraventricular haemorrhage and cerebral 
palsy and in allowing time for their administration, tocolysis can improve 
neonatal outcomes (Eriksson et al, 2009).  The secondary aim is to reduce 
perinatal morbidity and mortality associated with prematurity, however if the 
uterine environment is hostile with the presence of infection the additional time 
in utero can be harmful.  In the absence of clear benefits it is therefore 
considered acceptable not to use tocolytics (Keirse, 2003).  The difficult decision 
of when, or whether to use tocolysis, and which drug to use lies solely with the 
individual clinician.  A number of compounds have been investigated as 
tocolytics including cyclooxygenase inhibitors, beta agonists, L-type calcium 
channel antagonists, magnesium sulphate and Oxytocin receptor antagonists.  To 
date no tocolytic has been shown to reduce the incidence of perinatal morbidity 
and mortality and no study has been carried out with sufficient power to show 
such a benefit (Di Renzo & Roura, 2006).  With a static or rising (dependent on 
the data source) preterm birth rate, increasing demand on neonatal services and 
the distress and long term social impact that preterm birth brings, there is an 
urgent need for new and effective treatments. 
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1.3 Clinical challenges in tocolytic use 
The clinical guidelines produced by the Royal College of Obstetricians and 
Gynaecologists (RCOG 2011) suggest that there is no clear evidence that 
tocolytics improve pregnancy outcome and as such it is reasonable not to use 
them (RCOG 2011). However, other interventions that have been demonstrated 
to improve neonatal outcomes include moving the expectant mother to a clinical 
area with availability of high level neonatal critical care facilities and expertise 
(in-utero transfer) (Marlow et al 2014), and the administration of corticosteroids 
to promote lung maturation (Roberts and Dalziel 2006). The antenatal 
administration of corticosteroids has been shown to significantly reduce the risk 
of neonatal death, respiratory distress syndrome, cerebroventricular 
haemorrhage, necrotising enterocolitis, need for respiratory support, intensive 
care admissions and systemic infections within the first 48 hours after birth 
(Roberts and Dalziel 2006). Current RCOG guidelines recommend either two 
intramuscular doses of betamethasone 12mg, 24 hours apart or four 
intramuscular doses of dexamethasone 6mg, 12 hours apart (RCOG 2010). With 
such advantages to neonatal wellbeing, often the aim of tocolysis is to delay 
birth sufficiently to allow for full 48 hour administration of  corticosteroids.  
A number of pharmacological agents have been, or still are, used routinely as 
tocolytics. In the UK a commonly used tocolytic was the β-adrenergic receptor 
antagonist, ritodrine. Although being effective in increasing time from 
administration to birth, ritodrine was also associated with maternal side-effects 
such as palpations, nausea and vomiting, tremor and cardiovascular effects, 
often resulting in discontinuation of treatment (Gyetvia et al 1999, de Heus 
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2009). Indomethacin, a COX-1 and COX-2 inhibitor has similarly been shown to 
increase time to birth but carries significant fetal side effects including reduced 
fetal urine output (oligohydrmanious), and if used after 32 weeks gestation can 
bring about the premature closing of the ductus arteriosus which has a 
detrimental effect on fetal circulation (Groom et al 2005). In view of these 
detrimental side effects ritodrine and indomethacin are not recommended as 
tocolytics of choice by the RCOG (RCOG 2011). 
Magnesium sulphate (MgSO4) is also used as a tocolytic agent, however it has 
been shown in trials to be ineffective in delaying birth (Crowther et al 2002). 
There have been recent suggestions that MgSO4 is useful as a neuroprotective 
agent to benefit neonatal outcomes and as such is used by some clinicians, 
particularly favoured in the USA, but evidence for this is not yet conclusive 
(Doyle et al 2009). Atosiban, an Oxytocin receptor antagonist is licensed for use 
as a tocolytic in the UK. In terms of increasing time to birth from administration, 
it is comparable to Nifedipine with Nifedipine demonstrating a significant 
reduction in respiratory distress syndrome (OR 0.55 CI 0.32-0.97) over atosiban 
(Coomarasamy 2003). There is currently a Dutch clinical trial (Assessment of 
Perinatal Outcome after Specific Tocolysis in Early Labour: APOSTEL III-Trial) in 
progress directly comparing Nifedipine to atosiban (van Vliet et al 2014). The 
primary outcome is neonatal morbidity, with maternal side effects leading to 
discontinuation as a secondary outcome. Long-term developmental follow-up is 
desirable but dependent on future funding (van Vliet et al 2014). Due to the 
methods of administration of both agents, Nifedipine oral and atosiban IV, the 
study design is random treatment allocation but is not blinded to administration 
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(van Vliet et al 2014). The results of this trial will hopefully add information as to 
the clinical advantage, if any, of one agent over the other. Without a 
demonstrated advantage the clinical decision on which tocolytic to use within 
the context of the NHS is often economic and policy driven. The cost of a full 48 
hour course of atosiban is approximately £500 with each 5 ml vial costing £52.82, 
whereas Nifedipine is considerably cheaper at less than £1 for a 48 hour course 
(max 60 mg) with an 84-blister pack of 10mg Nifedipine costing £6.53 (BNF 
2015). Anecdotally many NHS local policies reserve the use of atosiban for 
situations where Nifedipine does not appear to be effective and the prescriptions 
often require consultant level agreement. 
Nifedipine is not licensed as a tocolytic but is a commonly used calcium channel 
blocker (CCB) for the purpose of delaying birth with a similar agent, nicardipine 
also used. In a large systematic review including 38 trials where CCB's were 
compared to other tocolytics, 35 used Nifedipine and the remaining 3; 
nicardipine (Flenady et al 2014). CCB's were compared to β-mimetics (23 trials), 
MgSO4 (7 trials), atosiban (2 trials), terbutaline (4 trials), indomethacin (2 trials) 
with 1 trial comparing high dose verses low dose CCB (Flenady et al 2014).  
Overall, there was a reduction in birth within 48 hours (RR 0.30, CI 0.21 to 0.43) 
after administration with CCB's compared with other tocolytics; but an increase 
in maternal side effects RR 49.89 CI 3.13 to 795.02). When Nifedipine was 
compared with β-mimetic specifically, there was a significant reduction in very 
preterm birth (before 34 completed weeks) (RR 0.78 CI 0.66 to 0.93) and an 
increase in interval between trial entry and birth (Average 4.38 days) (Flenady et 
al 2014). Again, a significant reduction in respiratory distress syndrome was seen 
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with CCB's but no significant difference in perinatal mortality. Fewer women 
required discontinuation of therapy for adverse effects (RR 0.21 CI 0.11 to 0.40). 
High dose Nifedipine resulted in a statistically significant higher gestational age 
at birth but other than that there were no significant outcomes with low-dose 
compared to high-dose. The varied dose regimes and durations studied in this 
review make interpretation problematic.  Long-term outcomes of death and 
neurosensory impairment was only available for one study (children aged 9-12) 
showed no difference between CCB's and Ritodrine in terms of parental reported 
quality of life, behaviour, emotion, educational and motor quality (Flenady et al 
2014).  In a review of side effects from tocolytic use, the most commonly 
occurring serious (4/5) and mild (4/6) adverse event associated with Nifedipine 
was hypotension. In 6/7 cases, hypotension developed within 2 to 4 hours after 
the start of tocolysis where the dose used was 2 to 4 doses of 10 mg sublingual 
Nifedipine every 15 minutes followed by 20 mg slow release every four hours (de 
Heus et al 2009). It is not clear if in these cases the treatment was continued 
beyond a total amount of 60 mg, which is used as a cautionary cut-off threshold 
for increased likelihood of side-effects within the RCOG guidelines (RCOG 2011). 
Despite these incidents there was an absence of associated fetal compromise (de 
Heus et al 2009). de Heus et al (2009) also demonstrated an increased likelihood 
of adverse effects if more than one type of tocolytic was used in combination 
and their caution against this practice is echoed in the RCOG guidelines (RCOG 
2011). When single doses were administered, the rate of serious adverse drug 
reactions associated with β-mimetics was 1.7% whereas with Nifedipine the rate 
was 0.9% (de Heus et al 2009).  
37 
 
Overall Nifedipine, used as a short-term tocolytic, has an effect in delaying time 
from administration to birth, is economically favourable over other tocolytics, 
and has a more favourable safety profile than alternative agents. However, the 
cardiovascular side-effects remain of concern, and in order to avoid increasing 
this risk the dose is limited within currently recommended dose regimes; which 
may not always be sufficient to delay birth for administration of antenatal 
corticosteroids or allow for safe in-utero transfer. As such a new tocolytic regime 
that can delay birth for up to 48 hours without adding to existing side effects 
would be desirable. Drug regimes currently clinically recommended for tocolysis 
and feto-protection are summarised in Table 1.2. 
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Drug Initial dose  Route Maintenance Source 
Tocolysis 
Atosiban 6.75 mg  Intravenous 18 mg/hour for 3 
hours, the 6 
mg/hour for up 
to 45 hours (max 
of 330 mg/48 
hrs) 
RCOG Green 
top guideline 
No 1B (2011) 
Nifedipine 20 mg Oral 10-20 mg three 
to four times 
daily up to 48 hrs 
(total dose over 
60 mg associated 
with three to 
four-fold increase 
in side effects 
RCOG Green 
top guideline 
No 1B (2011) 
Fetal protection 
Magnesium 
Sulphate 
(neuroprotection) 
4-6 mg Intravenous 1-2 mg/hour (up 
to 24 hours) 
ACOG 
Committee 
Opinion No. 
455 (2010 
(revised 
2015)) 
RCOG 
Scientific 
Impact Paper 
No. 29 (2011) 
Betamethasone 
(Fetal lung 
maturation) 
12 mg (2 
doses 24 
hours apart) 
Intramuscular Total dose (24 
mg) over 48 
hours - most 
effective from 24 
hours - 7 days 
from last dose 
RCOG Green–
top Guideline 
No. 7 (2010) 
Dexamethasone 
(Fetal lung 
maturation) 
6 mg (4 
doses 12 
hours apart) 
Intramuscular Total dose (24 
mg) over 48 
hours - most 
effective from 24 
hours - 7 days 
from last dose 
RCOG Green–
top Guideline 
No. 7 (2010) 
Table 1.2: Main tocolytic drugs and drugs for feto-protection currently 
recommended for use in the UK 
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1.4  The problem of Post-Partum Haemorrhage 
Post partum hemorrhage (PPH) remains a significant clinical issue in women’s 
health.  Primary PPH is a significant blood loss that occurs within 24hrs of 
delivery and secondary PPH when occurring from 24hrs to 6 weeks post-partum.  
PPH is defined as a blood loss of 500 mls or more; but further categorized as a 
minor PPH when the loss is from 500ml-1000 mls, major PPH if 1000mls-
2000mls, and severe PPH when over 2000mls (RCOG, 2009).  Despite these 
classifications any blood loss can be significant if it leads to hemodynamic 
instability.  This is of particular significance in women that are anemic prior to 
delivery. This is more common in developing countries where PPH poses a 
significant risk of death to childbearing women. In the UK it is estimated that PPH 
occurs in 18% of all births and with 3% of all vaginal deliveries resulting in a 
severe PPH. WHO estimates the rate worldwide to be 6% rising to 10.5% in 
Africa.  PPH accounts for 30% of all maternal deaths in Africa and Asia (WHO, 
2007). Interventions to prevent PPH are a priority in the UN Millennium 
development Goals global effort to reduce the maternal mortality rates by three-
quarters by 2015 (UN, 2010) (Figure 1.4). 
The causes of PPH are either traumatic bleeding or atonic bleeding. Traumatic 
bleeding is as a result of mechanical injury to the uterus, cervix or genito-urinary 
tract during delivery. Atonic bleeding is due to the inability of the uterus to 
contract preventing compression of blood vessels and control of bleeding. 
Conditions that can impair contraction are retained placenta, retained placental 
tissue or membrane fragments, or the accumulation of blood clots. Loss of 
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uterine tone is the most common cause of primary PPH. Risk factors for uterine 
atony include prolonged labour, high parity, multiple pregnancies, large babies 
and polyhydramnios (WHO, 2008).  
PPH is an obstetric emergency and remains a leading cause of morbidity and 
mortality due to difficulty in management. Despite active management of the 3rd 
stage being routinely practiced in the UK, deaths from post-partum hemorrhage 
continue to occur.  The most recent report on confidential enquiries into 
maternal deaths show the number of deaths has halved to 5 from the previous 
report. Although this is a welcome reduction the trend throughout triennial 
reports from 1985 remains stable (Figure 1.5).  These enquiries point to 
substandard care as contributing factors to maternal deaths from PPH, which are 
considered preventable. With a potential blood loss of 500mls per minute, death 
from exsanguination can occur within 10 mins with an untreated severe PPH 
(WHO, 2008). Renal damage is possible sequelae in survivors due to renal tissue 
damage from hypovolemia.  
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Figure 1.4: Causes of maternal deaths from developing countries (percentage) 
from (UN, 2010) 
 
 
Figure 1.5: Graph showing deaths per 100 000 from haemorrhage from triennial 
Confidential Enquiry reports into maternal deaths from 1985. Year to year 
variance is due to low overall numbers but the trend remains stable. 
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1.5 Current treatments for the prevention and management of Post-partum 
haemorrhage 
1.5.1 Prevention of PPH 
Antenatal observation for risk factors is essential for the prevention and 
expectant management of PPH, however PPH cannot always be predicted.  
Active management of the third stage of pregnancy is a strategy that combines 
prophylactic administration of Oxytocin by intramuscular injection combined 
with delivery of the placenta by controlled cord traction.  Active management of 
the 3rd stage reduces the risk of PPH by 60% and reduces the risk for additional 
therapeutic oxytocics by 50% (RCOG, 2009). There continues to be consistent 
evidence of the benefits of active management strategies from trials comparing 
Oxytocin prophylaxis with placebo or no treatment (Westhoff et al 2013).  Active 
management with the administration of Oxytocin over any other currently 
available pharmaceutical agents is recommended globally (WHO, 2007).  
However, in a review of international guidelines, little agreement was found in 
timing and type of uterotonic use and dosage (Bohlmann and Rath 2014). There 
was agreement on Oxytocin as the first line choice for both prevention and 
management but with varied dosing protocols and methods of administration 
and much disagreement on the order and administration of second line agents 
(Bohlmann and Rath 2014). 
In a comparison of misoprostol versus Oxytocin for the prevention of PPH, 12% 
of the study group had PPH and 10 % of the control. There were no significant 
difference in other outcomes or in side effect reporting suggesting that 
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misoprostol is equally effective as Oxytocin for prevention of PPH (Firouzbakht et 
al 2013), however this finding was not held up in systematic review which found 
Oxytocin to be most effective (Westhoff et al 2013) . One benefit of misoprostol 
over Oxytocin is it stability at various temperatures and ease of administration 
which makes it an ideal choice in areas where access to other drugs is difficult or 
in the hands of unskilled attendants (Nasreen et al 2011).  There is currently a 
planned study for the combination of the antifibrinolytic agent tranexamic acid 
with prophylactic Oxytocin administration after singleton term planned vaginal 
births in order to prevent PPH (Sentilhes et al 2015), which indicates the desire 
to seek more effective methods of PPH prevention.  
1.5.2 Management of PPH 
Management strategies include clinical interventions such as catheterization and 
manual compression of the uterus as well as pharmacological management with 
the administration of uterotonics, (Oxytocin by intravenous infusion, 
prostaglandins - carboprost (PGF2α) by infusion or direct intramyometrial 
injection, or misoprostal (prostaglandin E1) by rectal administration).  If 
pharmacological and clinical interventions fail then surgical interventions may be 
indicated (balloon tapenade, haemostatic suturing, internal iliac artery ligation) 
with ultimately obstetric hysterectomy being the only effective solution.  The 
RCOG guidelines on the management of PPH (Figure 1.6) re-iterate the gravity of 
such an obstetric emergency. Management includes effective and timely 
communication, escalation to clinical seniors and access to appropriate facilities 
as essential aspects of care and crucial to a successful outcome as any individual 
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treatment. Individual cases may require specific approaches to management and 
escalation of recue measures. Any additional therapeutic options that can 
prevent morbidity would improve outcomes for women at risk of PPH. 
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Figure 1.6: Algorithm from RCOG guidelines (green top guideline no.52, 2009) on 
the management of major PPH illustrating the complex aspect of management 
from communication, escalation and cascade of mechanical and medical and 
surgical therapies. 
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1.6. The physiology of myometrial contraction. 
1.6.1 Uterine quiescence 
1.6.1.1 Progesterone/Progesterone receptor 
The progestogen, progesterone (P4) plays an important role in the maintenance 
of quiescence by suppressing expression of genes that increase myometrial 
contractility and by inhibiting inflammatory pathways. 
In many mammalian species circulating progesterone withdrawal is critical for 
increased uterine contractility leading to labour. In humans, circulating P4 levels 
remain elevated throughout the third trimester of pregnancy and into labour; 
increasing uterine contractility and the onset of labour maybe due to events that 
impair progesterone  receptor (PR) function rather than a reduction of circulating 
P4. 
P4 is secreted from the corpus luteum following ovulation.  In absence of 
pregnancy, falling circulating progesterone in the late secretory phase of the 
menstrual cycle leads to sloughing of the decidual layer and menstruation. If 
pregnancy occurs, human chorionic gonadotropin (hCG) secreted by trophoblast 
cells maintain the corpus luteum stimulating steroid hormone secretion. 
Interaction with the lutenising hormone choriogonadotropin receptor (LHCGR) 
promotes the secretion of P4 (Järvelä 2008). Increased angiogeneis and increased 
blood supply supplies the cholesterol needed for P4 synthesis (Takasaki 2009). At 
around 7-8 weeks there is a shift from extra-uterine P4 production to intra-
uterine and the regression of the corpus luteum can be seen from 10 weeks 
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onwards after which hCG levels start to decline. (Rowan et al 2008, Järvelä 2008).  
The corpus luteum is declining at around week 5-7 with the secretion of P4 
reaching its lowest ebb before increasing once supported by the placenta 
(Järvelä 2008). 
P4 exerts its action through binding to progesterone receptor (PR). PR receptor is 
a ligand-activated transcription factor with sequence specific binding regions.  In 
in vitro experiments, P4 exerts a dose-dependent inhibitory effect on myometrial 
contractility (Anderson et al 2009, Chen at al 2014, Arrowsmith et al 2016) and 
maintains uterine quiescence by promoting relaxatory factors. P4 suppresses the 
expression of connexin-43 (CX-43); a protein which is essential for the formation 
of gap junctions in the myometrium (Petrocelli and Lye 1993, Sheldon et al 
2014). Gap junctions are vital for the propagation of the action potential across 
myometrial smooth muscle cells in order to elicit global excitability and 
contraction (Sheldon et al 2014). CX-43 ribonucleic acid demonstrates a 
gestation-dependent functional increase towards term with a further increase at 
the onset of labour (Chow and Lye 1994). P4 also promotes cAMP to inhibit the 
immune regulating protein nuclear factor kappa-light-chain-enhancer of 
activated B cells, (NF-κB) activation downstream of  protein kinase A (PKA); and 
in turn enhances P4 activity to drive gene expression (Chen at al 2014). PKA 
reverses progesterone-induced suppression of inflammation leading to the onset 
of labour (Chen at al 2014).  
Two estrogen-regulated promoters generate transcripts encoding two 
functionally different, co-expressed PR forms; A and B (Kastner et al 1990).  The 
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PR-A isoform can repress PR-B by sequestering P;  leaving less available to bind 
PR-B (Wei 1997). A further form of PR, PR-C is an N-terminally truncated and 
lacks the DNA binding domain which means this form of PR is unable to bind DNA 
but is able to bind P4 (Wei et al 1997).  Similarly PR-C can bind to PR-B reducing 
PR-B availability to bind to PR (Wei et al 1997).  An altered PR-C/PR-B ratio 
reduces capacity of PR-B to maintain quiescence (Condon et al 2006). PR-C 
expression is increased in human fundal myometrium at term as a result of NF-κB 
activation (Condon et al 2006). 
The Zinc finger E-box binding homeobox proteins ZEB-1 and ZEB-2, inhibit the 
expression of contractile associated protein (CAP) genes OXTR (Oxytocin 
receptor), and CXN-43 (connexin-43) (Renthal et al 2010). ZEB-1 is up-regulated 
by P4/PR by binding of the PR to ZEB-1 promoter. As PR declines there is a 
reduction in ZEB-1 expression leading to up-regulation of miR-200 family which 
in turn repress the expression of ZEB-1 allowing expression of CAP genes. 
(Renthal et al 2010) The contribution of this pathway to contractility is further 
supported by the finding that the miRNA family miR-200 is increased at term 
(Renthal et al 2010). 
Estrogen receptors do not increase steadily toward term, but an increase in 
responsiveness to estrogen in labour, is due to an increased expression of ERα 
and ERβ (Mesiano 2002). P4 inhibits ERα expression, preventing estrogen-
stimulated production of contractile associated protiens.  
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There appears to be a fine balance between P4, estrogen and PR forms, with 
varying ratios resulting in functional progesterone withdrawal  and estrogen 
activation at the onset of labour. 
1.6.1.2 Inflammation and labour onset 
In observations made by stimulating myometrial inflammation through 
activation of  NF-κB by IL-1β; IL-1β inhibited PR expression and possibly increased 
PR gene silencing (Lee et al 2012) highlighting the influence of inflammation on 
P4 action. PR was associated genes concerned with cellular development, growth 
and proliferation but not on contraction associated proteins,  failing to support  a 
significant anti-inflammatory role of progesterone via PR and suggesting that 
activation of inflammatory mediators is more likely driven by NF-κB rather than 
P4 withdrawal (Lee et al 2012). 
Pro-inflammatory cytokines IL-1β induce calcium entry via increased expression 
of sacroplasmic reticulum calcium ATPase (SERCA) 2b (Tribe et al 2003). 
Increased cell excitability enhanced increased basal calcium entry  were 
observed, indicating a role for inflammatory cytokines in the modulation of the 
electrophysiological thresholds of myometrium towards term (Tribe et al 2003). 
There is some indication that inflammatory pathways may depend on location 
within the uterus.  NF-κB activation in term human myometrium occurs in the 
fundus but not in the lower segment (Condon et al 2006) and pro-inflammatory 
cytokines IL-1b, IL-6, CXCL-8 are increased in the lower segment during term 
labour (Shynlova et al 2013). The myometrial stimulator prostaglandin F2 alpha 
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(PGF2α) receptor is reduced by P4; IL-1β increases PGF2α receptor expression via 
PKC and NF-κB  (Liang et al 2008) 
A number of additional agents have been associated with the onset of human 
labour. For example, labour is associated with a reduction in the G protein alpha 
subunit (Gαs) levels in myometrium. Gαs activates adenylyl cyclase and the 
cAMP-dependent pathway to relaxation. Gαs expression was found to be 
reduced in women in spontaneous labour (Europe-Finner 1994). A summary of 
signalling/effecting molecules involved in maintaining quiescence and promoting 
contractility is found in Table 1.3. 
 Activation Relaxation Source 
Stretch Activates COX-2 via 
AP-1 system 
Action supressed by 
P4 
 Sooranna et al (2004) 
Shynlova et al (2008) 
Fetal hormones (SP-A) Stimulates  
microphage migration  
and NF-kB p65 and IL-
1β 
 Reini and England 
(2015) 
Mendelson & Condon 
(2005) 
NF-κB 
 
Increases expression 
of contractile 
activating proteins 
PGF2α receptor 
CX-43 
COX-2 (promotes) 
prostagladins 
OXTR 
Inhibited PR 
expression 
 Lindeström and 
Bennett (2005) 
Lee et al (2012) 
Chemokines/cytokines IL-1β (Ca
2+
 activation) 
IL-6 
CXCL-8 activation of 
NF-κB 
 Tribe et al (2003) 
Lee et al (2012) 
cAMP  Via PKA 
Reduces NF-κB 
activity 
Enhances P4 activity 
to drive gene 
expression 
Chen et al (2014) 
Gαs Decreased expression 
leads to decreased 
relaxatory effect of 
Increased expression 
leads to agonist 
induced cAMP 
Europe-Finner et al 
(1994) 
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cAMP formation via 
adenylyl cyclase 
PKA Reverses P4 induced 
suppression of 
inflammation  
 Chen et al (2014) 
G-protein coupled 
receptor 
Lutenising hormone 
(LH) 
Human corionic 
gonadotrophin (hCG) 
Cortico-trophin 
releasing hormone 
(CRH) 
Relaxin (RLX) 
Prostaglandin E2 
(PGE2) 
 
Promotion of 
Gαs 
cAMP 
PKA 
Gellerson & Brosens 
(2003) 
Europe-Finner (1994) 
20 α-HSD  Maintains P4 Ishida et al (2007) 
Piekorz et al (2005) 
 Activation Relaxation Source 
STAT5b Suppress 20a-HSD 
which regulates mi-
R200a which is a 
regulator of ZEB1 & 2 
which promote OXTR 
& CX-43 
 Williams et al (2012) 
Estradiol (E2) Increase towards 
term promotes pro-
inflammatory events; 
induce influx of 
macrophages and 
neutrophils,  
Enhances 
transcription of 
contractile activating 
proteins. 
Reduced PR function 
 Mesiano et al (2002) 
 
Table 1.3: Summary of some of the signalling/effecting molecules involved in 
maintaining uterine quiescence/promoting contractility 
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1.6.2 Pathways to contractility. 
The uterus is a uniquely adaptive organ with gradual transition from quiescence, 
whilst harbouring the developing fetus, to contractions during labour followed by 
a rapid remodelling in the immediate post partum period (Young, 2007).  There is 
evidence that the initiating hormonal cascades of parturition are prone to 
redundancy  (Blanks & Thornton, 2007).  When the Oxytocin gene is deleted in 
the knockout mouse (OT -/-) parturition continues within normal timings and 
leads to delivery of live pups (Nishimori et al 1996, Young et al 1996). However, 
pups fail to thrive postpartum due to failure of maternal milk ejection suggesting 
that in mice, Oxytocin is essential to successful lactation but non-essential in 
labour and birth (Nishimori et al 1996, Young et al 1996). Also, manipulation of 
the cytosolic phospholipase A2 (cPLA2)and cyclooxygenase-1 (COX-1) pathways 
prevents the formation of PGF2α, a rise in which usually brings about luteolysis 
and the subsequent onset of labour in mice; prevents normal parturition 
(Uozumi et al 1997, Gross et al 1998). The non-labour phenotype can be rescued 
with the addition of PGF2α, and normal parturition is restored (Uozumi et al 1997, 
Gross et al 1998). In the COX-1/OT knockout mouse, luteolysis occurs on the 
normal day of gestation but labour is prolonged and pups do not survive (Gross 
et al 1998). As luteolysis fails in COX-1 (-/-) knockout mice, this suggests that 
Oxytocin has an influence on luteolysis. This points to a compensatory 
mechanism where more than one agent can influence pathways to contractility. 
These described pathways activate G-protein coupled receptors, ultimately 
leading to an increase in [Ca2+]i and opening of voltage gated calcium channels 
(VGCC). Further evidence of this dual pathway is the effectiveness of tocolysis 
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that targets both simultaneously. When preterm labour is induced in sheep using 
glucocorticosteroids, dual treatment with the prostaglandin synthase type-2 
inhibitor nimesulide, and the Oxytocin receptor antagonist atosiban, delivery 
within the 48 hour treatment phase is completely prevented (Scott et al 2001). 
Pathways to contractility are complex and compete with the pathways that 
maintain quiescence. This means that targeted inhibition of one pathway (i.e. 
Oxytocin or prostaglandins) can be bypassed in the medium term (24-48hrs) by 
alternative stimulatory cascades.  As a consequence of this fact it is the 
contention of this thesis that targeting of proteins, downstream of the 
stimulatory cascade, will demonstrate efficacy regardless of the activating 
mechanism.  The therapies proposed herein rely on targeting voltage-gated 
calcium entry during a contraction, which is the key point at which contractility 
will occur.  
1.6.3 Role of Calcium in contractility 
Contractility is initiated by an increase in intracellular calcium ([Ca2+]i) from two 
possible sources; i) entry of extracellular Ca2+ ([Ca2+]o) into the myocyte through 
voltage gated calcium channels and TRP Ca2+ channels and ii) the release of 
[Ca2+]i from the sarcoplasmic reticulum (SR) (Parkington et al, 1999, Shmygol et 
al, 2007, Babich et al, 2004).  Influx of [Ca2+]o is essential for the propagation of 
action potentials and the generation of contractile force (Shmygol et al, 2007).  In 
rat myometrial tissue, Ca2+ spikes resulted in Nifedipine sensitive action 
potentials with varied initiation sites, spatial spread and frequency (Burdyga et 
al, 2009).  The role of Ca2+ release from the SR may not play as significant a role 
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in activating the contractile machinery as influx of [Ca2+]o, but there are 
indications of a role for the SR in contraction regulation by moderating available 
[Ca2+]i (Wray & Shmygol, 2007) (Figure 1.7). Spatially and localised Ca
2+ signals 
may target specific signal transduction pathways such as the activation of Ca2+ 
activated K+ channels thus initiating hyperpolarisation (Wray & Shmygol, 2007). 
The gestational difference in expression in SR components (RyR's and BK 
channels) also point to a function of the SR in the regulation of quiescence (Wray 
& Shmygol, 2007). 
 The increase in [Ca2+]i activates, via calmodulin binding, the intracellular kinase 
myosin light chain kinase that phosphorylates myosin light chains allowing the 
interaction of myosin and actin resulting in contraction.  Myosin light chains are 
phosphorylated at its binding site by Ca2+-calmodulin dependant protein kinase 
II.  This drives the ATP dependent cross bridge cycling interaction between actin 
and myosin.  The excitation-contraction cycle is maintained by calcium entry 
during the length of the complex action potential thus creating the phasic 
contraction.  Myometrial relaxation is preceded by a repolarisation of the plasma 
membrane to resting membrane potential and a decrease in [Ca2+]i
  (McKillen et 
al, 1999, Parkington et al, 1999). 
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Figure 1.7: Mechanisms involved in smooth muscle calcium regulation from 
Sanborn, B found at: http://csu-
cvmbs.colostate.edu/academics/bms/Pages/barbara-sanborn.aspx 
 
1.6.4 Role of potassium in contractility 
Potassium is essential in all cell types in the control and maintenance of the 
membrane potential. Membrane potential is the difference that arises from the 
unequal distribution of ions either side of the membrane (Sanborn, 2000).  
Selective permeability of the plasma membrane and active transport of ions 
provide a mechanism by which the electro-chemical gradients are prevented 
from reaching equilibrium, generating a trans-membrane potential (Khan et al, 
2001).  The net direction of flux of a given ion is determined by the concentration 
gradient and the electromotive force (Sanborn, 2000) (Figure 1.8).  The net flux 
of a given ion is described by the Nernst equation where an ion reaches 
equilibrium (Ex) when the electromotive force exactly counters the force of the 
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concentration gradient.  If the membrane potential is more positive than the 
equilibrium potential for a specific ion, efflux of that ion from the cell is favoured 
(Sanborn, 2000).  Under these biophysical constraints potassium is responsible 
for setting the negative membrane potential in most excitable cell types.  This is 
a result of the increased permeability of the plasma membrane at rest to 
potassium when compared to the other important intracellular ions calcium, 
sodium and chloride.  In addition to the higher permeability to potassium of the 
plasma membrane, ionic pumps move potassium into the cell under active 
transport creating a trans-membrane gradient of high intracellular and low 
extracellular potassium.  Thus under resting conditions potassium ions constantly 
leak out of the cell down their chemical gradient shifting the trans-membrane 
potential towards the reversal potential for potassium Ek. 
The permeability of the plasma membrane to potassium at rest is conferred by a 
small subgroup of K+ channels that are active at negative potentials or are 
activated by [Ca2+]i.  It is the contention of this thesis that manipulation of these 
channels, specific to myometrial smooth muscle, will hyperpolarise the 
myometrial cell membrane and render it less likely to stimulation and hence a 
lower probability that L-type calcium entry will be triggered.   
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Figure 1.8: Electro-chemical gradient and membrane potentials for each ion in 
myometrial smooth muscle as calculated using the Nernst equation. Extracellular 
and intracellular volume data from Sanborn (2000) 
 
1.7. L-type calcium entry and the actions of Nifedipine 
The voltage gated L-type calcium channel (VGLCC) was first characterised by its 
binding to dihydropyridines (Kanngiesser 1988).  Several other types of voltage 
gated calcium channels have been identified through electrophysiology and are 
described as L,N,P/Q, R and T type channels.  The T type channel has been 
identified in human myometrium and when inhibited, contractile force is 
reduced (Young & Zhang, 2005).  There is no difference in the expression of this 
channel across gestation or with labour but it appears to be important in 
determining contractile frequency (Blanks et al, 2007).  The VGLCC allows for a 
large flux of calcium ions through the plasma membrane when activated by 
transmembrane voltage change. Ca2+ channel α subunits share a common 
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topology with four homologous domains, each of which is composed of six 
transmembrane segments (S1-S6) and two short segments that line the 
extracellular pore (SS1 and SS2) situated between S5 and S6 (Hockerman et al, 
1997). The S4 segments are the site of voltage activation sensors. 
Dihydropyridines can act as agonists or antagonists of the channel depending on 
the drug structure and specificity of action (Hockerman et al, 1997).  Antagonists 
favour inactivated state binding, stabilising a non-conducting blocked state that 
mimics a channel with a single Ca2+ ion in the filter (Hockerman et al, 1997, Wang 
et al, 2004).  The VGLCC is highly selective to Ca2+ and this is probably due to its 
size and charge (Boda et al, 2009). This theory of dual selectivity is referred to as 
charged/space competition or CSC.  Selectivity results from both the size of the 
cation and its carried charge.  In the case of the VGLCC it attracts divalent over 
monovalent selecting Ca2+ over Na+ when the two are of approximately similar 
size.   All other cations are excluded on the basis of size (Boda et al, 2009).  
Extracellular Ca2+ entry during a contraction is dependent on the opening of the 
VGLCC as confirmed by the action of Nifedipine in vitro on myometrium, 
whereby spontaneous or augmented contraction can be abolished by its 
administration (Shmigol et al, 1998, Brown et al, 2007).  Expression of the VGLCC 
modestly increases during pregnancy and labour (Mershon et al, 1994).  There is 
however a change in binding of Nifedipine with gestation and in labour in rat 
myometrium suggesting an isoform change of physiological significance 
(Mershon et al, 1994).  This suggests higher doses of Nifedipine may be 
necessary to inhibit contractions in preterm labour.  Further to blocking 
extracellular influx of Ca2+, Nifedipine also depletes [Ca2+]i  stores resulting in less 
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available calcium in the plasmalemmel space opening Ca2+ activated K+ channels 
(Young et al, 2001).  The action of Nifedipine is not specific to the uterus bringing 
about a simultaneous relaxatory effect on vascular smooth muscle through the 
VGLCC.  Nifedipine was shown to progressively dilate depolarisation-induced 
constrictions in rat mesenteric arteries but not veins despite similar expression of 
VGLCC in both tissues (Thakali et al, 2010).  This ‘silencing’ of VGLCC in venous 
smooth muscle suggests a mechanism by which Nifedipine reduces cardiac 
overload but not preload resulting in a relaxatory effect on arterial but not 
venous tone (Thakali et al, 2010).  Venous sensitivity to Nifedipine was increased 
when intracellular stores were depleted indicating a role for [Ca2+]i in providing 
negative feedback to VGLCCs supported by the proximity of the sarcoplasmic 
reticulum to the plasma membrane (Thakali et al, 2010).  Nifedipine was first 
introduced as a tocolytic in 1977 and despite never having been licensed for this 
purpose it continues to be used today (Keirse, 2003).  Nifedipine has commonly 
been used as an antihypertensive.  Advances in newer treatments for 
hypertension have led to this group of drugs becoming limited  
 
1.8. K+ channel openers in myometrial smooth muscle and vascular smooth 
muscle 
Prior to the establishing of this project, work undertaken in our laboratory 
identified a number of potassium channels that demonstrated differential 
expression between vascular and myometrial smooth muscle.  In a screen of 
laser captured material the expression levels of all known potassium channels in 
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the current build of the human genome were compared between vascular and 
myometrial smooth muscle.  A number of promising candidates were revealed in 
the screen and compounds were identified that might target these differentially 
expressed targets.  The hypothesis being that specific activation of potassium 
channels expressed in myometrial but not vascular smooth muscle would 
specifically hyperpolarise myometrial cells. It is hypothesised that by allowing K+ 
efflux the membrane potential is kept below the level at which VGCC activation 
occurs in addition to the therapeutically tolerated dose of Nifedipine, it is 
anticipated that the combined effect would be greater on maintaining 
hyperpolarisation than Nifedipine alone.  These compounds are summarised 
below. 
1.8.1 Pinacidil 
Pinacidil is an effective K+ channel opener functioning on the KATP channel and is 
used therapeutically as an antihypertensive. KATP channels are regulated by the 
metabolic messenger adenosine triphosphate (ATP) which couples energy 
metabolism to the electrical activity of the plasma membrane (Proks & Ashcroft, 
2009).  This protective function is important in many organ systems, including 
seizure protection in neurological cells, response to cardiac stress and ischemic 
preconditioning (Proks & Ashcroft, 2009).  This is best illustrated in pancreatic β-
cells where KATP function links plasma glucose levels with insulin secretion (Khan 
et al, 2001).  An increase in extracellular glucose and intracellular ATP 
metabolism results in the channel closing, allowing depolarisation via VGLCC and 
insulin secretion.   A fall in glucose, decreases ATP metabolism, opens the 
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channel bringing about hyperpolarisation and no insulin release (Proks & 
Ashcroft, 2009).  The KATP channel is made up of the KIR 6 pore forming subunit 
and the sulphonylurea receptor (SUR) subunits. This channel is an octomer made 
up of 4 KIR 6 subunits surrounded by 4 SUR subunits (Berridge, 2010).  The SUR 
subunits are responsible for trafficking, pharmacology and ATP sensitivity. The 
binding of the SUR subunit allows translocation of the channel to the plasma 
membrane as signalling from SUR is required for release from the ER/Golgi 
(Burke et al, 2008).  The SUR subunit is also important in regulation of channel 
function as demonstrated by the use of sulphonylureas as anti-diabetic drugs 
increasing insulin secretion by modulating channel function (Burke et al, 2008).  
In the rat uterus under hypoxic conditions which diminish ATP, an increase in K+ 
efflux is observed that is inhibited by the KATP blocker glibenclamide (Heaton et 
al, 1993).  This may be a protective mechanism to preserve myometrial integrity 
during labour (Heaton et al, 1993).  Investigations into the effect of Pinacidil on 
human myometrium have shown that Pinacidil reduces spontaneous and 
augmented contractility in both pregnant term and non-pregnant myometrium 
exerting a more potent relaxatory effect on term non-labouring tissue vs. 
preterm and labouring tissue (Morrison et al, 1993, Kostrzewska et al, 1996). 
Pinacidil has a endothelium-independent relaxatory effect on vascular smooth 
muscle by opening of KATP channels (Stojnic et al, 2007).  This is evidenced by 
reversal of this effect seen when the KATP channel blocker glibenclamide is added 
(Stojnic et al, 2007, Quast, 1993).  Since Pinacidil should work on both vascular 
and myometrial smooth muscle we utilised this as a positive control. 
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1.8.2 Riluzole 
Riluzole is a drug currently prescribed for the treatment of amyotrophic lateral 
sclerosis (ALS).  This progressive neurodegenerative disease results in muscle 
atrophy from motor neurone damage. Riluzole treatment has been shown to 
delay the time of death for ALS patients however the exact mechanisms of its 
neuroprotective effects are not fully understood (Table 1.4).  Some studies have 
shown that Riluzole potently reduces Na+ current particularly in neuronal tissues 
(Mohammadi et al, 2002, Hebert et al, 1994, Wang et al, 2008, Noh et al, 2000). 
Riluzole elicited a selective block of inactivated Na+ channels in rat brain tissue 
(Hebert et al, 1994).  Binding of Riluzole to closed and inactivated states 
preferentially blocks depolarised, hyperactive neurons and this targeting of 
abnormally active cells points to the neuroprotective effects of Riluzole and its 
usefulness as an anti seizure drug (Hebert et al, 1994).  Riluzole directly inhibits 
protein kinase C (PKC) by inhibition of the PKM catalytic domain rather than the 
ATP or DAG binding domains (Noh et al, 2000).  Inhibition by Riluzole of 
glutamate release has led to the investigation of its potential therapeutic use in 
psychological disorders, anxiety and depression as well as treatment for 
addictions (Besheer et al, 2009, Sofuoglu et al, 2008). In a small scale study into 
the possible interactions with d-amphetamines, 100 mg Riluzole was 
administered to healthy volunteers with no effect on blood pressure, heart rate 
or cortisol levels and reporting of a mild sedative effect (Sofuoglu et al, 2008). 
Riluzole may also have an effect of calcium currents.  Investigation into the effect 
of Riluzole on ionic currents in rat ganglion neurons showed an inhibition of P/Q 
and N type Ca2+ currents with no effect shown on L type currents (Huang et al, 
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1997).  This finding was supported by Siniscalchi et al (1997), who found that 
Riluzole increases the threshold for the generation of Ca2+ spikes, and thus limits 
the influx of Ca2+ ions.   
The dual action of Riluzole on the K2P channel TREK 1 channel results in rapid 
stimulation followed by a decline in activation and a strong inhibition of K+ 
current (Duprat et al, 2000).  This effect is also associated with an increase in 
intracellular cAMP which could be brought about by activation of the PKA 
pathway.  TREK 1 is expressed in human myometrium at term (Bai et al, 2005) 
and was described in our screen. 
A further channel identified in our screen and targeted by Riluzole is the SK3 
channel.  The small conductance calcium activated potassium channel SK3 is 
known to be expressed in myometrium (Brown et al, 2007).  Gating of the 
channel is dependent on calmodulin binding to Ca2+ which is constitutively bound 
to the channel (Nolting et al, 2007).  Calmodulin is also involved in trafficking the 
cell to the plasma membrane (Brainard et al, 2007).  SK channels are expressed in 
many sensory systems as well as in the heart, liver, skeletal muscle and urinary 
bladder.  They are widely expressed throughout the central nervous system 
(CNS) with activation by Ca2+ in these tissues having a neuroprotective effect 
(Dilly et al, 2005).  SK channels can be blocked by the bee venom toxin Apamin 
which assists in functional investigation (Nolting et al, 2007).  The SK3 channel is 
activated by Riluzole at concentrations at 3 µM and above (Grunnet et al, 2001).  
Brown et al (2007) describe the constitutive association with calmodulin and the 
SK3 channels sensitivity to [Ca
2+]i levels provide an effective negative feedback 
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mechanism to regulate [Ca2+]i.  In non pregnant murine myometrial strips from 
mice genetically modified to either under or over express SK3 contractility was 
altered (Brown et al, 2007). Strips from mice with an overexpression of SK3 often 
failed to contract or produced contractions with less amplitude and force.  
Contractions were completely inhibited by Nifedipine and there was impaired 
response to Oxytocin. Strips from mice with a reduced expression of SK3 
produced larger contractions when compared to wild type (Brown et al, 2007).  
Pierce et al (2008) confirmed that overexpression of SK3 reduced contractility in 
vitro strips but additionally mice in which preterm labour was induced failed to 
labour effectively and often suffered dystocia of pups in birth canal.  Wild type 
mice and mice with reduced expression of SK3 delivered normally.  Work in 
similarly modified mice has been conducted with the aim of investigating arterial 
tone and blood pressure (Taylor et al, 2003).  SK3 was expressed in the 
endothelium but not in vascular smooth muscle.  The suppression of SK3 resulted 
in an elevation of arterial tone and blood pressure.  Similar results were seen in 
Burnham et al's (2002) work into porcine coronary arteries where a SK3 activator, 
substance P, brought about hyperpolarisation in endothelial cells.  The only study 
into the SK3 activity in human pregnant myometrium was conducted by Gillham 
et al (2007).  The authors found that the SK3 blocker Apamin inhibited 
endothelium-derived hyperpolarising factor (EDHF) mediated relaxation in 
myometrial vasculature.  The authors suggest there may be some significance in 
this mechanism in pre-eclampsia or intrauterine growth restriction where there 
is evidence of abnormal EDHF mediated relaxation.  Further investigation into 
SK3 function in myometrial and vascular smooth muscle is warranted 
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Possible mechanisms of action of Riluzole 
 
Reduction of voltage gated Na channels 
 
Inhibition of protein kinase C 
 
Inhibition/attenuation of arachidonic acid 
release 
 
Inhibition of glutamate release 
 
Inhibition of P/Q & N Ca2+ channels 
 
Opening of TREK-1 (via AA)-Screen positive 
 
Opening of SK3 channels-Screen positive 
 
Table 1.4: Summary of possible mechanisms of action of Riluzole derived from the 
literature. 
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1.9 Maternal vascular adaptations to pregnancy; VSMC and endothelial 
function 
From the start of pregnancy the cardiovascular system goes through adaptations 
to provide increased blood supply required for the development and growth of 
the fetus. The main cardiovascular change is a significant increase in circulating 
blood volume, which is initiated by increased blood flow to the uterus (Palmer et 
al 1992). These vital cardiac adaptations happen early in pregnancy with over 
70% of the increase in cardiac output and 85% of the decrease in systemic 
vascular resistance occurring by the 16th week (Clap & Capeless 1997). Cardiac 
output was seen to increase significantly by week 5 from a mean of 4.88 l/min 
from conception to a maximum of 7.21 l/min by 32 weeks (Robson et al 1989). 
Total peripheral vascular resistance falls during the first 20 weeks (Robson et al 
1989), and persists in normal (non-hypertensive) pregnancies throughout and 
into the postnatal period, with 23% of the increase in cardiac output and 30% of 
the decrease in systemic vascular resistance being still present 1 year 
postpartum (Clap & Capeless 1997).  The observation that the drop from pre-
pregnancy to post-partum mean arterial pressure was more significant in women 
who had a pregnancy compared to non-pregnant women over the same time 
scale, suggests that pregnancy-associated cardiovascular remodelling can be 
beneficial and may persist to subsequent pregnancies (Morris et al 2015). Palmer 
et al (1992) observed through ultrasound scan that the uterine artery diameter 
doubled by week 21 from 1.4 ± 0.1 to 2.8 ± 0.2mm, did not change from 21-30 
and increased between 30-36 to 3.4±0.2mm. As well as increased diameter there 
was a significant increase in uterine artery mean flow velocity from early to late 
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pregnancy from - 8.4±2.2 to 61.4 ±3.0cm/second. Their observation was that in 
early pregnancy the increase in uterine flow was due to changes in uterine artery 
diameter and mean flow but in late pregnancy the rise in flow was mainly 
attributable to faster velocity (Palmer 1992). 
This increase in flow to the uterus leads to a compensatory increase in heart rate 
and activation of volume-restoring mechanisms (Duvecot 1993). Cardiac output 
then increases due to a rise in stroke volume resulting from an increase in 
circulating blood volume. Appropriate and successful vascular remodelling is vital 
for fetal wellbeing and a good pregnancy outcome, as well as having implications 
for long term maternal health.  
In a large UK cohort study (129,920 subjects), women who had a baby with birth 
weight on the lowest quintile for gestational age, a preterm delivery or pre-
eclampsia were at increased risk of ischemic heart disease related admission or 
death (hazard ratio 1.9 (CI 1.5-2.4), 1.8 (CI 1.3-2.5), 2.0 (1.5-2.5) respectively) 
(Smith et al 2001). These associations were additive in that women with all three 
risk factors had a seven times increased risk of ischemic heart disease related 
admission or death (CI 3.3-14.5) (Smith et al 2001). 
Women who had a preterm birth, regardless of any hypertension during 
pregnancy, had higher blood pressure after pregnancy when compared with 
women who had term births (Catov et al 2013). Data from the World 
Health Organization Calcium Supplementation for the Prevention of 
Preeclampsia Trial showed that in 5,167 singleton pregnancies, a rise in systolic 
pressure of over 30 mmHg or diastolic pressure over 15 mmHg was associated 
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with a 2 – 3-fold increase in risk of spontaneous preterm birth (Zhang et al 2007). 
These finding suggest a possible role of impaired endothelial function and 
adaptation to pregnancy in the pathology of preterm birth. 
As in myometrial smooth muscle, vascular smooth muscle contractions can be 
stimulated by mechanical, electrical and chemical stimuli. Passive stretch brings 
about a myogenic response, membrane potential changes open VGCC allowing 
Ca2+ efflux raising [Ca2+]i and facilitating the contractile mechanism. Chemical 
stimuli include norephinephrine, angiotensin II, vasopressin, endothelin-1 and 
thromboxane A2, which all bind to specific receptors (Klabunde 2014). The end 
result in each case is a rise in [Ca2+]i allowing for binding with calmodulin, 
activating MLCK, which in turn phosphorylates myosin light chains allowing for 
cross-bridge formation of the myosin head with actin filaments and contracting 
the cell (Klabunde 2014). 
At the small artery level, vasoconstriction and vasodilatation is controlled by 
communication between VSMC and the endothelial layer, which in turn regulates 
vascular homeostasis. Bayliss (1902) first identified that regulation of arterial 
tone occurred independently of central nervous system involvement and was 
both peripheral and myogenic in nature, demonstrating an effect both in vivo 
and in vitro.  Endothelial cells are in contact with blood, and blood borne 
components, and are responsive to signalling to bring about constriction and 
relaxation. The endothelium is considered an endocrine organ and is made up of 
a monolayer of endothelial cells which line the entire vascular system. Versatile 
and multifunctional, the endothelium regulates thrombosis and thrombolysis, 
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platelet adherence, modulation of vascular tone and blood flow, and regulation 
of immune and inflammatory responses by controlling leucocyte monocyte and 
lymphocyte interactions with the vessel wall (Sumpio et al 2002) (Figure 1.9). 
Endothelial cells produce and release a variety of vasoactive substances such as 
prostacyclin and nitric oxide (NO), which inhibit platelet aggregation and cause 
vasodilation (Sumpio et al 2002). Endothelial cells from different locations, vessel 
types and individuals can differ in response to stimuli. Endothelial cells are 
exposed to a variety of microenvironments, when removed from native tissue for 
growth in tissue culture they undergo phenotypic changes making it very difficult 
to study cultured endothelial cells (Aird 2012).  
 
Figure 1.9: Known secretory/expression products of endothelial cells relating to 
vessel physiology; from: Sumpio et al 2002 
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Endothelial-derived vasodilation is regulated by NO. The enzyme endothelial 
nitric oxide synthase (eNOS) generates NO from L-arginine and O2 using 
nicotinamide adenine dinucleotide phosphate (NAPH+). NO stimulates soluble 
guanylyl cyclase, increasing cyclic guanosine monophosphate (cGMP), which 
brings about relaxation of the VSMC (Förstermann & Münzel 2006). NO can also 
generate superoxide anions (O2
-) in conditions of oxidative stress, this reacts with 
NO to form peroxynitrate and vascular protection diminishes (Förstermann & 
Münzel 2006). Peroxynitrate interacts with lipids, DNA and proteins via direct 
and indirect oxidative reactions resulting in oxidative injury, necrosis or 
apoptosis (Pacher et al 2007).  L-arginine availability is important for eNOS 
production of NO. Arginase II is an enzyme involved in the urea cycle in which the 
body eliminates harmful amonia which also utilises L-arginine as a common 
substrate and so competes for availability. Lower levels of L-arginine are found in 
pre-eclamptic placenta compared to normotensive, with levels of arginase II 
higher (Noris et al 2004). This suggests raised arginase II in pre-eclampsia leads 
to a deficiency in available L-arginine impeding NO production. NO is important 
in placental angiogensis and regulation of vascular tone and maladaption of 
endothelial cells to pregnancy is a contributing factor to the development of 
pregnancy related conditions such as pre-eclampsia and IUGR. In animal studies 
the long-term inhibition of eNOS can elicit a pre-eclampsia type phenotype(Salas 
et al 1999). 
Furchgott & Zawaszki (1980) found the vasodilator effect of acetylcholine is 
dependent on the presence of endothelium. They proposed that acetylcholine 
stimulated the release of unknown substance(s), which bring about a relaxation 
71 
 
of VSMC, and this factor still remains to be identified. This unknown form of 
communication was named as endothelial dependant hyperpolarisation factor 
(EDHF). There have been many theories relating to the nature of what EDHF may 
be. Adaptations of the NO pathway, endothelial-vascular gap junctions as well as 
Ca2+ signalling and K+ channels have all been identified as possible candidates for 
EDHF or play a contributing role in EDHF.  Although prostacyclin and NO were the 
earliest identified endothelium dependant vasodilation factors, it was found that 
vasodilation persisted with suppression of these factors and K+ channels were 
proposed as having a role in EDHF (Taylor and Weston 1988). 
Possible mechanism includes a spatial increase in [Ca2+]i which activates Ca
2+ 
dependent K+ channels, leading to K+ efflux, and hyperpolarisation; or synthesis 
of a substance or generation of electrical signals which are capable of moving 
through membranes or myoendothelial gap junctions to influence VSMC (Luksha 
et al 2009). EDGF represents an additional layer of pathway to vasodilation. It 
has been proposed that EDHF may step in when the NO pathway is compromised 
(Luksha et al 2009) .It appears that the smaller the vessel , the larger the effect of 
EDHF (Taylor and Weston 1988).  In human gastroepiploic arteries the role of 
EDHF is significantly greater in microvessels than in large arteries, with NO and 
EDHF having equal effect in large arteries and EDHF having most effect in 
microvessels (Urakami-Harasawa et al 1996). This may be because EDHF more 
easily diffuses to VSMC in microvessels due to less tissue density or perhaps 
increased myoendothelial gap junctions. 
SK3 and IK3 have been identified as candidates for a role in EDHF and are located 
within endothelial cells and not in the VSMC (Luksha et al 2009), which is in 
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agreement with our own screen of VSMC's. While Ca2+ activated K+ channels, and 
SK3 in particular, are implicated as having a role in EDHF it is unclear how much 
this single protein contributes to the overall regulation of vascular tone (Luksah 
et al 2009, Lin et al 2012). While our initial screen differentiated channel 
expression between VSMC and MSMC the role these channels play in 
contributing to EDHF and therefore affect vascular tone is less clear and would 
require functional experiments to observe. 
Riluzole, which has been used therapeutically and has been the subject of long 
term use in clinical trials does not have cardiovascular side effects within its 
profile (Bensimon et al 1994)  
1.10  Inwardly rectifying potassium channel Kir 7.1 
A previous screen of K+ channel expression in myometrium identified the 
inwardly rectifying potassium channel Kir 7.1 as a channel of interest.  An 8-fold 
increase in the gene encoding Kir 7.1 KCNJ13 mRNA was seen in laser capture 
selected human myometrial smooth muscle compared to whole biopsy tissue at 
term.  An increase in KCNJ13 mRNA expression was also observed in murine 
myometrium, which peaked at D15 predicting a functional increase in expression 
towards term (Figure 1.10). 
Inwardly rectifying K+ channels demonstrate a greater flow into the cell rather 
than out as would be predicted by the Nernst equation and were previously 
described as anomalous rectifier K currents.  The behaviour of these channels is 
clearly different from Kv channels and instead of voltage-dependant activation 
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they rely on an electrochemical gradient minus equilibrium potential (Em-EK) 
(Hibino et al., 2010) (Figure 1.11). 
Under correct physiological conditions Kir channels generate large inward K
+ 
conductance at potentials negative to EK and small outward currents when 
positive to EK (Nakamura et al., 1999). Cells that express a large Kir conductance 
are expected to have a resting membrane potential close to EK and generally 
have no spontaneous activity. The voltage independent nature of the channels 
allows Kir to play a key role in setting and maintaining resting potential and 
action potential duration.  This is demonstrated in vascular smooth muscle cells 
where Kir 2 influences K
+ conductance at near resting potential modulated by 
hypoxia, hypo-osmotic stress and agonists. (Park et al., 2008).  The myometrial 
specific and gestational dependant increased expression of this channel 
observed by our group suggests Kir 7.1 may be involved in gestational dependant 
depolarisation of resting membrane potential in myometrium towards term. 
On studying Kir7.1 unique pore properties were observed (Krapivinsky et al., 
1998). Widely expressed in the purjinke layer of the cerebellum and pyramidial 
cells of the hippocampus both cells that demonstrate electrical excitability and 
where K+ channels play a role in the timing and duration of action potentials. A 
high expression was shown in kidney and small intestine but a low expression 
was found in the heart, placenta and ovary (Figure 1.12).  In thyroid follicular 
cells Kir 7.1 was found to co-localise with the Na
+K+ATPase (Nakamura et al., 
1999).  A low single channel conductance was suggested to support a 
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hypothetical functional coupling, with Kir 7.1 providing K
+ recycling required for 
Na+ pumping and maintaining resting membrane potential.  
Kir 7.1 was seen to be only 38% identical to its closest relative in the ROMK family 
Kir 1.3.  Among the unique features of Kir 7.1 is its low estimated single channel 
conductance ~50fS and a low sensitivity to Ba2+, Cs and Mg2+ block which is 
characteristic of ROMK.  The amino acids in the pore sequence differ from all 
other Kir channel proteins.  The channel consists of 360 amino acids with 95% 
identity rat- human.  The amino acid sequence of the pore region reveals 3 
differences in conserved locations when compared to homologous sequences of 
other Kir subunits.  Novel sequences at Ser-111, Met-125 and Gly-129 appear to 
be responsible for the channels unique properties and its voltage independent 
nature(Krapivinsky et al., 1998) (Figure 1.13).  
The specific function of Kir 7.1 has not been previously studied in myometrium.  
Study in other tissues was impeded by a lack of a specific pharmacological 
blocker.  The small molecule intracellular blocker of Kir 7.1 VU590 has been 
described by investigators searching for inhibitors of ROMK (Lewis et al., 2009) 
(Figure 1.14). They showed that at 10μM VU590 would elicit a 60% inhibition of 
Kir 7.1 current at 120mV. The availability of a pharmacological blocker provided 
an opportunity to investigate the functional contribution of Kir 7.1 to myometrial 
contractility.  Predicted enhanced contractility may be of clinical interest in the 
development of therapies for PPH. 
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Figure 1.10: Fold change in mRNA expression of KCNJ13 in cDNA generated from 
laser captured mouse myometrial smooth muscle mRNA. Individual points denote 
mean±SE for 5 mice. 
Figure 1.11: Topology of voltage gated and inward rectifier K+ channels. Kir 
channels have 2 hydrophobic membrane spanning domains whereas KV channels 
have 6. From (Brown, 1997) 
! $!
A      B   
 
Figure 1. A. Fold change in mRNA expression of KCNJ13 in cDNA generated from laser captured 
mouse myometrial smooth muscle mRNA.  Individual points denote mean±SE for 5 mice. Fold 
change calculated by the 2-! ! Ct method. B. Gestation dependent change in RMP in rats (From 
Casteels and Kuriyama J. Physiol. 1965;177;263-287)  
Analysis of KCNJ13 mRNA expression in human samples revealed that there was an 8-fold 
increase i  expression (! Ct 22.57±0.17 (n=7), Total cDNA vs ! Ct 19.27±1.73 (n=5), Laser 
captured material) when comparing pure MSM population with total biopsy cDNA in term (prior to 
labour) a ples.  At this ge tation, mRNA for KCNJ13 was the 4th/22 most abundant gene 
transcript behind the previously well-described genes encoding the BKCa
2+ (KCNMA1 and 
KCNMB1)24 and the voltage-gated channel subunit KCNE425.  Expression of KCNJ13 mRNA in laser 
captured MSM from term (prior to labour) samples was not significantly different to laser 
captured MSM from non-pregnant patients.  During this proposal we determine whether KCNJ13 
mRNA expression is up regulated in women in a similar manner to the rodent in mid-gestation.  
A (d13 Mice Pre-absorbed) B (d15 Mice Pre-absorbed) C (Term NIL Human Pre-abs) 
 
D (d13 Mouse Kir7.1) E (d15 Mouse Kir7.1) F (term NIL Human Kir7.1) 
 
Figure  2. Immunohistochemistry using anti-Kir7.1 antibody(brown colour) with haematoxylin 
counterstain.  In mice staining was most prominent on d15 in MSM under the placental bed (e). 
In term human samples, staining was present and specific for MSM (f). 
To support our observations using qRT-PCR analysis from laser captured MSM mRNA we 
undertook immuno-histochemical analysis of the protein product of KCNJ13, the inwardly 
rectifying channel Kir7.1.  In the mouse, we demonstrated specific Kir7.1-like immunoreactivity in 
longitudinal and circular myometrial cells at all gestational ages (d13, d15, d18).  Staining was 
most intense on d15, particularly in myocytes immediately under the site of placentation (Figure 
2e).  This is particularly interesting since it has been demonstrated that RMP is most negative 
under the site of placentation26.  We have also demonstrated specific Kir7.1-like immunoreactivity 
in MSM taken from women at term (prior to labour). (Figure 2f). 
The biophysics of Kir7.1 
Kir7.1 was first cloned in 1998 and is only 38% identical to its closest relative, Kir1.327-29.  Kir7.1 
displays none of the functional properties of the ATP-regulated inward rectifier (ROMK) class of K+ 
channel, instead displaying several unique properties such as low sensitivity to Ba2+ and Cs+, low 
single channel conductance, no internal block by Mg2+ ions, and a relative insensitivity to external 
K+ concentration, tetraethylammonium (TEA) (IC50>10mM), and 4-aminopyridine (4-AP) (IC50 
~10mM). In in vitro expression systems, Kir7.1 demonstrates rapid activation kinetics (²act=0.8 to 
1.8ms for Em -140 to -40mV)
28 and is essentially non-inactivating at potentials negative to 
40mV27 with a small single channel conductance in both recombinant (50fS to 1pS) and native 
cells (2pS in bovine retinal epithelium)30.  Since the channel has a low conductance, little voltage 
or time dependence in physiological ranges, is most highly expressed in mid-gestation and is 
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Figure 1.12: Human multiple tissue cDNA panel PCR screening demonstrates 
expression of Kir7.1 in kidney, brain, and intestine and to a lesser extent in testis, 
liver, and prostate: (1) brain, (2) heart, (3) kidney, (4) liver, (5) lung, (6) pancreas, 
(7) placenta, (8) skeletal muscle, (9) colon, (10) ovary, (11) peripheral blood 
leucocyte, (12) prostate, (13) small intestine, (14) spleen, (15) testis, and (16) 
thymus. From (Krapivinsky et al., 1998) 
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Figure 1.13: Comparison of the amino acid sequences of Kir7.1 with representative 
subunits of other Kir subfamilies. The predicted 360 amino acids of human Kir7.1 (single-
letter code) are shown aligned with sequences of human Kir1.2 (GenBank accession 
number U73192), human Kir2.1 (U12507), human Kir3.3 (U52152), rat Kir5.1 (X83581), 
and human Kir6.2 (D50582). Residues are shaded in black in instances in which other 
subunits are identical to Kir 7.1; asterisks denote residues conserved in all known Kir 
channels, and boxed residues (arrowheads) indicate where Kir7.1 is different from the 
consensus of all other Kir channels. Outlined also are the transmembrane segments M1 
and M2 and the pore-forming P-region (H5). Amino acid gaps within the alignment are 
indicated by short bars. The GenBank accession number for the human and rat Kir7.1 
sequences are AJ006128 and AJ006129, respectively.From (Döring et al., 1998) 
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Figure 1.14:  Inhibition of K+ channels with novel small molecule intracellular 
channel blocker VU590. A 60% inhibition of Kir 7.1 current at 120mV is seen with 
10 μM VU590 From: Lewis et al 2009. 
 
1.12 Summary 
In a previous screen carried out within our group a number of K+ channels were 
identified of interest due to the level of expression, gestational dependent 
nature of expression or relative abundance when compared with vascular 
smooth muscle. This has led to the prospect of further examination of the 
function of these ion channels in myometrium with a view their potential as 
therapeutic targets. Crucially, in the contractility pathway, modulation of K+ 
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channel function has the potential to significantly impact on myometrial 
membrane resting potential and action potential, directly modifying contractility 
downstream of chemical stimuli or signalling (Figure 1.15). 
1.11.1  K+ channel openers combined with Nifedipine as potential targets for 
tocolysis 
The problem of preterm labour has not diminished in recent years.  There is a 
choice of tocolytic drugs available to clinicians for the treatment of preterm 
labour however none have demonstrated improved neonatal outcomes and 
efficacy is limited.  Nifedipine is a widely chosen tocolytic due to a relatively good 
safety profile at tentative doses but full tocolytic effect cannot be elicited 
without inducing maternal hypotension.  The use of K+ channel openers in 
combination with Nifedipine in myometrium may be a way to enhance the effect 
of Nifedipine as a tocolytic by modulating membrane potential and preventing 
opening of VGCC (Figure 1.15b).  Most importantly, in order to avoid 
exacerbation of the associated side effect of hypotension K+ channels targeted 
should show preferential expression and function in myometrial tissue over 
vascular smooth muscle. Selective targeting of myometrial specific K+ channels 
by specific K+ channel openers, in combination with Nifedipine, could provide a 
useful clinical tocolytic therapy. The first part of this thesis includes experiments 
aimed at confirming this theoretical possibility by examining the effects of select 
K+ channel openers, and thus K+channel function; together with Nifedipine in 
human myometrium and myometrial small arteries. 
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1.12.2 K+ channel blockers as potential therapeutic target for PPH 
PPH also continues to be an obstetric problem that threatens morbidity and 
mortality of women globally. Current prevention and management strategies 
rely heavily on the use of Oxytocin, which in the case of uterine atony is not 
always effective often leading to a further cascade of mechanical and chemical 
rescue measures. Morbidity and mortality can heavily depend on maternal 
location and level of skill and resources available. A uterotonic that would 
provide reliable contractile force would be of great benefit. The K+ channel Kir 7.1 
was identified as being expressed in myometrial smooth muscle. Theoretically it 
is possible that this channel contributes to maintaining resting membrane 
potential (Figure 1.15c). The action of Kir 7.1 has not previously been studied in 
myometrium, but this is now possible due to the availability of the selective Kir 
7.1 blocker, VU590.  The second part of this thesis aims to examine the effects of 
VU590, and thus the function of Kir 7.1 in murine and human myometrium with a 
view to a therapeutic potential for PPH. 
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Figure 1.15a: Exogenous activators of contractile action (such as Oxytocin, PGF2α) 
provide exogenous activation of the G-protein coupled receptors (GPCR) on the 
cell membrane. Intracellular signalling of the alpha subunit Gαs activates 
phospholipase C (PLC) which cleaves the phospholipid phosphatidylinositol 4,5-
biphosphate (PIP2) into diacyl glycerol (DAG) and inositol 1, 4, 5-triphopshate 
(IP3). IP3 activates calcium channels located in the sacroplasmic reticulum (SR), to 
release Ca2+ from stores into the cytoplasm. This increases the internal voltage of 
the cell, depolarising the cell membrane, allowing voltage-activated gating of the 
L-type calcium channel and Ca2+ entry. [Ca2+]i binds to calmodulin and the Ca-
calmodulin complex binds to myosin light chain kinase and phosphorylates 
myosin light chains. This allows binding with actin and ATP dependent cross-
bridge cycling, leading to contraction of the smooth muscle cell. This continues as 
long as [Ca2+]i is available. 
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Figure 15.1b: Application the Ca2+ channel blocker Nifedipine provides an external 
block L-type voltage gated calcium channel (LVGCC), reducing Ca2+ influx via a 
chemical block. The hypothesis is that application of  K+ channel openers will 
allow K+ efflux from the myometrial smooth muscle cell, maintaining a polarised 
state within the cell which prevents internal voltage-activation of the LVGCC, 
further suppressing the ability of Ca2+ and thus reducing the ability of the cell to 
contract. Concerns about maternal side-effects limits the dose of Nifedipine that 
can be safely administered as a tocolytic in current obstetric practice. The 
addition of a K+ channel opener that targets a myometrial specific K+ channel, 
could increase the potency of the effect of Nifedipine. 
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Figure 15.1c: The compound VU590 has been shown to inhibit the inwardly 
rectifying K+ channel Kir 7.1 in other tissues but has not previously been studied in 
myometrium. The hypothesised effect of a chemical block of Kir 7.1 in myometrial 
smooth muscle cells will lead to an accumulation of [K+]i and sustained 
depolarisation. This will allow continued voltage-gated activation of the VGLCC 
and sustained Ca2+ entry, this enhancing the action potential and increasing 
contractility. 
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2.  Materials and Methods 
2.1 Contractility 
2.1.1 General laboratory reagents 
Krebs TES: NaCl 125.72 mM, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 10 mM, D+-glucose 10 mM, KCL 4.68 mM, NaHCO3 4.16 mM, sucrose 2.9 
mM, CaCl2 1.8 mM, MgCl2 0.5 mM, KH2PO4 0.44 mM, MgSO4 0.4 mM and K2HPO4 
0.34 mM, pH 7.4 
Krebs-Henseleit solution (KHS): NaCl 118 mM, NaHCO3 25 mM, KCL 4.8 mM, KH2PO4 
1.2 mM MgSO4 1.2 mM, glucose 11.1 mM and CaCl2 1.25 mM, pH 7.4 
 
2.1.2 Reagents and drugs 
Potassium channel openers, Dimethyl-sulphoxide (DMSO) and Nifedipine were 
obtained from Sigma Aldrich Chemical Co, MO, USA. Riluzole and Nifedipine were 
dissolved in DMSO, pinacidil in 0.1 M HCL and linoleic acid in 100% methanol and 
stored in aliquots at -20°C. Dosing concentrations were prepared by serial dilution 
from stock solution with fresh KHS immediately prior to addition to the organ bath 
(Table 2.1). 
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Riluzole DMSO  Pinacidil HCL 
(0.1M) 
 Linoleic 
Acid 
 Methanol  Nifedipine DMSO 
0.3 µM 0.0001%  0.3 µM 1 µM  3 µM 0.001%  3nM 0.003% 
1 µM 0.0003%  1 µM 3.3 µM  10 µM 0.003%  10nM 0.01% 
3 µM 0.001%  3 µM 10 µM  30 µM 0.01%  30nM 0.03% 
10 µM 0.003%  10 µM 33.3 µM  100 µM 0.03%  100nM 0.1% 
30 µM 0.01%  30 µM 0.1 µM  300 µM 1%    
 
Table 2.1: Table showing the doses of each drug used and their volume equivalent 
dilution in final concentration when added to 10 mls organ bath as vehicle controls. 
2.1.3 Isolation of tissue 
2.1.3.1 Mouse 
Experiments were carried out on whole tissue from day 15 (D15) and 18 (D18) B6 
CB F1 pregnant mice, killed by CO2 asphyxiation at the University of Warwick. The 
uterus was removed, stored in ice cold Krebs–Henseleit (KHS) solution and 
transported to the Clinical Sciences Research Laboratories where it was dissected 
within 4 hours. Strips of myometrium from the longitudinal layer (2 x 2 x 20 mm) 
were dissected and used for isometric force recording as per the following 
description (2.1.4 Measurement isometric tension). 
 
86 
 
2.1.3.2 Human 
Myometrial biopsies were obtained at elective caesarean section from women prior 
to the onset of labour.  Biopsies were taken from the lower edge of the upper part 
of the incision, placed in Krebs TES solution, stored at 4˚C and used within 24 hours. 
All participants were singleton pregnancies at term; defined as pregnancy at 37-41 
completed weeks (see Figure 2.1 & 2.2).  Local ethical committee approval was in 
place for the collection of myometrial biopsies and informed written consent was 
obtained from each participant (see appendix).  Women were eligible for elective 
caesarean surgery due to breech presentation, previous caesarean section, low-
lying placenta or unstable lie.  There was one participant with gestational diabetes 
and all others had no significant medical conditions. 
 
Figure 2.1: The distribution of gestation age of participants for dose response 
experiments. All participants were term; as defined by 37-41 completed weeks of 
pregnancy. The same biopsy was used for more than one experiment and so there is 
replication within the groups. 
0
1
2
3
4
5
6
7
8
9
10
11
12
R
ilu
zo
le
N
o
 p
re
tr
ea
t
3
 n
M
1
0
 n
M
3
0
 n
M
1
0
0
 n
M
P
in
ac
id
il
N
o
 p
re
tr
ea
t
3
 n
M
1
0
 n
M
3
0
 n
M
1
0
0
 n
M LA
N
o
 p
re
tr
ea
t
3
 n
M
1
0
 n
M
3
0
 n
M
1
0
0
 n
M
41 weeks
40 weeks
39 weeks
38 weeks
37 weeks
87 
 
 
 
Figure 2.2: The distribution of gestation age of participants for combined dose 
experiments. All participants were term; as defined by 37-41 completed weeks of 
pregnancy. The same biopsy was used for more than one experiment and so there is 
replication within the groups 
2.1.4 Measurement of isometric tension 
Strips of myometrium (approx 10 x 2 x 2 mm) were mounted in 10ml organ bath 
chambers containing KHS at 37˚C, perfused with 95% O2/5% CO2 to maintain pH 7.4, 
and under 2mN tension (LSI Letica automated organ bath, AD Instruments Ltd, 
Oxfordshire, UK) (Figure 2.3).  Isometric force was measured with ML TO201/D 
transducers and recorded digitally with PowerLab Chart software (AD Instruments 
Ltd, Oxfordshire, UK).  Strips that failed to contract spontaneously within a 120 
minute equilibration period were excluded. Approximately 1:10 strips would fail to 
contract. Baseline activity was recorded for 30 minutes before the addition of study 
drug.  For dose response experiments drugs were added in a cumulative manner at 
0
2
4
6
8
10
12
41 weeks
40 weeks
39 weeks
38 weeks
37 weeks
88 
 
20 minute intervals following addition of Nifedipine (3nM, 10nM, 30nM, 100nM) 
whereas in combined dosing contractile activity was recorded for 40 min following 
dosing.  Simultaneous recordings were made from vehicle-exposed strips taken 
from the same biopsy.  
 
 
 
 
 
 
Figure 2.3: Diagramatic representation of tissue strip mounted in organ bath 
 
2.1.5 Data analysis & Statistics 
Each contractile phase was recorded using LabChart software and the following 
parameters were measured to quantify the phase plot of each contraction (Figure 
2.4). 
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Figure 2.4: Parameters of each contraction phase plot used for analysis of 
contractility. A. Represents maximal force and duration, with activity integral 
representing the area under the curve. B. Represents frequency of contractions 
observed over a 20 min period. 
Means of these parameters for pre-dose contractions (over 20 minutes) and 
contractions following each dose (per 20 min period) were calculated for both 
treated and paired vehicle control strips.  
2.1.5.1 Dose response experiments: 
Percentage inhibition from pre-dose period was compared to control for each dose 
period.  Data was tested for normal distribution by Shapiro-Wilk normality test.  
Data did not fit a normal distribution and so the non-parametric Wilcoxon Signed 
rank test was selected for sample group comparison.  Activity integral data was 
fitted to dose response curves for calculation of IC50. 
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2.1.5.2 Combined dosing: 
Data was analysed as described above.  Percentage inhibition from pre-dose period 
was compared to control for each matched dose.  Data was tested for normal 
distribution by Shapiro-Wilk normality test.  All data did not fit a normal distribution 
and so the non parametric Wilcoxon Signed Rank test was selected for sample 
group comparison.  There appeared to be a time dependent effect of riluzole 
combined with Nifedipine and so data at doses with significant results was further 
analysed in 4 separate 10 min periods from dosing. As the desired clinical outcome 
would be an immediate cessation of contractions combined dosing data was also 
tested for binomial distribution. A sign test with cessation of contractions within 40 
minutes following dosing was considered a successful outcome verses continuation 
of contractions. 
 
2.2 Electrophoresis 
2.2.1 General Laboratory Reagents 
RIPA Lysis buffer: (10x) 0.5M Tris-HCl, pH 7.4, 1.5M NaCl, 2.5% deoxycholic acid, 
10% NP-40, 10mM EDTA (Millipore, MA USA) 
Complete, Mini, EDTA-free Protease Inhibitor Cocktail tablets: (Roche) 
Laemmli Sample Buffer: 62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 0.01% 
Bromophenol Blue  
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Bio-Rad DC Protein Assay Kit: used as per manufacturer's instructions(Bio-Rad CA, 
USA) 
Transfer buffer (1 litre): Glycine 2.93g, Tris 5.81g, SDS 0.375g, methanol 200 ml, 
ddH2O 800ml. Solution made in the lab. Powder ingredients from Sigma Aldrich 
10x Tris Buffered Saline (TBS): Tris HCL 24.2g (pH 7.6), NaCl 80g, ddH2O 1L Solution 
made in the lab 
Tris Buffered Solution-Tween (TBS-T): TBS x10 100 ml, ddH2O 900 ml, Tween-20  
1ml Solution made in the lab Tween-20 from Sigma Aldrich 
Blocking buffer: TBS-T 100 ml, Marvel 5g (5%) 
Primary antibody dilution buffer: TBS-T 20 ml, 1g Bovine Serum Albumin (BSA) (5%) 
 
2.2.2. Isolation of tissue and sample preparation 
Myometrial tissue samples were flash frozen in liquid nitrogen on retrieval from 
caesarean section and stored at -80 until use. Samples were selected that fell into 4 
equal groups, pre-term labour, pre-term non-labour, term labour and term non-
labour (Table 2.2). Samples were kept frozen, weighed and crushed. Tissue was 
suspended in RIPA lysis buffer (RIPA Lysis buffer (10x) 0.5M Tris-HCl, pH 7.4, 1.5M 
NaCl, 2.5% deoxycholic acid, 10% NP-40, 10mM EDTA, Millipore UK) containing 
protease inhibitor cocktail tablets (Complete, Mini, EDTA-free Protease Inhibitor 
Cocktail tablets, Roche) at a ratio of 3 mls per 1 g of tissue. Lysate was mechanically 
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homogenised and allowed to settle on ice, centrifuged at 12,000g for 15 mins at 
4°C. The supernatant was aliquoted and frozen and the pellet discarded. 
 
2.2.3 Protein quantification 
Lysate protein quantification was performed by creating a range of protein 
standards. These were quantified by using the colorimetric Bio-Rad DC protein 
assay kits as per manufacturer's instructions. 
2.2.4 Sample loading 
An initial set of experiments was undertaken using a range of µg/µl loading of 
samples prepared in either reducing or non-reducing buffer to optimise results. 
Following this the appropriate volume of each sample to achieve 20 µg loading was 
added to 35µl of Laemmli buffer. Some antibodies required ‘boiling’ prior to 
electrophoresis at 95˚C for 5 mins. Other proteins were found to aggregate at high 
temperatures and therefore did not separate during electrophoresis. For these 
experiments samples were incubated at 37oC for 30 mins prior to loading in the gels 
(Table 2.3). All samples were settled on ice following heating and centrifuged at 
13,000 rpm for 5 mins prior to loading. 
2.2.5 Protein separation by SDS-PAGE  
Novex© Tris-Glycine polyacrylamide gels from invitrogen were used in Invitrogen 
NuPage system tanks. Gels were run for 90-120 mins at 125V (constant) with 
Novex© Tris-glycine SDS running buffer (Novex©). Protein migration and transfer 
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was monitored with the use of Spectra Multicolor broad range protein ladder 
(Thermo Scientific, MA, USA).  
Proteins were transferred onto Amersham ECL nitrocellulose membrane using Bio-
Rad Trans Blot SD semi-dry blotting system. Transfer was achieved at 100mV for 50 
mins. Successful transfer was assessed by staining using Poncaeu S and once 
visualised washed with 0.1nM NaOH prior to blocking. 
Blocking of non-specific binding was achieved by washing in TBS-T blocking buffer 
solution for minimum of 4 hours at room temperature or overnight at 4°C. 
Following blocking, membranes were washed in TBS-T 3 times at 5 mins each wash 
prior to incubation with primary antibody. 
2.2.6 Primary, Secondary antibodies and loading control 
Incubation with primary antibody was at the appropriate dilution (Tables 2.3 & 2.4) 
in primary antibody dilution buffer for minimum of 2 hours at room temperature or 
overnight at 4˚C. Membranes were then washed 3 times for 5 mins each wash prior 
to incubation with secondary antibodies. Secondary antibody used was Dako 
polyclonal goat anti-rabbit HRP antibody at a dilution of 1:500 and was incubated in 
TBS-T blocking buffer for 1 hour. Membranes were washed for 1 hour (10min, 20 
min, 30 min wash) prior to electro-chemiluminescence. 
Following electro-chemiluminescence membranes were washed in TBS-T overnight 
at 4°C. They were then exposed to anti-β actin antibody at a dilution of 1:50,000 for 
1 hour before being washed in TBT-T 3 times for 5 mins each wash and then 
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incubated in anti- mouse secondary antibody for 30 mins, washed in TBS-T for 1 
hour before electrochemiluminescence.  
 
2.2.7 Electrochemiluminescence detection 
Membranes were incubated for 5 mins in SuperSignal West Pico Substrate (Thermo 
Scientific, MA, USA) for detection of horseradish peroxidase (HRP). Membranes 
were then exposed to Kodak medical x-ray film (general purpose, blue) until bands 
were visible. Size approximation was made on films from ladder visible on the 
membrane. 
 
2.2.8 Data analysis and statistics 
Film images were scanned and band density was measured using Image J software 
and the analyze gels function for measurement of density of bands in individual 
lanes. The density of each lane is plotted and area under the curve measured. Ratio 
of value of band from antibody of interest was calculated against β-actin band 
value. Ratios from each sample group were statistically compared using ANOVA for 
significant difference. 
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Group R number Gest age Indication for LSCS 
PTL R448 35 EMLSCS for premature labour in Twins 
PTL R385 35+3 EMLSCS previous LSCS plus Group B Strep infection 
PTL R611 35+3 EMLSCS Antepartum Haemorrhage  
PTL R525 35 EMLSCS failed induction for IUGR 
PTL R494 36+3 EMLSCS for Pre-eclampsia 
PTL R940 34 EMLSCS for fetal distress 
    PTNL R456 35 EMLSCS for  Pre-eclampsia  (2x prev LSCS) 
PTNL R1010 34 ELLSCS for Twins plus hypertension 
PTNL R766 33+6 EMLSCS for IUGR (1 x prev LSCS) 
PTNL R529 29 EMLSCS for Antepartum Haemorrhage 
PTNL R582 34 EMLSCS for maternal hypertension 
PTNL R898 29 EMLSCS for  Antepartum Haemorrhage 
    TL R829 40+1 EMLSCS failure to progress in 1st stage 
TL R1032 40 EMLSCS  failure to progress in 1st stage 
TL R814 39 EMLSCS  failure to progress in 1st stage 
TL R858 40 EMLSCS  failure to progress in 1st stage 
TL R886 40+3 EMLSCS sub optimal CTG plus poor blood gases 
TL R1017 40 
EMLSCS failure to progress in 1st stage plus fetal 
distress 
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Table 2.2: Characteristics of frozen samples used in western blotting protocol. Split 
into groups of interest – Pre-Term Labour (PTL), Pre-Term non-Labour (PTNL), Term 
Labour (TL), Term non-Labour (TNL). 
 
 
 
 
 
 
 
Table 2.3: preparation of samples, dilutions and gels used for each antibody plus 
expected kDa of proteins in western blotting protocol. 
 
TNL R971 41 ELLSCS breech presentation 
TNL R999 39 ELLSCS 1x previous LSCS 
TNL R981 39 ELLSCS breech 
TNL R1013 39 ELLSCS maternal cerebral palsy 
TNL R990 39+5 ELLSCS breech 
TNL R1302 39 ELLSCS 1 x previous LSCS 
Antibody dilution kDa of 
protein 
Sample 
preparation 
Gel 
Anti - Kv 2.1 1:200 96  37°C for 30 
mins 
8% gel 
Anti - Kir 7.1 1:200 55 95°C for 5 mins 8% gel 
Anti – SK 3 1:500 75 37°C for 30 
mins  
8% gel 
Anti – Trek 1 1:250 55 95°C for 5 mins 8% gel 
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Table 2.4: Details of antibodies used in western blotting protocol 
2.5 Wire myography 
Experiments on myometrial small arteries were performed at the Institute of 
Cellular Medicine’ department of Reproductive and Vascular Research at Newcastle 
University under the supervision of Professor Mike Taggart and Dr Michele Sweeney. 
2.5.1 General Laboratory Reagents 
Physiological salt solution (PSS): NaCl 127 mM, KCl 4.7 mM, MgSO4.7H2O 2.4 
mM,NaHCO2 25 mM, KH2PO4 1.18 mM, EDTA 0.07 mM, Glucose 6.05 mM, 
CaCl2.2H2O 1.6 at pH 7.4 gassed with 5% CO2 in air 
Antibody Raised in  gene Binding site Sourced 
from 
Anti - Kv 2.1 Rabbit 
polyclonal 
KCNB1 Amino acid residues 
755-804 
Abcam PLC 
Anti K2P2.1 
(TREK-1) 
Rabbit 
polyclonal 
KCNK2 Amino acid residues 8 
-25 
Alomone 
Labs UK 
Anti – KCa2.3 
(SK3) 
Rabbit 
polyclonal 
KCNN3 Amino acid residues 2 
-21 
Alomone 
Labs UK 
Anti- Kir 7.1 Rabbit 
polyclonal 
KCNJ13 Amino acid residues 
80-94 (rat, 13/15 
residues identical in 
human) 
Alomone 
Labs UK 
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Physiological Salt solution – high potassium (KPSS): PSS plus 60mM KCL 
2.5.2 Isolation of tissue 
Myometrial biopsies were obtained with consent from women undergoing elective 
cesarean section at term (39-41 weeks gestation) and stored in ice-cold KHS. Small 
diameter arterial branches (<300 µM) were dissected from the surrounding 
connective tissue from the whole biopsy and placed in ice cold PSS. Artery branches 
were trimmed to approx. 2-3mm in length as measured using a calibrated eyepiece 
micrometer ahead of mounting. 
Dissected arterial segments were threaded with 40μm wire as shown in Figure 2.5, 
and mounted in the M610-wire myograph (Danish Myotech, Aarhus, Denmark), one 
side attached to a force transducer and the other to a movable micrometer. Vessels 
were submerged in 6 mls of PSS pre-warmed to 37˚C and gassed with 5% CO2 in air.  
 
 
  
   
  
Figure 2.5: Small artery mounted within force transducer mechanism. Figure 
adapted from: Mulvany AND Aalkjkeir (1990) Structure and Function of Small 
Arteries The American Physiological Society Vol. 70, No. 4 
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2.5.3 Normalisation and measurement 
Following the mounting procedure vessels were left to equilibrate for 10 mins. 
Vessels were then partially stretched by widening the wires and allowed to 
equilibrate again for a few minutes. This stretching and equilibrium cycle was 
repeated for approx. 6-7 stretches until the vessels reached beyond a passive 
tension of approx. 13.3 kPa. Measurement and normalisation software (Myodata, 
Danish Myotech) calculated internal vessel diameter and wire tension was adjusted 
accordingly to create a passive tension of equivalent of 100mmHg/13.3kPa for each 
vessel. 
Following normalisation and equilibrium, vessels were assessed for tissue sample 
viability and constricted to maximal vessel tone using KPSS. A washout period of 30 
minutes allowed full return to resting tension. A thromboxane mimetic and known 
vessel constrictor U46619 (1 µM) was added for a baseline contractile response. 
Following a further washout period and resumption to baseline equilibrium, the 
experimental protocol was commenced. Drugs were added either alone or in 
combination with some vessels exposed to vehicle only to act as controls. Any 
change to baseline tension was noted over a 30 minute incubation period before 
re-exposure to U46619 (1 µM). Further washout periods were commenced at the 
end of drug exposure completed by a final exposure to U46619 (1 µM) for each 
vessel. 
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2.5.4 Data analysis and statistics 
Changes in maximal tension achieved by U46619 (1 µM) from pre, during and and 
post drug incubation exposure was measured using the Myodaq software (Version 
2.02 M Danish Myotech). This was expressed as a ratio of the maximal tension 
achieved under pre-experiment exposure to U46619 (1 µM). Difference in kPa 
achieved was calculated using vessel diameter and difference of contraction 
achieved (maximal contraction – baseline tone). 
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3. Results 
3.1 The effects of potassium channel openers on myometrial contractility 
3.1.1 Clinical relevance & background 
Calcium influx is essential for propagation of an action potential and also allows, 
via calmodulin, the interaction between actin and myosin that brings about 
contraction of the myocyte (Word et al, 1993).  This mechanism of action is 
mirrored in vascular smooth muscle with myogenic tone being attenuated in 
calcium free media and increased with additional extracellular calcium (Davis & 
Hill, 1999).  The resting potential for vascular smooth muscle ranges from -60 to -
75 in unpressurised arteries and arterioles with a graded depolarization as 
pressure increases (Davis & Hill, 1999).  This mechano-sensitive response is 
crucial for systemic blood pressure control.  The L-type calcium channels are 
voltage gated (VGLCC) and as such open in response to de-polarisation of the 
membrane potential allowing calcium entry and further de-polarising of the 
smooth muscle cell.  The activation threshold for the VGLCC is between -50 to -
60 mV (Davis & Hill, 1999).  In pregnancy the uterus is quiescent with resting 
potential of between -75 to -60 mV (Parkington et al, 1999).   As contractile 
associated proteins increase there is a shift in balance towards excitability with 
resting potential reaching -55 mV (Parkington et al, 1999). In blocking calcium 
entry via the VGLCC, the dihydropyridine Nifedipine impedes contractility in both 
vascular smooth muscle and myometrium. It is this that leads to the unwanted 
side effect of hypotension when Nifedipine is used as a tocolytic and makes the 
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optimal therapeutic dose required to abolish contractions impossible to 
administer (further detail found in introduction).  
Work carried out within our group, using laser capture micro-dissection, and PCR 
analysis has measured the expression of specific ion channels in myometrium in 
comparison to their expression in vascular smooth muscle.  Channels identified 
as of interest were potassium channels, which demonstrated higher expression 
in myometrium over vascular smooth muscle.  Potassium channels when open 
allow K+ efflux resulting in membrane repolarisation.   With the combined effect 
of less Ca2+ entry and increased K+ efflux, membrane potential should be 
‘dampened’ reducing the probability of the generation of action potentials and 
contractile activity (Figure 3.1.1). 
Our hypothesis was thereby developed that improving the potency of Nifedipine 
in the myometrium, but not vasculature, could be achieved by modulation of 
membrane potential via myometrial specific K+ channels.  K+ channels identified 
in the work detailed above that had known openers available were selected as 
targets for investigation.  Drugs chosen were Riluzole, a known activator of SK3, 
TREK-1 and an inhibitor of voltage gated Na+ channels; and linoleic acid, a known 
activator of KV2.1. Pinacidil a known activator of KATP channels has been shown to 
reduce myometrial contractility and is used as a clinical anti-hypertensive. In 
offering no selectivity between myometrium and vasculature, Pinacidil was 
expected to act as a positive control for the other compounds. 
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Figure 3.1.1: Diagram shows ion channels involved in modulation of membrane 
potential. Nifedipine blocks calcium entry through voltage gated calcium 
channels and potassium channel openers increase K+ efflux resulting in 
repolarisation of membrane potential. Modulating membrane potential in this 
way should reduce the probability of the formation of action potentials and 
contractile activity (diagram drawn by Henggui Zhang). 
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3.1.2 Aims 
3.1.2.1 Dose response experiments: 
The first aim was to establish the dose response effect of the selected potassium 
channel openers on myometrial contractility. Following this, the same dose 
response was applied to strips pre-treated with a range of concentration of 
Nifedipine. Percentage inhibition from pre-dose period was compared to control 
for each dose period.  Data was tested for normal distribution by Shapiro-Wilk 
normality test.  Data did not fit a normal distribution and so the non-parametric 
Wilcoxon Signed rank test was selected for sample group comparison.  Activity 
integral data was fitted to dose response curves to determine the IC50. 
3.1.2.2 Combined dosing: 
In an extension to this investigation a combined dose protocol was added. It was 
envisaged that a dual dose regimen would be used in clinical application and so 
dual dosing was performed in the organ bath. Data was analysed as described 
above.  Percentage inhibition from pre-dose period was compared to control for 
each matched dose.  Data was tested for normal distribution by Shapiro-Wilk 
normality test.  All data did not fit a normal distribution and so the non 
parametric Wilcoxon Signed Rank test was selected for sample group 
comparison.  There appeared to be a time dependent effect of Riluzole 
combined with Nifedipine and so data at doses with significant results was 
further analysed in 4 separate 10 min periods from dosing. As the desired clinical 
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outcome would be an immediate cessation of contractions following combined 
dosing, data was also tested for binomial distribution and sign test with cessation 
of contractions within 40 minutes following dosing considered a successful 
outcome verses continuation of contractions. 
 
3.1.3 Objective: 
i) To determine the effect of selective K+ channel openers, linoleic acid, Pinacidil 
and Riluzole, on the contractility of spontaneously contracting myometrial strips. 
ii) To determine the effect of selective K+ channel openers, linoleic acid, Pinacidil 
and Riluzole on the contractility of spontaneously contracting myometrial strips 
following pre-treatment with Nifedipine.  
 
3.1.4 Results   
3.1.4.1 Results - The effect of linoleic acid on myometrial contractility 
Linoleic acid showed no significant effect on any of the measured parameters 
either alone or when combined with Nifedipine (Figure 3.1.2). 
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Figure 3.1.2: Linoleic acid: Graphs showing mean inhibition of activity integral ± 
SEM when (A) Linoleic acid added to spontaneously contracting strips either not 
pre-treated (n=10) or treated with Nifedipine (3 nM (n=12), 10 nM (n=11), 30 nM 
(n=9), 100 nM (n=8)); or (B) vehicle control equivalent. There was no significant 
difference in inhibition between Linoleic Acid and vehicle control. 
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3.1.4.2 Results – The effect of Pinacidil on myometrial contractility 
Pinacidil reduced activity integral when added to spontaneously contracting 
strips alone at 3 µM (P=0.003) , 10 µM (P=0.0019) and 30 µM (P=0.0019) (Figure 
3.1.3) (IC50 1.85(± 0.03) µM) (Table 2). When pre-treated with 3 nM Nifedipine 
activity integral was also reduced at 3 µM (P=0.007), 10 µM (P=0.015) and 30 µM 
(P=0.015) (IC50 1.49(± 0.04) µM) (Table 3.1).  When pre-treated with 10 nM 
Nifedipine activity integral was reduced at 3 µM (P=0.005), 10 µM (P=0.0019) 
and 30 µM (P=0.003) (IC50 0.52(± 0.12) µM) (Table 3.1).  Pinacidil either alone or 
combined with 3 nM or 10 nM Nifedipine had similarly significant reduction in 
maximal force, contraction duration and frequency (Figures 3.1.3, 3.1.4, 3.1.5, 
3.1.6, 3.1.7, 3.1.8, 3.1.9, 3.1.10).  The lack of significant results in strips pre-
treated with 30 nM Nifedipine or higher reflects the inhibitory effect of 
Nifedipine at these doses, which exceeds any discernible effect of Pinacidil over 
control strips. The time dependent effect of Nifedipine seen in the reduction in 
contractility in control strips may also explain the lessening power of significant 
results at higher combined doses. 
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Figure 3.1.3:  Mean inhibition of activity integral ± SEM when Pinacidil (0.3, 1, 3, 
10 and 30 μM) added to spontaneously contracting strips either alone (n=11) or 
pre-treated with Nifedipine (3 nM (n=10), 10 nM (n=10), 30 nM (n=10), 100 nM 
(n=10)) . Activity integral is completely abolished at Pinacidil 10 μM alone. 
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Figure 3.1.4: Significant inhibition of activity integral as seen when compared to 
vehicle control equivalent in (A) Pinacidil alone (A: 3 µM P=0.003, B: 10 µM 
P=0.0019, C: 30 µM P=0.0019 n=11)  (B) Nifedipine 3 nM + Pinacidil (A: 3 µM 
P=0.007, B: 10 µM P=0.015, C: 30 µM P=0.015 n=10) and (C) Nifedipine 10 nM + 
Pinacidil (A: 3 µM P=0.005, B: 10 µM P=0.0019, C: 30 µM P=0.003 n= 10). 
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Figure 3.1.5: Mean inhibition of maximal force ± SEM after addition of Pinacidil 
(0.3, 1, 3, 10 and 30 μM) to spontaneously contracting strips either alone (n=11) 
or pre-treated with Nifedipine (3 nM (n=10), 10 nM (n=10), 30 nM (n=10), 100 
nM (n=10)). Maximal Force is completely abolished at Pinacidil 10 μM alone. 
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Figure 3.1.6: Significant inhibition of maximal force as seen when compared to 
vehicle control equivalent in (A) Pinacidil alone (A: 3 µM P=0.0009, B: 10 µM 
P=0.0009, C: 30 µM P=0.0009 n=11)  (B) Nifedipine 3 nM + Pinacidil (A: 10 µM 
P=0.015, B: 30 µM P=0.015 n=10) and (C) Nifedipine 10 nM + Pinacidil (A: 3 µM 
P=0.013, B: 10 µM P=0.0019, C: 30 µM P=0.003 n= 10). 
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Figure 3.1.7: Mean inhibition of contraction duration ± SEM when Pinacidil (0.3, 
1, 3, 10 and 30 μM) added to spontaneously contracting strips either alone (n=11) 
or pre-treated with Nifedipine (3 nM (n=10), 10 nM (n=10), 30 nM (n=10), 100 
nM (n=10)). Contraction duration is at zero by Pinacidil 30 μM alone 
 
 
 
 
 
0.01 0.1 1 10
0.0
0.2
0.4
0.6
0.8
1.0
D
u
ra
ti
o
n
 (
m
e
a
n
 
 S
E
M
)
[log Pinacidil] (M)
 No pretreat
 3nM nifedipine
 10nM nifedipine
 30nM nifedipine
 100nM nifedipine
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.8: Significant inhibition of contraction duration as seen when 
compared to vehicle control equivalent in (A) Pinacidil alone (A: 10 µM P=0.0019, 
B: 30 µM P=0.0019 n=11)  (B) Nifedipine 3 nM + Pinacidil (A: 10 µM P=0.015, 
n=10) and (C) Nifedipine 10 nM + Pinacidil (A: 30 µM P=0.003 n= 10). 
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Figure 3.1.9: Mean inhibition of contraction frequency ± SEM when Pinacidil (0.3, 
1, 3, 10 and 30 μM) added to spontaneously contracting strips either alone (n=11) 
or pre-treated with Nifedipine (3 nM (n=10), 10 nM (n=10), 30 nM (n=10), 100 
nM (n=10)). Contraction frequency is at zero by Pinacidil 30 μM alone. 
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Figure 3.1.10: Significant inhibition of contraction frequency when compared to 
vehicle control equivalent in (A) Pinacidil alone (A: 3 µM P=0.03, B: 10 µM 
P=0.0019, C: 30 µM P=0.03 n=11)  (B) Nifedipine 3 nM + Pinacidil (A: 10 µM 
P=0.006, B: 30 µM P=0.015 n=10) and (C) Nifedipine 10 nM + Pinacidil (A: 3 µM 
P=0.03, B: 10 µM P=0.0015, C: 30 µM P=0.03 n= 10) and (D) Nifedipine 30 nM + 
Pinacidil (A: 10 µM P=0.015 n=10). 
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Table 3.1: IC50 for Pinacidil either alone (n=11) or with Nifedipine pre-treatment 
based on activity integral data (3 nM (n=10), 10 nM (n=10)). IC50s not calculated 
for higher doses of Nifedipine pre-treatment due to lack of significant results in 
these series. 
 
 
 IC50 ±SEM 
No pre-
treatment 
1.85 0.03 
Nifedipine 3 nM 1.49 0.04 
Nifedipine 10 nM 0.52 0.12 
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3.1.4.3 Results – The effect of Riluzole on myometrial contractility 
Riluzole significantly reduced activity integral and maximal force of contraction 
at 30 µM (P= 0.0078) when administered alone (Figure 3.1.11) (IC50 26.4 (± 0.06) 
µM) (Table 3.2). When combined with Nifedipine 3 nM activity integral was 
reduced at 3 µM (P=0.04) (Figure 3.1.12) (IC50 5.4 (± 0.04) µM) (Table 3.2) and 
maximal force reduced at 10 µM (P=0.041) and 30 µM (P=0.006) (Figure 
3.1.13,3.1.14).  There was an increased duration at 10 µM when pre-treated with 
Nifedipine 30 nM (P=0.0019) (Figure 3.1.15, 3.1.16).  On further investigation, it 
was observed that the phase plot shape of contraction had altered at this dose 
(Figure 3.1.17).  The duration of the upstroke of contraction was increased at this 
dose (Figure 3.1.17) illustrating that the increased duration is due to a slower 
climb to maximal force.  A similar change was evident in strips pre-treated with 
other doses of Nifedipine however analysis did not yield significant results in 
other strips.  This may be down to variance of sample group response, 
particularly at higher doses where contractions were small and short by duration 
bringing down duration average.  The lack of effect on frequency reflects the 
small short contractions that persisted at higher doses.  Again, as with Pinacidil 
experiments, the lack of significant results in strips pre-treated with 30 nM 
Nifedipine or higher reflects the inhibitory effect of Nifedipine at these doses 
being equal to control. 
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Figure 3.1.11: Mean inhibition of activity integral ± SEM when Riluzole (0.3, 1, 3, 
10 and 30 μM) added to spontaneously contracting strips either alone (n=9) or 
pre-treated with Nifedipine (3 nM (n=12), 10 nM (n=10), 30 nM (n=9), 100 nM 
n=10)). Activity integral was never completely abolished by Riluzole alone. 
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Figure 3.1.12: Significant inhibition of activity integral compared to vehicle 
control equivalent in (A) Riluzole alone (A: 30 µM P=0.0078 n=9) and (B) 
Nifedipine 3 nM + Riluzole (A: 30 µM P=0.04 n=12). 
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Figure 3.1.13: Mean inhibition of maximal force ± SEM when Riluzole (0.3, 1, 3, 
10 and 30 μM) added to spontaneously contracting strips either alone (n=9) or 
pre-treated with Nifedipine (3 nM (n=12), 10 nM (n=10), 30 nM (n=9), 100 nM 
n=10)). Maximal force was never completely abolished by Riluzole alone. 
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Figure 3.1.14 Significant inhibition of maximal force when compared to vehicle 
control equivalent in (A) Riluzole alone (A: 30 µM P=0.007 n=9), and (B) 
Nifedipine 3 nM + Riluzole (A: 10 µM P=0.04 n=10, and B: 30 µM P=0.006 n=12) 
0.01 0.1 1 10
0.0
0.2
0.4
0.6
0.8
1.0
M
a
x
im
a
l 
F
o
rc
e
 (
m
e
a
n
 
 S
E
M
)
[log Riluzole] (M)
 Riluzole
 DMSO
0.01 0.1 1 10
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
M
a
x
im
a
l 
F
o
rc
e
 (
m
e
a
n
 
 S
E
M
)
[log Riluzole] (M)
 Nifedipine 3 nM + Riluzole
 Nifedipine 3 nM + DMSO
 
A
B 
B 
122 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.15: Mean inhibition of contraction duration ± SEM when Riluzole (0.3, 
1, 3, 10 and 30 μM) added to spontaneously contracting strips either alone (n=9) 
or pre-treated with Nifedipine (3 nM (n=12), 10 nM (n=10), 30 nM (n=9), 100 nM 
n=10)). 
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Figure 3.1.16: Significant increase in contraction duration in strips pre-treated 
with (A) Nifedipine 30 nM + Riluzole (A: 10 µM P=0.0019 n=9). Mean inhibition of 
contraction duration upstroke in (B) Riluzole ± SEM when compared with vehicle 
strip and Pinacidil at same dose (A: 10 µM P<0.05 n=11). 
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Figure 3.1.17: Phase plots showing (A) a typical ‘plateau’ shape contraction seen 
in spontaneous contractions and (B) a ‘spike’ shape contraction seen following 
treatment with Riluzole with interrupted upstroke phase leading to longer 
contraction duration. 
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Figure 3.1.18:  Mean inhibition of frequency of contractions ± SEM when (A) 
Riluzole added to spontaneously contracting strips either alone (n=10) or pre-
treated with Nifedipine (3 nM (n=12), 10 nM (n=10), 30 nM (n=9), 100 nM (n= 
10)). Significant inhibition when Riluzole compared to vehicle control equivalent 
(B). There was no significant change in frequency at any other doses and the 
significant result shown (10 µM P=0.04 n=10) may be due to uncharacteristic rise 
in frequency in control data. 
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Table 3.2:  IC50 for Riluzole either alone (n=9) or with Nifedipine pre-treatment (3 
nM n=12) based on activity integral data. IC50s not calculated for higher doses of 
Nifedipine pre-treatment due to lack of significant results in these series. 
 
 
 
 
 
 IC50 ±SEM 
No pre-treatment 26.4 0.06 
Nifedipine 3 nM 5.4 0.04 
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3.2 The effects of combined dose of Nifedipine with potassium channel 
openers on myometrial contractility 
3.2.1 Clinical relevance and background 
Following results from previous experimental series where Nifedipine was used 
as pre-treatment and cumulative doses of compounds added, further 
contractility work was undertaken to assess the impact on spontaneous 
contractions of a combination of Riluzole + Nifedipine and Pinacidil + Nifedipine 
when administered simultaneously.  Due to the lack of effect shown with linoliec 
acid, it was omitted from further work.  Larger doses of Nifedipine appeared to 
mask any combinatory effect in previous work and so combined doses of 
Nifedipine was limited to 3 nM and 10nM.  A higher dose of Riluzole was added 
in this series as complete inhibition was not previously achieved at 30 µM. In 
order observe if the response Riluzole is mediated in the presence of 
physiologically occurring stimulators of contraction, combined doses were 
undertaken along with Oxytocin (1nM) and PGF2α (10 µM). The dose of 1 nM of 
Oxytocin was selected as this has previously been shown to be the EC50 of 
Oxytocin and this dose has been used previously in our laboratories with 
sufficient effect on contractility to increase tone and prolong the phase-plot 
(Åkerlund et al 1999, Gullam et al 2009). The increase in activity integral of 150% 
of control produced here is similar to that seen by other published work at the 
same dose, although variation was noted between the response of term tissue 
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and preterm so sample gestation/time to onset of labour variation may influence  
the response (Åkerlund et al 1999, Gullam et al 2009). 
Similarly, PGF2α 10 µM, has been shown to produce enhanced activity integral 
ranging from 125% to 259% in other publications with variation seen between 
term, non-labouring and early or late stage labouring tissue at the same doses 
(Fischer et al 2008, Friel et al 2015). 
 
3.2.2 Objective: 
I. To determine the effect of selective K+ channel openers, Pinacidil and 
Riluzole on the contractility of spontaneously contracting myometrial 
strips when administered simultaneously with 3 nM or 10 nM of 
Nifedipine. 
II. To determine the effect of Riluzole alone and in combination with 
Nifedipine in the presence of Oxytocin and PGF2α. 
3.2.3 Results 
3.2.3.1 Nifedipine combined with Pinacidil 
When Nifedipine 3 nM and 10 nM were combined with Pinacidil, contractions 
were frequently abolished from 3 µM dose and above.  Simultaneous dosing of 
Pinacidil + Nifedipine at all dose intervals resulted in either complete inhibition 
or continuation of contractions. Strips that continued to contract did so with no 
significant difference from control (Figure 3.2.1, 3.2.2). As the combined dosage 
of both compounds increased strips were more likely to discontinue contracting 
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altogether and all strips were inhibited by Pinacidil 30 µM combined with 
Nifedipine at 3 nM or 10 nM. Binomial sign test was applied to predict at what 
dose strips were significantly likely to have ceased 40 mins following 
administration of the dose (Figure 3.2.3). Strips were significantly likely to cease 
at a dose of, Nifedipine 10 nM + Pinacidil 3 µM (87% P < 0.05), 10 µM Pinacidil 
alone (80% P <0.05), Nifedipine 10 nM + Pinacidil 10 µM (87% P < 0.05), Pinacidil 
30 µM alone (100% P < 0.001), Nifedipine 3 nM  + Pinacidil 30 µM (100% P < 
0.01) and Nifedipine 10 nM  + Pinacidil 30 µM (100% P < 0.001). Combined doses 
administered simultaneously brought about complete inhibition in a greater 
percentage of strips at doses of Pinacidil 0.3 µM – 3 µM than when strips were 
pre-treated with Nifedipine in the same combinations although there was no 
significance with binomial sign test most likely due to insufficient n numbers to 
power the test (Figure 3.2.3). Strips pre-treated with Nifedipine at either 3 nM or 
10 nM with Pinacidil added at 10 µM from the experimental series presented in 
section 3.1.3.2 were significantly likely to result in complete inhibition (100% P < 
0.01) whereas this was not the case for the same dose combination in 
simultaneous dosing (Figure 3.2.4). 
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Figure 3.2.1: Inhibition of contraction activity integral (A), maximal force (B), 
contraction duration (D) and frequency (D) with the dual administration of 
Nifedipine 3 nM combined with either Pinacidil (0.3 µM (n=6/10), 1 µM (n=6/10), 
3 µM (n=3/10), 10 µM (n=2/8), 30 µM n=0/8) or control. All contractions were 
abolished at the Nifedipine 3nM + Pinacidil 30 µM dose hence no data shown. 
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Figure 3.2.2: Inhibition of contraction activity integral (A), maximal force (B), 
contraction duration (D) and frequency (D) with the dual administration of 
Nifedipine 10 nM combined with either Pinacidil (0.3 µM (n=3/10), 1 µM 
(n=4/10), 3 µM (n=1/8), 10 µM (n=1/8), 30 µM n=0/11) or control. All 
contractions were abolished at the Nifedipine 10 nM + Pinacidil 30 µM dose 
hence no data shown. 
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Figure 3.2.3: Graph showing the % of strips in each series that ceased to contract 
on addition of drug combinations. (A: Nifedipine 10 nM + Pinacidil 3 μM 87% 
P<0.05 n=8, B: Pinacidil 10 μM 80% P<0.05 n=10, C: Nifedipine 10 nM + Pinacidil 
10 μM 87% P, 0.05 n=8, D: Pinacidil 30 μM 100% <0.001 n=10, E: Nifedipine 3 nM 
+ Pinacidil 30 μM 100% <0.001 n=8, F: Nifedipine 10 nM + Pinacidil 30 μM 100% 
P<0.001 n=11) Statistical significance of likelihood to cease was calculated using 
binomial sign test. 
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Figure 3.2.4: Graph showing the % of strips in each series that ceased to contract 
on addition of either simultaneously added drug combinations (grey) or where 
strips were pre-treated with (A) Nifedipine at 3 nM (A, B, C P,0.05) or (B) 
Nifedipine 10 nM (A, B: P<0.05, C: P< 0.01 D: P< 0.001, E: P<0.01) prior to the 
addition of Pinacidil (red). Statistical significance of likelihood to cease was 
calculated using binomial sign test. 
 
B 
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3.2.3.2 Nifedipine combined with Riluzole 
 
Data was initially analysed by averaging parameters over 40 min dosing period.  
When combined with 3 nM of Nifedipine, Riluzole reduced the maximal force of 
contraction at 3 µM, the maximal force, activity integral and contraction 
duration at 30 µM and the maximal force and activity integral at 100 µM.  There 
was no effect on frequency at any dose.  When combined with 10 nM Nifedipine  
Riluzole reduced the maximal force, activity integral and contraction duration at 
100 µM only (Figure 3.2.5 & 3.2.6).  When data from doses showing significant 
results was analysed in 4 separate 10 min periods from dosing the observed time 
dependent effect was confirmed. Significant results were seen when compared 
to control data at the same time interval following dosing (Figure 3.2.7 & 3.2.8).  
There is a more potent effect apparent when Nifedipine of either dose was 
combined with Riluzole 100 µM compared to Riluzole 30 µM. 
When the shape of the phase plot is examined, the maximal force is reduced, 
contraction duration increased and time from baseline to maximal force or the 
upstroke period is increased (Figure 3.2.9). The activity integral will be of similar 
value explaining the lesser significance of reduction of activity integral seen 
compared reduction in maximal force (Figure 3.2.10). 
The pattern seen with Pinacidil, where contractions were fully inhibited at 
certain combined doses was not seen in Riluzole with no combination likely to 
bring about total inhibition (Figure 3.2.11).  
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Figure 3.2.5: Mean inhibition of (A) activity integral (A: 30 µM P=0.03 n=11), (B) 
maximal force (A: 3 µM P= 0.007 n=9, B: 30 µM P=0.02 n=11, C: 100 µM n=0.03 
n=6) (C) contraction duration (A: 30 µM P=0.004 n=11) and (D) frequency ± SEM 
when Riluzole added to spontaneously contracting strips in combination with 3 
nM Nifedipine. 
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Figure 3.2.6: Mean (± SEM) inhibition of (A) activity integral (100 µM P=0.007 
n=10), (B) maximal force (A: 100 µM P=0.007 n=10), (C) contraction duration (A: 
100 µM P=0.015 n=10) and (D) frequency when Riluzole added to spontaneously 
contracting strips in combination with 10 nM Nifedipine. 
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Figure 3.2.7: Mean (± SEM) inhibition of spontaneously contracting strips: (A) 
activity integral following addition of Nifedipine 3 nM + Riluzole 30 µM (A: 20-30 
mins P=0.05 n11, B: 30-40 mins P=0.06 n=11), (B) maximal force following 
addition Nifedipine 3 nM  + Riluzole 30 µM (A:20-30 mins P=0.04 n=11 & B: 30-40 
mins P=0.02 n=11)  (C) activity integral flowing addition of Nifedipine 10 nM + 
Riluzole 30 µM, (D) maximal force following addition Nifedipine 10 nM  + Riluzole 
30 µM (A: 20-30 mins P=0.03 n=11) 
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Figure 3.2.8: Mean (± SEM) inhibition of (A) activity integral when Nifedipine 3 
nM added in combination with Riluzole 100 µM (A: 10-20 mins P=0.03 n=6), and 
(B) maximal force (A: 10-20 mins P=0.03 n=6 & B: 30-40 mins P=0.03 n=6), (C) 
activity integral when Nifedipine 10 nM added in combination with Riluzole 100 
µM (A: 0-10 mins P=0.007, B: 10-20 mins P=0.03, C: 20-30 mins P=0.007, D:30-40 
mins P=0.007 n=6), and (D) maximal force (A: 0-10 mins P=0.007, B: 10-20 mins 
P=0.007, C: 20-30 mins P=0.007, D: 30-40 mins P=0.007 n=6) 
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Figure 3.2.9: Mean (± SEM) inhibition of contraction upstroke in (A) Nifedipine 3 
nM added in combination with Riluzole 30 µM (A: 0-10 mins & B: 30-40 mins 
P=0.02 n=11), and (B) Nifedipine 3 nM added in combination with Riluzole 100 
µM (A: 10-20 mins P=0.03 n=6), (C) Nifedipine 10 nM added in combination with 
Riluzole 30 µM (n=11), and (D) Nifedipine 10 nM added in combination with 
Riluzole 100 µM (n=10) 
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Figure 3.2.10: Changed shape of the phase plot when dosed with Riluzole. 
Maximal force is reduced, contraction duration increased and time from baseline 
to maximal force or the upstroke period is increased, but with a similar area 
under the curve. 
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Figure 3.2.11: Graph showing the % of strips in each series that ceased to 
contract on addition of drug combinations. Statistical significance of likelihood to 
cease was calculated using binomial sign test. With Riluzole no combination was 
statistically likely to inhibit contractions. 
 
 
 
 
 
 
RIL 0.3 RIL 1 RIL 3 RIL 10 RIL 30 RIL 100 
0
20
40
60
80
100
c
o
m
p
le
te
 i
n
h
ib
it
io
n
 (
%
) 
Riluzole [M]
 Riluzole
 Nifedipine 3 nM + Riluzole 
 Nifedipine 10 nM + Riluzole
142 
 
 
3.2.3.3 Riluzole in combination with Nifedipine, PGF2α or Oxytocin 
 
Riuzole 100 µM alone, and dosed in combination with Nifedipine 3 nM was 
added to strips together with PGF2α 10 µM or oxytocin 1 nM in order to measure 
if these physiologically available contractile agents would mediate any previously 
seen effect. 
As expected, PGF2α and oxytocin alone brought about an increase contraction 
parameters when added to strips alone (Figure 3.2.12 & 3.2.13). When Riluzole 
100 µM was added along with PGF2α and oxytocin the contraction inhibition was 
similar to that seen without either PGF2α or oxytocin being present. These 
contractile promoters do not seem to inhibit the effect of Riluzole (Figure 3.2.12 
& 3.2.13). 
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Figure 3.2.12: Mean (± SEM) inhibition of activity integral, maximal force, 
and contraction duration in strips dosed with either 10 µM PGF2α (n=7), 
Riluzole 100 µM combined with 10 µM PGF2α (A: AI P=0.01, B: MF P=0.01, 
n=7), Nifedipine 3 nM combined with Riluzole 100 µM and 10 µM PGF2α 
(C: MF P=0.05 n=7), or Nifedipine 3 nM combined with 10 µM PGF2α (D: AI 
P=0.01, E: MF P=0.01 n=7). 
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Figure 3.2.13: Mean (± SEM) inhibition of activity integral, maximal force, 
and contraction duration in strips dosed with either 1 nM oxytocin, 1 nM 
oxytocin and Riluzole 100 µM (A: AI P=0.03, B: MF P=0.01 C: Dur P=0.03 
n=7), 1 nM oxytocin with Riluzole 100 µM and Nifedipine 3 nM (D: AI 
P=0.01, E: MF P=0.01, F: Dur P=0.01 n=7), and 1 nM oxytocin and 
Nifedipine 3 nM (G: AI P=0.01, H: MF P=0.01, I: Dur P=0.01 n=7). 
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3.2.3 Conclusion 
There was no effect on contractility but linoloeic acid seen in these 
experiments. This could be because the target channel for this drug Kv 2.1 
does not contribute to resting membrane potential. However it could be to 
functional issues with the substance, as LA is a fatty acid full permeation of 
the drug into the myometrial strips could have not been successful and so 
there was no cellular level action. It could be that the dose range selected 
was insufficient to have an effect in the organ bath strips. In order to verify 
the original hypothesis, other substances to target Kv 2.1 could be sought. 
Pinacidil alone was effective at inhibiting contractions with total inhibition 
achievable within the dose range used. These findings support the hypothesis 
that by activating KATP channels in myometrium, a hyperpolarised state is 
maintained, preventing depolarisation and calcium entry via VGCC thus fully 
inhibiting contractions. The addition of Nifedipine further inhibits Ca2+ entry 
and critical threshold for action potential cannot be achieved at lower doses. 
Combination of Nifedipine with Pinacidil abolished contractions at a 
significantly lower dose than with Nifedipine alone (complete inhibition at 
Nifedipine 3 nM plus Pinacidil 10 µM, verses Nifedipine 30 nM alone). 
Pinacidil is well tolerated as an antihypertensive with also a good safety 
profile but chances of side-effect are higher due to its hypertensive action 
and further work on vascular effects will be required to assess this risk fully.  
Riluzole alone inhibited contractions, but within the dose range used, total 
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inhibition was not achieved. The inhibitory effect of Riluzole was further 
enhanced when combined with Nifedipine in increasing doses. Riluzole at 
most concentrated combinations brought about a diminishment of 
contractions over time and changed the shape of the contraction. Whether in 
vivo this diminishment would be sufficient to delay preterm labour is hard to 
determine. Riluzole is currently used as a long term therapy for delaying the 
progression of ALS, is not associated with hypotension and has a good safety 
profile. Combination with Riluzole in vivo may reduce the dose strength of 
Nifedipine required to inhibit contractions in preterm labour without 
additional side-effects. 
The mechanism of action underlying the effect of Riluzole on myometrial 
tissue is unknown. A number of possible mechanisms of actions that have 
been observed in other tissues points to a number of possibilities that would 
need further investigation. It may be that the inhibition seen is due to 
opening of potassium channel, either SK3 or TREK or a combination of these 
or other ion channels; and this is further explored in the discussion. If 
Riluzole is functioning on SK3 or TREK then perhaps a higher dose would be 
required to achieve sufficient K+ efflux to maintain hyperpolarisation. The 
effect seen was not mediated by PGF2α or oxytocin. 
Prior to considering clinical use of a combination of potassium channel 
openers with Nifedipine, effects on vascular smooth muscle must be 
investigated.  There needs to be strong indication that additional hypotensive 
effects will be avoided.  
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3.3 The effects of combined dose of Nifedipine with potassium channel 
openers on myometrial small arteries 
 
3.3.1 Clinical relevance and background 
 
The most commonly reported side effect associated with Nifedipine use as a 
tocolytic is hypotension, with concerns for fetal wellbeing as a result (de Heus et 
al 2009).  The overall efficacy of Nifedipine in halting labour and reducing length 
of time form treatment to birth is similar to other tocolytics, some of which are 
associated with additional maternal and fetal side-effects (de Heus 2009). Often 
tocolytic compounds lack full clinical effectiveness and preterm birth is not 
prevented. This could be attributed to incomplete inhibition of the contractile 
pathway. In theory, calcium channel blockers will halt the contractile 
mechanism definitively but preventing large conductance calcium entry. As 
demonstrated in the previous experiments an optimal dose of Nifedipine will 
entirely inhibit contractions, but the real and clear barrier to achieving this in 
vivo is the fact that higher dose of Nifedipine would have more significant 
cardiovascular side-effects leading to poorer outcomes and as such the 
Nifedipine dose for tocolysis is limited (RCOG 2011).  It has been the aim so far 
to establish the efficacy of a combined effect of Nifedipine with select 
potassium channel openers to enhance the tocolytic effect in the myometrium 
without additional cardiovascular impact. A previous screen has indicated that 
selected target K+ channels are not as abundantly expressed in VSMC as in 
MSMC. This led to the hypothesis that adverse cardiovascular effects would be 
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avoided. This would be vital to establishing any possible clinical relevance of 
drug combinations and would need to take into consideration the influence of 
endothelial- mediated response to these agents. Previous experiments have 
demonstrated the combined effects of select potassium channel openers and 
Nifedipine on myometrium. Therefore we undertook the next set of 
experiments to explore the effect of these drug combinations on myometrial 
small arteries. Small arteries were dissected from myometrial biopsies obtained 
with consent at elective caesarean section at term. After a period of 
normalisation myometrial small arteries were exposed to the thromboxane A2 
receptor agonist U46619 (1 µM), which also mimics the effect of vasopressin to 
bring about constriction of the artery. Following a washout period the selected 
drug combinations (or vehicle) were added for incubation to the myograph 
before a repeated exposure to U46619 (Figure 3.3.1). Data was analysed in 
terms of the ratio of pre-drug incubation constriction force/post-drug 
incubation constriction force (please see chapter 2 of this thesis for full details 
of methods used). 
 In addition we sought to quantify the expression of the target channels for 
these drugs, SK3  and TREK-1 in myometrial small arteries compared to 
myometrial smooth muscle to demonstrate selectivity.  
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Figure 3.3.1: Typical image of screen recording of artery contractile response to 
(A) U46691 alone, (B) response to U46619 following incubation with drug of 
interest (in this example Riluzole 100 µM), and (C) response to U46619 following 
washout. (The spikes in between contractile phases are artefacts caused by 
organ bath washout and fluid replenishing at approx 20 min intervals). Recorded 
using Miodaq 2.0 
 
 
3.3.2 Objective 
I. To determine the effect of selected combined doses of Nifedipine plus 
Pinacidil and Riluzole on the contractile responses of myometrial small 
arteries to U46619 
II. To determine the expression of SK3 and TREK-1 in human pregnant 
myometrium and human pregnant myometrial small arteries. 
 
 
A B C 
150 
 
 
3.3.3. Results 
 
 3.3.3.1 Results – the effect of Nifedipine on myometrial small arteries 
 
Nifedipine at 10 nM brought about a reduction in baseline tension of -2.31 ± 
0.72% from pre-incubation tone. When U46619 was added in the presence of 
Nifedipine 10 nM the maximal tone was significantly reduced at 56.84 ± 7.13% 
(P= 0.00006 n=8) of the non-treated response. Following a washout of the drug, 
re-exposure to U46619 elicited 89.04 ± 5.66% of the pre-treatment maximal 
tone (Figure 3.3.2). 
 
3.3.3.2 Results – the effect of Pinacidil on myometral small arteries 
 
Pinacidil at 3 μM brought about a mean reduction in baseline tension of -2.82 ± 
0.72% from pre-incubation tone. Contractile response to U46619 in the 
presence of Pinacidil 3 μM significantly reduced at a mean of 54.15 ± 16.32% 
(P= 0.039 n=6) of the non-treated response to U46619. As with the myometrial 
smooth muscle experiments, there were some arteries that showed a greater 
response and some less at 13.52, 20, 20, 85.56, 89.53, 96.30% respectively. 
Following a washout of the drug, re-exposure to U46619 elicited a mean of 
96.96 ± 13.18% of the pre-treatment maximal tone. 
Pinacidil at 10 μM resulted in a slight increase of mean baseline tone of 0.27 
±1.05, and when U46619 was added a mean of 35.49 ± 24.6% (P= 0.054 n=4) of 
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non-treated response was achieved. As in other experiments there was a split in 
response with individual responses of 6.75, 7.10, 19.08, 108.73% hence non-
significant results from the mean value. 
Following drug washout, exposure to U46619 resulted in mean 97.84 ±5.93% of 
pre-treatment maximal tone (Figure 3.3.2). 
 
3.3.3.3 Results – the effect of Nifedipine combined with Pinacidil on myometrial 
small arteries 
 
Simultaneous pre-dose incubation of Nifedipine 10 nM and Pinacidil 3 μM 
resulted in a slight reduction in mean baseline tension of -1.70 ±1.05%. When 
U46619 was added, there was a significant reduction in mean maximal tone of 
37.8 ±7.4% (P= 0.0005 n=6) of the pre-dose response. There was a less polarised 
response seen in this group with a range of 11.92-62.96%, hence the significant 
result. After the washout, a mean maximal tone achieved was 92.1 ±5.34% of 
the pre-dose response. 
Nifedipine 10 nM and Pinacidil 10 μM resulted in a mean baseline tension of 6.2 
±4.59%. With the addition of U46619 a mean maximal tone of 53.48 ±19.6% 
(P=0.74 n=5) of the pre-dose response. Once again there was a polarised 
response with individual artery responses of 3.49, 10.82, 69.84 and 101.28% 
explaining the non-significant result from the mean response. Following drug 
washout there was a mean maximal tone of 72 ±19.78% of the pre-dose 
response (Figure 3.3.2). 
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3.3.3.4 Results – the effect of Riluzole on myometrial small arteries 
 
Pre-dose incubation of Riluzole 100 μM resulted in a slight increase in mean 
baseline tone of 1.90 ± 1.15%. On addition of U46619, mean maximal tone 
achieved was 92 ±5.19 (P= 0.364 n=6) of the pre-dosed response.  The response 
was more consistent than seen with Pinacidil with a range of 72.77-96.30%. 
Following drug washout the mean maximal tone was 92 ±6.48% (Figure 3.3.2). 
 
3.3.3.5 Results – the effect of Nifedipine combined with Riluzole on myometrial 
small arteries 
 
Simultaneous pre-dose incubation of Nifedipine 10 nM and Riluzole 100 μM 
brought about a slight increase of baseline tension 0.75 ±0.56%. Following 
addition of U46619, mean maximal tone was 70.6 ±7.51% (P= 0.0102 n=5). 
After drug washout the mean baseline tone was 101.9 ±2.2% of the pre-dose 
tone (Figure 3.3.2). 
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Figure 3.3.2: Graph to show % of pre-incubation response to U46619 following 
20 minute incubation of the drug (black), response to U46619 while drug present 
(red) and response to U46619 following drug washout (blue) for the following 
drugs/combinations:  Vehicle control (VC) (n=5), Nifedipine 10 nM (A: P=0.00006 
n=8), Pinacidil 3 µM (B: P=0.039 n=6), Pinacidil 3 µM plus Nifedipine 10 nM (C: 
P=0.0005 n=6), Pinacidil 10 µM (n=4), Pinacidil 10 µM plus Nifedipine 10 nM 
(n=5), Riluzole 100 µM (n=6), Nifedipine 10 nM plus Riluzole  100 µM (D: 
P=0.0102 n=5). 
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Drug Vehicle 
Control 
NIF 10 PIN 3 PIN 3+ 
NIF 10 
PIN 
10 
PIN 10 
+ NIF 
10 
RIL 100 RIL 100 + 
NIF 10 
Drug incubation (% 
of pre-dosed 
maximal tone) 
-0.9 -2.31 -2.82 -1.70 0.27 6.2 1.90 -0.75 
± SEM (%) 0.911 0.72 1.32 0.7 1.05 4.59 1.15 0.56 
With U46619 
(% of pre-dosed 
maximal tone) 
89.69 56.84 54.15 37.8 35.41 53.48 92 70.6 
± SEM (%) 7 7.13 16.32 7.4 24.6 19.6 5.19 7.51 
T-test P value 0.4223
2 
0.0000
6*** 
0.039
* 
0.0005
*** 
0.054 0.074 0.364 0.0102* 
With U46619 
following drug 
washout 
(% of pre-dosed 
maximal tone) 
85.7 89.04 96.96 92.1 97.84 72 92 101.9 
± SEM (%) 11.9 5.66 13.18 5.34 5.93 19.78 6.48 2.2 
N 5 8 6 6 4 5 6 5 
 
Table 3.3: Summary of results (mean values) 
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3.3.3.6 Results – the expression of SK3 in human pregnant myometrium 
 
Tissue samples consisted of 4 groups of myometrium samples, pre-term labour 
(PTL n=6), pre-term non-labour (PTNL n=6), term labour (TL n=6), term non-
labour (TNL n=6) and quantified by western blotting. There was no significant 
difference in the expression of SK3 by gestation in myometrium, and no 
significant difference between labour and non-labour samples (Figure 3.3.3).  
 
 
 
 
 
 
 
 
 
Figure 3.3.3:  The expression of SK3 in myometrial tissue (ratio SK3/β-
actin) from 4 groups of samples: pre-term labour (PTL n=6), pre-term 
non-labour (PTNL n=6), term labour (TL n=6), term non-labour (TNL n=6) 
quantified by western blot. 
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3.3.3.7 Results – the expression of SK3 in human pregnant myometrial 
small arteries compared to expression in myometrium 
 
Myometrial small arteries were dissected from term non-labour (TNL 
n=6) myometrial biopsies and quantified by western blotting along with 
whole sample myometrium from additional term non-labour samples 
(n=2) (Figure 3.3.4). There was a non-significant difference in expression 
of SK3 with a tendency to higher expression in myometrial tissue 
compared to myometrial small arteries (Figure 3.3.5).  
 
 
 
 
 
 
 
 
 
Figure 3.3.4: Image of exposed western blot film to show bands detected 
for SK3 in myometrial small arteries (MA; term non-labor; n=6) and 
myometrial tissue (MYO; term non-labour; n=2) compared to the control 
protein β-actin. 
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Figure 3.3.5: Expression of SK3 (ratio SK3/β-actin) in myometrial small 
arteries (MA; term non-labour; n=6) and myometrial tissue (MYO; term 
non-labour; n=2). 
 
 
3.3.3.8 Results – the expression of TREK-1 in human pregnant myometrium 
Tissue samples consisted of 4 groups of myometrium samples, pre-term labour 
(PTL n=4), pre-term non-labour (PTNL n=4), term labour (TL n=4), term non-
labour (TNL n=3, (1 outlier excluded)) and quantified by western blotting. There 
was no significant difference in the expression of TREK-1 by gestation in 
myometrium, and no significant difference between labour and non-labour 
samples (Figure 3.3.6).  
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Figure 3.3.6:  The expression of TREK-1 in myometrial tissue (ratio TREK-1/β-
actin) from 4 groups of samples: pre-term labour (PTL n=4), pre-term non-labour 
(PTNL n=4), term labour (TL n=4), term non-labour (TNL n=3) quantified by 
western blot. 
 
3.3.3.9  Results - the expression of TREK-1 in human pregnant myometrial small 
arteries compared to expression in myometrium 
 
Myometrial small arteries were dissected from term non-labour (TNL n=6) 
myometrial biopsies and quantified by western blotting along with whole 
sample myometrium from additional term non-labour samples (n=2) (Figure 
3.3.7). No TREK-1 was detected in myometrial small arteries, but was detected 
in myometrial whole tissue (Figure 3.3.8). 
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Figure 3.3.7: Image of exposed western blot film to show bands detected for 
TREK-1 in myometrial small arteries (MA; term non-labor; n=6) and myometrial 
tissue (MYO; term non-labour; n=2) compared to the control protein β-actin. 
 
 
 
 
 
 
 
 
 
Figure 3.3.8: Expression of TREK-1 (ratio TREK-1/β-actin) in myometrial small 
arteries (MA; term non-labour; n=6) and myometrial tissue (MYO; term non-
labour; n=2). 
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3.3.4 Conclusion 
 
This group of experiments aimed to measure the effect of drug combinations on 
myometrial small arteries and the expression of select drug target K+ channels 
in myometrial small arteries compared to whole myometrial tissue in order to 
speculate as to the possible clinical side effects that may be seen with this 
regime.  
The myography experiments were conducted at Newcastle University's Institute 
of Cellular medicine under their guidance and the kind use of their equipment. 
There was a limited time available to conduct this work and so this is reflected 
in the low N in these experiments. Additional experiments with greater N would 
be beneficial to confirm the reliability of the results shown here and as such 
interpretation of findings is with caution.  
Pinacidil showed a relaxatory effect on small artery function, which was 
anticipated. There were polarised responses to Pinacidil with some tissue 
samples, which could be classified as 'non-responders' which is a phenomenon 
observed in previous contractility experiments. Nifedipine alone had a 
significant effect at near halving the response to U46619 than seen before drug 
incubation. Combination with Pinacidil 3 µM showed a cumulative effect on 
further relaxation, a trend that may have been evident at the 10 µM dose were 
it not for the 'non-responders' to Pinacidil.    
The reduced relaxatory effect on small arteries shown with Riluzole was initially 
reassuring as to its therapeutic potential. When combined with Nifedipine 
however, it appeared that the combination with Riluzole had a protective effect 
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on relaxation with less of a relaxatory response than when Nifedipine was 
dosed alone (70.6% vs 56.8%).  
Crane & Garland (2004) found that U46619 blocked SK3 channel in rat 
mesenteric artery, Riluzole (100 µM) evoked membrane hyperpolarisation from 
-55±2 mV to -71±3 mV (n=5) and this was reduced with repeated exposure to 
U46619 (incremental doses 1 nM to 0.1 µM) to 58±2 mV. Hyperpolarisation 
following application of levcromakalin (KATP activator) was unaffected by repeat 
exposure to U46619. 
Although this effect was only seen in repeated exposure to U46619 and in this 
set of experiments the dosing period was the second exposure to U46619 with 
drug pre-incubation preceding exposure (following a washout period) it is 
unclear to what extent there may have been a block of SK3 channels from 
U46619 that may have inhibited the effect of Riluzole in these experiments. 
Tissue samples used for protein quantification through Western blotting was 
obtained by dissecting myometrial small arteries from whole biopsies. This 
yielded a very small amount of tissue for sampling. Band variation in size and 
quality of blots mean that the results presented above are less than conclusive. 
Further, more accurate quantification of channel expression through techniques 
such as reverse transcription polymerase chain reaction (RT-PCR), or 
immunohistochemistry would be desirable before drawing any conclusions on 
difference in expression between myometrial smooth muscle and myometrial 
smooth arteries.   
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3.4. The effect of VU590 on myometrial contractility and expression of Kir7.1 
and Kv2.1 in human myometrium 
 
3.4.1 Clinical relevance and background 
3.4.1.1 Clinical relevance 
Post-partum haemorrhage (PPH) is a significant blood loss (> 500 mls) during or 
after the 3rd stage of labour and can occur following a normal, assisted or 
surgical birth.  Primary PPH is a significant blood loss in the 24 hours post birth 
with a secondary PPH occurring anywhere up to 6 weeks post-partum. Such a 
significant blood loss can lead to a rapid loss in haemodynamic stability, 
represents a risk to maternal morbidity and mortality; can often be 
unanticipated and is considered an obstetric emergency. 
Uterine atony is the most common cause of PPH. Clinical strategies to manage 
PPH include mechanical methods such as catheterisation, manual compression, 
balloon tamponade, internal iliac ligation; or pharmacoloigcal. 
Current pharmacological approaches include synthetic Oxytocin, ergot alkaloids, 
prostaglandins (PGF2α, prostaglandin E1). All of these have different 
pharmacological mechanism of action but ultimately result in increased Ca2+  
entry and therefore an increase in contractions. Often, more than one 
pharmacological agent or a mix of pharmacology and mechanical treatments are 
required to maintain uterine tone and haemostasis. If unsuccessful, then an 
obstetric hysterectomy is the only option. 
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3.4.1.2 Scientific background 
 
The inwardly rectifying potassium channel Kir 7.1 was identified as a channel of 
interest in a previous screen of myometrial specific K+ channel expression.   
In laser capture selected human myometrial smooth muscle, an 8-fold increase 
in the gene encoding Kir 7.1 KCNJ13 mRNA was seen compared to whole biopsy 
tissue at term as well as increased expression observed in murine myometrium 
which peaked at D15. 
Kir channels function through electrochemical gradient and are voltage 
independent and therefore have a potential role in setting and maintaining 
resting potential and action potential duration. The gestational dependant 
decrease in expression towards term observed in murine tissue points to a 
possible role for Kir 7.1 in the gestational-dependent depolarisation in resting 
membrane potential towards term in myometrium. The function of Kir 7.1 had 
not previously been investigated in myometrium but the availability of the novel 
intracellular blocker of Kir 7.1, VU590 has made investigation possible. Building 
on the previous work that identified expression of Kir 7.1 in human myometrium 
it is yet to be demonstrated if there is a gestational variation in expression in 
human myometrium which was observed in murine myometrium. 
We hypothesise that by blocking inwardly rectifying K+ current via Kir 7.1 would 
prevent repolarisation and prolong action potential by prolonging the voltage 
threshold for calcium entry via VGCCs. 
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3.4.2 Objective 
 
I. To assess the differential effect of the selective Kir 7.1 blocker VU590 on 
spontaneous murine myometrial contractility at day 15 and day 18 
gestation. To assess the combined impact of Oxytocin plus VU590 on 
spontaneous murine myometrial contractility at day 15 or day 18 
gestation. 
 
II. To assess the impact of VU590 on spontaneously contracting human 
myometrial strips. To assess the combined impact of Oxytocin plus VU590 
on spontaneously contracting human myometrial strips. 
 
III. To assess the expression of VU590 targets Kir 7.1 and Kv 2.1 in human 
pregnant myometrium 
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3.4.3 Results – the effect of VU590 on contractility of murine myometrium 
 
3.4.3.1 VU590 elicits a significant rise in baseline tone in murine myometrium 
with gestational dependent differences. 
 
Dose series administration of VU590 in D18 murine myometrium elicited a 
significant increase in baseline tone at 30 μM (167±45% (P<0.001 n=4)) and 100 
μM (343±113% (P<0.001 n=4)). No other parameters differed significantly from 
pre-dose values (Figure 3.4.1 (A)). VU590 10 μM elicited a baseline rise of 
112±28% (n=6) in D18 murine myometrium whereas the same dose in D15 tissue 
saw an increased baseline rise of 180±59% (n=6) demonstrating a gestational 
dependant difference in response to VU590 (Figure 3.4.1 (B&C)). 
 
3.4.3.2 VU590 combined with Oxytocin elicits a significant rise in baseline  
 
In combination with Oxytocin a more significant rise in baseline was observed in 
D18 (466±161% (n=3)) myometrium than D15 (252±75% (P<0.001)) (Figure 3.4.1 
(B&C)). The combination with Oxytocin had an effect that mimicked a 10 fold 
higher dose of VU590 alone in D18 tissue.  There was again no significant effect 
on other parameters. 
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Figure 3.4.1: % change in measured parameters from pre-dose contractions with 
dose spread of VU590 alone in D18 murine myometrium (A) (A: P<0.001 n=4, 
B:P<0.001 n=6), and 1 nM Oxytocin, 10 μM VU590 with and without Oxytocin in 
D15 (n=5) (B) (A: P<0.001, B: P<0.001 n=5) and D18 murine myometrium (n=5) (C) 
(A: P<0.0001 n=3). 
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3.4.3.3 VU590 alone and combined with Oxytocin elicits a significant rise in total 
activity integral in murine myometrium 
 
Such was the rise in baseline observed in the previously described experiments, 
with additional small contractile peaks above the baseline, re-analysis was 
undertaken where the whole time rise from baseline was recorded as activity 
integral and compared to pre-dose contraction activity integral. There was a 
dose-dependent and gestational differentiated increase in activity integral, rising 
to 1596±543% in day 18 myometrium and 1024±203% in day 15 myometrium 
following the highest dose of VU590 100 µM (Figure 3.4.2). 
With the combination of Oxytocin 1 nM and VU590 10 µM there was a 
17294±1457% increase in activity integral in day 15 and 8825±4310% in day 18 
myometrium compared to an increase with VU590 10 µM alone of 935±429% at 
day 15 and 528±78% at day 18 (Figure3.4.3). 
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Figure 3.4.2: Gestation and dose dependent effect of VU590 on total activity 
integral as a % of pre-dose contractions, mean and SE (*D15 vs D18 A,B,C: 
P=<0.05 n=5). 
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Figure 3.4.3: Gestation dependent effect of VU590 10µ M with and without 
Oxytocin 1 nM on total activity integral as a % of pre-dose contractions, mean 
and SE (*OT vs OT+VU590 A: P<0.05(D15) B:<0.05 (D18) n=5). 
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3.4.4 Results – the effect of VU590 on contractility of human myometrium 
 
3.4.4.1 VU590 alone 
Following administration of VU590 the effect on contractility differed from the 
immediate post-dose time period, through a prolonged contraction phase to 
remaining contractile activity. Based on this observation the overall effect was 
split into three phases in order to allow for more accurate quantification and 
comparison of effect (Figure 3.4.4).  Analysis was split in 3 phases (1) first five 
contractions following dosing, (2) prolonged contraction phase and (3) remaining 
contractions (Figure 3.4.4). For each phase the activity integral (AI), maximal 
force (MF) and contraction duration (CD) per contraction was measured and 
expressed as a percentage of mean baseline activity before dose.  Results are 
expressed as ±SEM. Significance was determined by Wilcoxon signed-rank test. 
 
3.4.4.2 VU590 augments spontaneous human myometrial contractions with 
prolonged contractile phase. 
 
Phase (1) First 5 contractions 
In the first 5 contractions AI increased on a contraction-by-contraction manner 
until reaching 167±22% (P=0.001 n=9) by contraction 5 following 1 μM VU590 
(Figure 3.4.5 (B)).  Following the first five contractions the 1 μM dose 
contractions continued at a regular rate and did not achieve the prolonged 
contraction phase seen in other doses. 
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There was also a dose dependent increase in AI at 3 μM (146±14% (P=0.05 
n=10)) increase by contraction 5 and 10 μM (171±38% (n=6)) increase by 
contraction 5. There was minimal effect of CD and MF within the first 5 
contractions.  At 30 μM there was a slight reduction in all parameters and at 100 
μM there was an increase in AI by contraction 5 where other parameters 
decreased (Figure 3.4.5).  
In strips dosed with either 30 μM or 100 μM, 40% and 60% respectively had 
already begun the prolonged contraction phase before the 5th contraction 
reducing the n numbers contributing to the data in the graphs. 
Phase (2) Prolonged contraction phase 
From 3 μM and higher a prolonged contraction was observed (table 3.4.1). This 
contraction would start with a regular upstroke and continue for a prolonged but 
gradually diminishing contraction. Peak effect was at 10 μM VU590 with CD of 
6.7±1.9 hrs (P= 0.001 n=7) (Figure 3.4.6) accompanied by increase in AI 
1139±305% (P<0.001, n=7) (Figure 3.4.7). 
Phase (3) Remaining contractions 
Of those experiments where contractions continued or resumed following 
prolonged contraction (Table 3.4.1) the remaining contractions were analysed 
(Figure 3.4.8). Experiments were often left running overnight meaning that the 
timescale for each experiment was an average of 18 hours. If contractions 
resumed they would continue until the experiment was discontinued. Maximal 
increase in AI from pre-dose at 203±27% (P<0.05, n=9) was with 3 μM VU590. All 
doses saw an increased AI and SD with diminishing MF reflecting a change in  
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contraction shape. The shape changed from a typical plateau shape to a box 
shape contraction with regular frequency (Figure 3.4.9). 
 
 
 
 
 
 
 
 
Figure 4.3.4: An example of a dose response to VU590 in spontaneously 
contracting human myometrium with illustration of divisions for analysis. 
Phase (1) – the first 5 contractions following dose (A), Phase (2) – the prolonged 
contraction phase (B), Phase (3) averaged remaining contractions (C). 
 
 
 
 
 
 
 
 
B C A 
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Figure 3.4.5: The percentage of activity integral, maximal force, and selection 
duration of pre-dose contractions of each of the first 5 contractions following 
dosing with either 1 μM (B)(A: P<0.001 n=9), 3 μM (A: P<0.001 n=10) (C), 10 μM 
(A: P<0.001 n=7) (D), 30 μM (n=6) (E), 100 μM (n=6)(F) VU590 or time matched 
control (A). 
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VU590 
dose 
Number of 
experiments with 
prolonged 
contraction 
Number of experiments 
with prolonged 
contraction that 
continued contracting 
3 μM 3/10 0 
10 μM 7/10 2/7 (28.5%) 
30 μM 8/10 6/8 (75%) 
100 μM 10/10 3/10 (30%) 
 
Table 3.4.1: Table showing the number of experiments with each dose that had a 
prolonged contraction phase and the number of those that continued to contract 
following the prolonged contraction. 
 
 
 
 
 
 
 
 
Figure 3.4.6: The average duration of the prolonged contraction phase in hours 
for each dose of VU590(n=7) 
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Figure 3.4.7: The percentage of activity integral, maximal force, and selection 
duration of pre-dose contractions of the prolonged contraction phase following 
dosing with VU590 vs a time match control (A,B,C,D,E,F: P <0.05) 
 
 
 
 
 
 
 
 
Figure 3.4.8: The percentage of activity integral, maximal force, and selection 
duration of pre-dose contractions of average of remaining contractions at 1 μM 
(A: P< 0.05, B: P<0.05 n=10), 3 μM (C: P<0.001, D: P<0.01 n=7), 10 μM (n=5), 30 
μM (E: P< 0.01 n=8), 100 μM (F: P< 0.05 n=3). 
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Figure 3.4.9: Examples of pre-dose contraction shape (A) and post-dose/recovery 
contraction shape (B) that was observed in all experiments with VU590 with 
Oxytocin or without. 
 
3.4.5  VU590 combined with Oxytocin 
 
The effect seen when VU590 was combined with VU590 was similarly suitable for 
division into three phases for analysis (Figure 3.4.4). 
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at higher doses than when VU590 used alone. 
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present and so it is concluded that the immediate effect seen on the first 
contraction following dosing is due to the immediate effect of Oxytocin. When 
Oxytocin is combined with 1 μM VU590 there is a time dependant increase in 
activity integral similar to that seen with VU590 alone but with additive effects. 
At 1 μM VU590 + 1 nM Oxytocin AI has increased by 217±32 % (P<0.001 n=9) by 
contraction 5 whereas 1 nM OT alone reached 139±16% and VU590 alone 
reached 167±22% increase by contraction 5 (Figure 3.4.11). This time dependant 
increase was less significant with rising doses and a combined dose of 1nM 
Oxytocin with 100 μM VU590 demonstrated a clear time dependant diminishing 
effect (table 3.4.2). 
Phase (2) Prolonged contraction phase 
A prolonged contractile phase was seen in all doses including 1 μM VU590 + 1 
nM Oxytocin where this was not observed with 1 μM VU590 alone (table 3.4.2). 
The prolonged phase CD was maximal at 10 μM (3.3±1.2 hrs (n=5)), which was 
less than with 10 μM VU590 alone but demonstrated a greater increase in AI  
(2256±961 % (P<0.001, n=6)). (Figures 3.4.12,13,14).  MF was significantly 
reduced to 47±5.7% (P<0.001 n=7) average of predose contractions at 30 µM 
combined with 1 nM OT, with a similar reduction at 100 µM VU590 alone 
(46±6.5% (P<0.001 n=10)) (Figure 3.4.13 B). 
Phase (3) Remaining contractions 
All the strips dosed with 1 μM and 3 μM VU590 + 1 nM Oxytocin resumed 
contractions following the prolonged contraction phase (table 3.4.2).  Maximal 
increase in AI was at 3 VU590 + 1 nM OT (281±33% (P<0.05, n=10)).A similar 
shape change was observed in remaining contractions with an increased activity 
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integral, selection duration and reduction in maximal force. When compared to 
VU590 alone, combination with 1 nM Oxytocin resulted in a further increase in 
activity integral and selection duration at all doses with the exception of 3 μM 
which showed a greater effect when dosed alone and 100μM which was similar 
alone or combined (Figure 3.4.15). 
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Figure 3.4.10: The percentage of activity integral, maximal force, and selection 
duration of pre-dose contractions of each of the first 5 contractions following 
dosing with 1 nM Oxytocin alone (A) (A: <0.01 n=10) or combined with either 1 
μM (A: P<0.01, B,C,D,E: P<0.001n=9) (B), 3 μM ( n=10) (C), 10 μM (A: P<0.01, B: 
P<0.05 n= 6) (D), 30 μM (A, B, C: P<0.01, n=7) (E), 100 μM (A: P<0.01 n=7) (F) 
VU590 (A-F P<0.01, G-L P<0.05 n=7). 
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Figure 3.4.11: The percentage of pre-dose contractions of activity integral of each 
of the first 5 contractions following dosing with 1 nM Oxytocin (A, D,G,J,M P<0.01 
n=10), 1 μM VU590 (B,E,H,K: P<0.01 n=7) and 1 μM VU590 combined with 1nM 
Oxytocin (C,F: P<0.05, I,L,N: P<0.0001 n=9). 
VU590 
dose 
Number of 
experiments with 
prolonged 
contraction 
Number of experiments 
with prolonged 
contraction that 
continued contracting 
1 μM 3/10 3/3 (100%) 
3 μM 7/10 7/7 (100%) 
10μM 6/10 3/6 (50%) 
30μM 9/10 6/9 (66.6%) 
100 μM 7/10 3/7 (42.8%) 
Table 3.4.2:Table showing the number of experiments with each dose combined 
with 1 nM Oxytocin that had a prolonged contraction phase and the number of 
those that continued to contract following the prolonged contraction. 
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Figure 3.4.12:The percentage of activity integral, maximal force, and selection 
duration of pre-dose contractions of the prolonged contraction phase following 
dosing with 1 nM Oxytocin combined with VU590 1 μM (n=9), 3 μM (A,B,C: 
P<0.001 n=10), 10 μM (D,E,F: P<0.001 n= 6), 30 μM (G: P<0.01,H,I: P<0.001 n=7), 
and 100 μM (J,K,L: P<0.01 n=7). 
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Figure 3.4.13:The percentage of activity integral (A) (A,B,C: P< 0.001, D: P<0.01, 
E,F: P< 0.001), maximal force (B)(A, B: P< 0.001,C,D: P<0.01, E<F: P<0.001) and 
selection duration (C) (A,B,C: P<0.001, D:P<0.01, E,F,G P<0.001) of pre-dose 
contractions of the prolonged contraction phase following dosing with 1 nM 
Oxytocin combined with VU590 (right) or VU590 alone (left). 
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Figure 3.4.14: The average duration of the prolonged contraction phase in hours 
for each dose of VU590 alone and when combined with 1 nM Oxytocin 
 
 
 
 
 
 
 
 
Figure 3.4.15: The percentage of activity integral, maximal force, and selection 
duration of pre-dose contractions of remaining contractions with 1 nM OT and 
combination with 1 μM (A: AI P<0.05, B: Dur P<0.05, n=10), 3 μM (C: AI P<0.05, 
D: Dur P<0.05n=7), 10 μM (n=7), 30 μM (E: Dur P<0.05 n=7), 100 μM (n=6) VU590 
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      3.4.6 Results - The expression of Kir 7.1and Kv2.1 in human myometrium 
 
3.4.6.1 The expression of Kir 7.1 in human myometrium 
 
Western blotting was performed on myometrial tissue samples flash frozen 
at caesarean section for quantification of the expression of the protein Kir7.1. 
Samples used were from women grouped as being either in labour or not in 
labour at term or pre-term gestation (n=6 each group).  
Kir 7.1 expression in TL was significantly less than TNL (P=0.047), and 
expression in PTL was significantly less than TNL (P=0.049) (Figure 3.4.16,17).  
This is suggestive of a down-regulation of Kir 7.1 channel expression with the 
onset of labour. 
In order to explore the gestation-dependant expression of Kir 7.1 data was 
analysed on a gestational time-line for both labouring and non-labouring 
samples. The labour samples’ expression was lower with a downward trend 
towards term, with the opposite of a rising trend towards term seen in the 
non-labour group (Figure 3.4.18).  
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Figure 3.4.16: A typical film of a western blot quantifying the expression of Kir 7.1 
against the expression of the control protein β actin for pre-term labouring (PTL), 
pre-term non-labouring (PTNL), term labouring (TL), term non-labouring (TNL) 
samples of human myometrium. 
 
 
 
 
 
 
 
 
 
Figure 3.4.17: Graph showing individual Kir 7.1/β-actin ratios for blots in each 
group of samples of human myometrium - pre-term labouring (PTL), pre-term 
non-labouring (PTNL), term labouring (TL), term non-labouring (TNL). Kir 7.1 
expression in the pre-term labouring (PTL) group was significantly less than the 
term non-labouring (TNL) group by ANOVA (A: P=0.049 PTL: n=6 TNL: n=5). Kir 7.1 
expression in the term labouring (TL) group was significantly less than the term 
non-labouring (TNL) group by ANOVA (B: P=0.047 TL: n=6 TNL: n=5).  
** 
** 
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Figure 3.4.18: Kir 7.1 expression plotted by gestational age at delivery with a 
lower expression and a downward trend towards term in labouring samples (A) 
and with a higher expression and an upward trend towards term in the non-
labouring group (B) 
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3.4.6.2 The expression of Kv 2.1 in human myometrium 
 
Western blotting was performed on the same myometrial tissue samples as 
described above for quantification of the expression of the protein Kv 2.1.  
There was no significant difference in expression of Kv2.1 seen between 
either group of labouring or term or preterm samples (Figure 3.4.19,20). 
 
 
 
 
 
Figure 3.4.19: A typical film of a western blot quantifying the expression of Kv2.1 
against the expression of the control protein β actin for pre-term labouring (PTL), 
pre-term non-labouring (PTNL), term labouring (TL), term non-labouring (TNL) 
samples of human myometrium. 
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Figure 3.4.20: Graph showing individual Kv 2.1/β-actin ratios for blots in each 
group of samples of human myometrium - pre-term labouring (PTL)(n=6), pre-
term non-labouring (PTNL) (n=6), term labouring (TL) (n=6), term non-labouring 
(TNL) (n=6). There was no significant difference between any of the groups by 
ANOVA. 
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3.4.7 Conclusion 
 
 
VU590 increased baseline tone in murine myometrium. Gestational dependent 
effect was seen in dosing VU590 alone.  Addition of Oxytocin increased the effect 
10-fold in D18 mice. 
 
In human myometrium VU590 alone or with Oxytocin brought about a significant 
augmentation of contractility at lower doses. This exceeded the effect of 
Oxytocin alone with a further doubling of effect by contraction 5 when Oxytocin 
was combined with 1 μM VU590.  In higher doses a prolonged contraction phase 
was seen. VU590 combined with Oxytocin had a shorter CD in prolonged phase 
but a higher AI reflecting an improved maintenance of tone throughout the 
phase when compared to VU590 alone.  A change in the shape of contractions 
reflects a pro-longed depolarised state and delay in repolarisation and 
contraction relaxation. 
It appears that by blocking Kir 7,1 with VU590 resting membrane potential is 
maintained in a depolarised state allowing  for continued Ca2+ influx and 
sustained contraction. This suggests VU590 is a potent contractile agent and a 
potential therapeutic target for PPH. 
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4. Discussion 
4.1 Potassium channel openers combined with Nifedipine  as potential 
therapeutic targets for tocolysis 
4.1.1 Linoleic Acid and Kv 2.1 
With the exception of linoleic acid, the addition of potassium channel openers, 
independent of any other agents, to spontaneously contracting myometrial strips 
resulted in a reduction in contractility.  The lack of effect seen by linoleic acid may 
be due to a lack of perfusion into the tissue strip so it was unable to act at a cellular 
level.  Alternatively it may not act as expected on potassium channels, or the 
channels targeted may not be functional in reducing membrane potential.  It is 
worth noting that in western blotting experiments presented in section 3.4 of this 
thesis, Kv 2.1 was not found to have a significant gestational-dependent expression, 
which may support the theory that it does not significantly contribute to membrane 
resting potential in human myometrium. In further work (unpublished data) 
conducted within our research group, transgenic expression data and mathematical 
modelling was used to predict the function and contribution of specific ion channels 
in myometrial contractility. Predicted function of Kv 2.1 was tested in voltage-clamp 
experiments in murine myometrium and an increased action potential frequency 
and amplitude was observed in response to the Kv 2.1 blocker stromatoxin. 
However there was little change in resting membrane potential. Although it is 
problematic to infer open state function from experimental work from blockers, 
this data (unpublished) suggests a role for Kv 2.1 in modulating contractility 
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frequency and amplitude but a limited role in contributing to the resting membrane 
potential.  
Although LA and n-6 fatty acids appear to have a role in prostaglandin production 
and influence pregnancy duration (Wathes et al 2007, Allen & Harris 2001), it does 
not appear LA exerts a significant effect via membrane potential modulation. 
4.1.2 Pinacidil and Riluzole combined with Nifedipine 
Pinacidil resulted in a dose-dependent reduction of all parameters and achieved 
complete inhibition at higher doses.  This result is consistent with the findings of 
Mandi et al (2005), Kostrzewska et al (1996) and Khan et al (1998).  When Pinacidil 
was added following pre-treatment with Nifedipine, additional inhibition was 
observed.  Riluzole showed less potency but still elicited a significant inhibition 
when administered alone which was enhanced when combined with Nifedipine. 
The effect of Riluzole and Nifedipine together on the slow climbing phase and 
shape of contractions points to a possible ‘swinging’ of action potentials due to 
unstable membrane potential across cells within the strip.  This supports the 
hypothesis that the combination of potassium channel openers with a calcium 
channel blocker elicits a more potent inhibitory effect than calcium channel 
blockers alone.  This effect is mediated by dose as seen at the higher doses of 
Nifedipine due to the potency of Nifedipine effect on control strips.  In strips pre-
treated with Nifedipine followed by Pinacidil, Riluzole and their controls, 
contractions were almost completely abolished at the 100 nM (0.1 µM) Nifedipine 
dose.  
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With a typical tocolytic dose regimen, steady state in vivo plasma levels of 
Nifedipine reach 0.195±0.082 μM (Papatsonis et al, 2007), however the optimal 
dose of Nifedipine has not been defined and the different release characteristics of 
the formulations available may affect the dosage required to abolish contractions.  
An increased dose would induce increased incidence of maternal and fetal side 
effects (RCOG 2011). 
Pinacidil reduced contractility both on its own and inhibition became more potent 
when combined with Nifedipine.  The effect of Pinacidil on myometrial smooth 
arteries was similar to that of Nifedipine in limiting arterial response to U46619 1 
µM (56.84 ± 7.13% of pre-dose constriction with Nifedipine 10 nM and 54.15 ± 
16.32% with Pinacidil 3 µM). This was not particularly surprising as Pinacidil has 
been used clinically as a hypertensive and has been shown to have a high binding 
affinity and potent effect on the KATP channel which elicits an endothelial-
independent relaxatory effect on VSMC (Stojnic et al 2007, Atwal, K 1994). Pinacidil 
was selected to act as a positive control and performed as such within these 
experiments but supported the hypothesis that modulation of K+ current would 
inhibit VGCC Ca2+ entry. 
A surprising finding from this series of experiments was the apparent response or 
non-response to Pinacidil.  Consistently across myometrial smooth muscle and 
artery experiments there was a sub-group of tissue samples that failed to respond 
to Pinacidil with others exhibiting total inhibition of contractile force. There has 
been some discussion in other published work about the possible existence of 
different receptor sub-types that may influence the effect of KATP openers(Atwal 
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1994). Inagaki et al (1996) identified a novel sulfonylurea receptor SUR2, which they 
found bound to glibenclamide with a lower affinity than SUR1(Inagaki et al 1996). 
They identified that SUR2 is co-expressed with Kir 6.2 which reconstitutes some 
KATP channels that appear to have properties distinct from the β-cell KATP. The 
SUR2-Kir6.2 sub-type is less sensitive to ATP, glibenclamide and is not activated by 
the KATP opener diazoxide (Inagaki et al 1996). A similar selective effect is 
described by Liss et al (1999) who identified a sub-population of substantia nigra 
(SN) neurons that were not affected by pre-incubation with the ATP blocker 
rotenone. Whereas some SN neurons exhibited a large KATP current and 
membrane hyperpolarisation with pre-incubation of rotenone 100 nM, others were 
only partially activated by doses of rotenone 1-10 µM (Liss et al 1999). Those that 
were sensitive to rotenone expressed the subunit combination SUR1+Kir 6.2 and 
those that were non-sensitive expressed the subunit combination SUR2B+ Kir 6.2 
(Liss et al 1999). This suggests a metabolic sensitivity with particular subunit types. 
Further evidence of channel sensitivity comes from Nui et al (2011) who identified a 
sex specific response to Pinacidil in trigeminal ganglia in Sprague Dawley rats. All 
subunit components Kir 6.1, 6.2 and SUR1 and SUR2 were confirmed present in the 
tissue by PCR; but where 20 µg Pinacidil blocked capsaicin-induced mechanical 
sensitivity to pain in male rats, in females the maximum dose of 300 µ was only 
partially effective (Nui et al 2011). Some Type 2 diabetic patients fail to respond to 
sulfonylurea therapy while others appear over-sensitive with genetic 
polymorphisms possibly responsible for inter-individual variability (Aquilante 2010).  
With the burgeoning interest from drug companies into pharmacogenetics some of 
these variances and sensitivities will continued to be studied in future. Type 2 
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diabetes is a polygenetic disease with a complex aetiological pathway (Aquilante 
2010). Polymorphisms that influence an individual's risk of developing the disease 
or which are altered in disease progression may underlie variance in response to 
sulfonylurea therapy. It must be taken into consideration the rise in the incidence 
of Type 2 diabetes and other metabolic syndromes in the general population and 
the childbearing population. Diabetes and metabolic conditions are known risk 
factors for poor pregnancy outcomes and continue to be of concern to 
obstetricians. In our sample population there was a very low number of known 
diabetics, but it cannot be known if there was underlying metabolic impairment or 
simply variance in genetics of the sample population that led to a proportion being 
resistant to Pinacidil. This warrants further laboratory investigation, perhaps into 
the different subtypes of SUR receptors expressed in a diverse population of 
women. 
An additional factor to consider regarding variation in results and response to 
particular drugs, is the variability in the composition of myometrial muscle samples 
used.  Within strip control for analysis should have diminished variability due to 
strip size and muscle fibre density. Patient to patient differences in myometrial 
composition and variances in gestation and time to onset of spontaneous labour 
may have influenced response. All samples included in this experimental work were 
obtained from the lower segment of the uterus. The uterus is made up of the upper 
uterine body and corpus, the lower segment and cervix; and the uterine wall 
consists of three layers the endometrium (inner layer) the perimetrium  (outer 
layer) and the thickest layer between the two of the myometrium. The 
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myometrium consists mainly of smooth-muscle bundles and connective-tissue and 
is further structured within an external layer (stratum supravasculare), middle layer 
(stratum vasculare) and inner layer (stratum subvasculare) (Weiss et al 2005). 
Muscle fibres of the inner myometrium have a predominantly circular orientation 
whereas the intermediate and outer layers have a longitudinal orientation (Naftalin 
and Jurkovic 2009).  The endometrial-myometrial junction zone differs according to 
pregnant and non-pregnant state, as well as phase of menstrual cycle, with the 
subendometrial myometrium modulating uterine contractions throughout the 
menstrual cycle and implantation (Brosens et al 1995). In pregnancy, trophoblast 
invasion and vascular re-modelling reaches as far as the inner myometrium 
(Pijnenborg et al 2011). Myometrial zonal layers become less distinct in pregnancy 
and it is possible that in pregnancy there is endometrial infiltration into the 
myometrium, and there may be structural and functional differences in this layer 
(Turnbull et al 1995, Brosens et al 1995). 
Viewed through high resolution magnetic resonance diffusion tensor imaging, the 
uterus appears to be an anisotropic organ, but with a muscle fibre architecture that 
is complex. Muscle fibres in the different areas and different layers of the uterus 
were seen to be overlapping and multi directional (Weiss et al 2005). Differences in 
gene expression before and after the onset of labour, between the fundus,  lower 
segment and cervix have been demonstrated (Bukowski et al 2006, Romero et al 
2006). As all samples used within this work came from the inner edge of the lower 
segment, it is possible that functional variability may exist in the tissue samples 
received which may be an explanation for variation in responses or non-response in 
some biopsies. 
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Despite this demonstrated spacial variation; work by Luckas and Wray (2000) 
provide reassurance in their observation that there was no difference in the 
contractile rate, force production and area under the curve produced by 
myometrium from the upper and lower segments. The authors conclude that for 
contactility, the use of lower segment biopsy is appropriate (Luckas and Wray 
2000).  
Riluzole reduced contractility on its own and inhibition became more potent when 
combined with Nifedipine but to a lesser effect than Pinacidil.  Riluzole has a more 
promising safety profile which points to its suitability as a potential tocolytic when 
combined with Nifedipine.  Riluzole is currently used as a long term drug therapy 
thought to be effective in delaying the progression of amyotrophic lateral sclerosis 
(ALS), is not associated with hypotension and has a good safety profile (Lipp et al, 
2003, Bensimon & Doble, 2004).  Combination of Nifedipine with Riluzole in vivo 
may reduce the dose of Nifedipine required to inhibit contractions in preterm 
labour without additional side-effects.  It is envisaged that in clinical practice these 
drugs would be administered simultaneously.  As the above experiments 
investigated dose response following pre-treatment, further work was indicated to 
investigate simultaneous dosing to identify an optimal combined dose. 
Significant effects on contractility were observed with addition of Riluzole 
combined with Nifedipine at similar doses as was shown when doses were added 
incrementally. With Pinacidil there appears to be an immediate abolition of 
contraction whereas with Riluzole there appears to be a time-dependent effect. 
This could be due to a delay in this agent infiltrating the tissue strips or impedance 
in binding at a cellular level. This may also point to the fact that Nifedipine is more 
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potent than Riluzole when combined and so inhibition reflects that time dependent 
effect of Nifedipine. The faster response of Pinacidil and Nifedipine combined may 
point to a matched or increased contribution of Pinacidil into the combined effect. 
Riluzole had less of an effect on myometrial small arteries which is reassuring 
regarding it's potential as a tocolytic. Combined with Nifedipine the relaxatory 
effect was less than when Nifedipine was added alone. This could be an artefact of 
the experiments due to low n numbers, but could also indicate an effect of Riluzole 
in VSMC that mediates the function or affinity of Nifedipine to VGCC. As a 
significant effect on myometrial arteries was not observed with Riluzole this 
suggests endothelial-mediated relaxation of VSMC via SK3 was also not observed in 
these experiments. Previously, it has been demonstrated that suppression of SK3 
expression resulted in an elevation of arterial tone and blood pressure in modified 
mice, and in porcine arteries under exposure to the SK3 activator substance P 
(Taylor et al 2003, Burnham et al 2002). In view of this it was reasonable to expect 
prior to experimentation that in opening SK3 via Riluzole a more significant 
relaxatory effect may have been seen. 
Crane & Garland (2004) found that U46619 blocked SK3 channel in rat mesenteric 
artery, Riluzole (100 µM) evoked membrane hyperpolarisation from -55±2 mV to -
71±3 mV (n=5) and this was reduced with repeated exposure to U46619 
(incremental doses 1 nM to 0.1 µM) to 58±2 mV. Hyperpolarisation following 
application of levcromakalin (KATP activator) was unaffected by repeat exposure to 
U46619. Although this effect was only seen in repeated exposure to U46619 and in 
this set of experiments the dosing period was the second exposure to U46619 with 
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drug pre-incubation preceding exposure (following a washout period) it is unclear 
to what extent there may have been a block of SK3 channels from U46619 that may 
have inhibited the effect of Riluzole in these experiments. Repetition with a 
different vessel constricting agent may confirm whether this is the case. There 
appeared to be a non-significant reduction in the expression of SK3 in myometrial 
small arteries compared with whole myometrium, and in this set of tissue, TREK-1 
was absent from myometrial arteries. If Riluzole is predominantly targeting TREK-1 
in this tissue then this could be an explanation for the reduced relaxatory effect 
seen in the myography experiments.  Work by Duprat et al (2000) confirmed with 
patch-clamp experiments that Riluzole opens TREK-1 and allows K+ flow leading to 
hyperpolarisation. They observed that the current was not consistent, with a rapid 
stimulation followed by a decline and then inhibition of TREK-1 current (figure 4.1 
Duprat et al 2000). In the same set of experiments, it was also observed that TREK 1 
response is sensitive to variation in cAMP. After inhibition with exposure to 8-(4-
chlorophenylthio)(8CPT) cAMP 500 µM, the channel could not be re-activated by 
Riluzole. The authors conclude that Riluzole has an inhibitory effect on the PKA 
pathway, which they suggest is responsible for the inhibitory effect Riluzole on 
TREK-1 following initial activation (Duprat et al 2000). This described pattern of 
activation followed by inhibition of TREK-1 by Riluzole may present an explanation 
for the change in contraction shape seen in myometrial contractions following 
Riluzole. It may also explain why no dose brought about total inhibition. Whether 
the change in myometrial shape and strength with Riluzole and Nifedipine 
combined would be sufficient to decrease uterine tone in vivo requires further 
investigation. 
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Figure 4.1: Reproduction of figure 2 from Duprat et al (2000) - Dual effect of Riluzole 
on TREK-1 current. A, example of transient stimulation of TREK-1 current followed 
by an inhibition, recorded at 0 mV, during 90 s perfusion with 100 mM of Riluzole. B, 
bar graph of TREK-1 mean currents, recorded at 150 mV, before perfusion with  
Riluzole (100 mM) (control) and after 30 s and 90 s of perfusion (n 5 29, P 5 .002). 
 
4.2 The potassium channel blocker VU590 as potential therapeutic target for PPH 
In human myometrium VU590 alone or with Oxytocin brought about a significant 
augmentation of contractility at lower doses. This exceeded the effect of Oxytocin 
alone with a doubling of effect by contraction 5 when Oxytocin was combined with 
1 μM VU590.  In higher doses a prolonged contraction phase was seen. VU590 
combined with Oxytocin had a shorter CD in prolonged phase but a higher AI 
reflecting an improved maintenance of tone throughout the phase when compared 
to VU590 alone.  A change in the shape of contractions reflects a pro-longed 
depolarised state and delay in repolarisation and contraction relaxation. 
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It is hypothesised that the effect seen by VU590 in these experiments is due to the 
blockade of Kir 7.1.  In order to confirm this some preliminary contractility 
experiments (full data not available for this thesis) were performed with VU591 a 
compound developed to specifically target ROMK with no block of Kir 7.1.  No effect 
on contractility was seen on addition of this compound at the same dose spread 
used in VU590. This added confidence to the effects seen being due to Kir 7.1 
blockade. 
Other investigators have explored the effects of K+ channel blockers in 
myometrium.  BKCa blockers paxilline, iberiotoxin & penitrem A have not been 
shown to increase in contractility when dosed alone but have attenuated inhibitory 
effect of BKCa openers (Aaronson et al., 2006; Doheny et al., 2003). KV channel 
blockers tetraethylammonium (TEA) and 4-aminopyridine (4-AP) have 
demonstrated an augmenting effect on myometrial contractility.  TEA 
demonstrated a 20% increase in maximum contraction amplitude by 20% (5mM) 
and 4-AP demonstrating a 121% increase in maximal contraction amplitude in late 
pregnant rat tissue but with reduced potency on early pregnant tissue (Aaronson et 
al., 2006). A similar effect of 4-AP was seen in non-pregnant murine myometrium 
with no effect in pregnant murine myometrium with an absence of expression of KV 
4.3 in pregnant tissue compared to non-pregnant revealed in western blotting.  A 
difference in response between these tissues combined with the change of 
expression led to the conclusion that 4-AP targets KV 4.3 (Smith et al., 2007).  To 
date no other K+ channel blockers have elicited the degree of response seen with 
the application of VU590.  
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Effects seen in this thesis suggest that Kir 7.1 plays a role in setting resting 
membrane potential in murine myometrium with blockade resulting in a rise in 
baseline tension that is gestation mediated. Kir 7.1 appears to play an important 
role in the repolarisation of membrane potential and the termination of action 
potential in human myometrium with blockade resulting in prolonged plateau 
phase of contraction and increased force with lower doses and with increasing dose 
profound and prolonged contractile phase.  
Together with results presented here and building on aforementioned work into K ir 
7.1 expression in myometrium, the results of additional study (and published paper) 
undertaken by our research team and collaborators support this hypothesis. 
Electrophysiology experiments on murine myometrial cells have demonstrated an 
inwardly rectifying potassium current was inhibited by VU590 under voltage-clamp 
conditions, and that this current was stronger at GD15 than GD18 in line with 
gestational decrease in expression of Kir 7.1 (Figure 4.2 from McCloskey et al 2014 
Appendix 2). This was further confirmed by modulation of expression of Kir 7.1 in 
murine myometrial strips. Using Anti-Kir 7.1 or +Kir 7.1 lentiviral vectors the 
channel was either over-expressed or under-expressed before tissue was used in 
contractility (organ bath) or voltage-clamp experiments. When Kir 7.1 is under-
expressed there was a significant increase in activity integral, maximal force and 
contraction duration in contractility, as well as a depolarised resting membrane 
potential with extended periods of excitability (McCloskey et al 2014 (Appendix 2)). 
When Kir 7.1 was over-expressed there was a decrease in measured contractility 
parameters and an observed hyperpolarisation and suppression of excitability 
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(McCloskey et al 2014 (Appendix 2)). This is strong and novel evidence of the 
contribution made to resting membrane potential and myometrial contractility of 
Kir 7.1. 
 
 
 
Figure 4.2: Results of electrophysiology experiments from our research group: 
Measurement of inwardly rectifying, VU590 sensitive current in GD15 murine 
myomentrial cells – voltage clamp recordings in the presesnce and absence of 10 
μM of VU590 (A), Current-voltage relation of current density (VU590 subtracted 
from from control (vehicle alone) n=5; mean ±SD) (B), and current density (pA/pF) at 
-150 mV and 500 ms in murine myometrial cells from GD15 and GD18 (n=5; mean 
±SD) *P<0.05 by Student’s t test (C). 
 
4.3 Overall conclusions 
This thesis set out to build on findings of a previous screen carried out within our 
group where a number of K+ channels were identified of interest. This led to further 
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examination of the function of these ion channels in myometrium with a view their 
potential as therapeutic targets.  
Pinacidil proved a successful positive control and demonstrated that by activating 
KATP and allowing K
+ efflux myometrial contractility was diminished or abolished. 
This effect was further enhanced with the combination of Nifedipine bringing about 
abolition of contractions at a lower dose than with Nifedipine alone. 
Riluzole diminished myometrial contractility but was not able to abolish with the 
range of doses used.  This may not be down to lack of full tissue perfusion but may 
be down to the specific effect of Riluzole on smooth muscle. The specific K+ channel 
targeted by Riluzole cannot be determined. Although Riluzole is a known activator 
of SK3 some of the findings of experimental work presented here suggest that TREK-
1 may be the predominant channel targeted by Riluzole. There is the possibility that 
Riluzole is activating both SK3 and TREK-1. There was a cumulative relaxatory effect 
when Riluzole was dosed in combination with Nifedipine, again confirming our 
hypothesis that activation of K+ channels hyperpolarises membrane potential 
sufficiently to block VGCC Ca2+ entry and improve the potency of Nifedipine. The 
effect seen appears to be myometrial specific due to the reassuring nature of the 
artery experiments, suggesting that in vivo additional cardiovascular side-effects 
may be avoided. This makes Riluzole in combination with Nifedipine of further 
consideration as a potential tocolytic therapy. 
The K+ channel Kir 7.1 was identified as being expressed in myometrial smooth 
muscle and the availability of VU590 made experimental investigation of its action 
in MSMC possible. VU590 brought about significant and sustained myometrial 
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contraction in both human and myometrial smooth muscle. Further patch-clamp 
work has confirmed that VU590 is blocking Kir 7.1 in human myometrium as 
hypothesised. Together with the contractility experiments present in 3.4 of this 
thesis there is compelling evidence that blockade of Kir 7.1 via VU590 has potential 
therapeutic value in the treatment of PPH and warrants further investigation. 
This thesis has investigated how modulation of specific K+ channels in murine and 
human myometrium can modulate contractility with a view to therapeutic targets. 
This represents a novel set of observations that will add to knowledge of 
myometrial function and will inform further work which has the potential to benefit 
pregnancy outcomes. 
 
4.4 Future work 
4.4.1 The combination of K+ channel openers with Nifedipine for tocolysis 
This thesis did not determine the mechanism through which Riluzole exerted its 
action on myometrial contractility. K+ channel modulation was our hypothesised 
mode of action but which channel, or set of ion channels influenced by Riluzole is 
yet to be determined. Electrophysiology experiments to determine the effect of 
Riluzole on specific channels of interest would inform this further and advance 
understanding crucial for any prospective application of Riluzole as a tocolytic 
either on its own or in combination with Nifedipine. 
Further consideration of either Pinacidil alone or the combination of Pinacidil and 
Nifedipine at low doses as tocolytics. Careful consideration should be given to 
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potential cardiovascular side-effects and whether these may be improved or 
increased over Nifedipine as used in current practice. Additional in vitro myogenic 
tone experiments (pressure-induced flow) may inform this further.  
4.4.2 K+ channel expression quantification in myometrial small arteries compared to 
myometrial smooth muscle. 
The Western blots presented in this thesis did not provide data of sufficient quality 
to draw conclusions on variation of the relative expression of K+ channels in 
myometrial small arteries compared to myometrial smooth muscle. Further work in 
RT-PCR or immunohistochemistry or channel gene expression in these tissues is 
required to evidence tissue selectivity in expression. 
Further myometrial small arteries in functional response to drug combinations woul 
be beneficial including using pressure-flow technique. The N numbers used within 
this set of experiments was restricted by time demands and availability of 
equipment kindly supported by Newcastle University. Further work would 
strengthen the quality and reliability of the initial findings presented here. 
4.4.3 The potential of VU590 as a stimulator of myometrial contractility 
This thesis together with additional published work (McCloskey et al 2014 
Appendix) builds a strong case for VU590 blockade of Kir 7.1 as potent promoter of 
myometrial contractility. The potential of this compound or variations of this 
compound are worth future consideration as therapeutic agents for treatment or 
prevention of PPH, or labour augmentation. 
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Abstract
Abnormal uterine activity in pregnancy causes a range of impor-
tant clinical disorders, including preterm birth, dysfunctional
labour and post-partum haemorrhage. Uterine contractile patterns
are controlled by the generation of complex electrical signals at
the myometrial smooth muscle plasma membrane. To identify
novel targets to treat conditions associated with uterine dysfunc-
tion, we undertook a genome-wide screen of potassium channels
that are enriched in myometrial smooth muscle. Computational
modelling identified Kir7.1 as potentially important in regulating
uterine excitability during pregnancy. We demonstrate Kir7.1
current hyper-polarizes uterine myocytes and promotes quies-
cence during gestation. Labour is associated with a decline, but
not loss, of Kir7.1 expression. Knockdown of Kir7.1 by lentiviral
expression of miRNA was sufficient to increase uterine contractile
force and duration significantly. Conversely, overexpression of
Kir7.1 inhibited uterine contractility. Finally, we demonstrate that
the Kir7.1 inhibitor VU590 as well as novel derivative compounds
induces profound, long-lasting contractions in mouse and human
myometrium; the activity of these inhibitors exceeds that of other
uterotonic drugs. We conclude Kir7.1 regulates the transition from
quiescence to contractions in the pregnant uterus and may be a
target for therapies to control uterine contractility.
Keywords pregnancy; parturition; potassium channels; uterus; myometrium
Subject Categories Pharmacology & Drug Discovery; Urogenital System
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Introduction
At the end of pregnancy, the quiescent uterus must become highly
contractile to mediate parturition. While the mechanisms initiating
parturition in mammals are diverse (Smith, 2007), a final common
pathway of uterine transition to a contractile phenotype appears to
converge on the expression of a group of proteins, including the
oxytocin receptor, prostaglandin endoperoxidase synthase 2, ion
channels and connexin 43, that alter the uterine myometrial smooth
muscle (MSM) cell from a state of low intrinsic excitability and
refractory to stimulation, to a state that has high intrinsic excitabil-
ity and is susceptible to stimulation (Garfield et al, 1977; Fuchs
et al, 1982; Slater et al, 1995; Garfield & Maner, 2007). Control of
stimulation is itself subject to complex gene-environment interac-
tions, which act either independently of, or complimentary to, the
underlying physiological changes of the uterus (Cha et al, 2013).
Irrespective of the underlying stimulus, the regulation of the
duration and frequency of the myometrial contraction critically
depends on control of calcium entry through voltage-gated L- and
T-type calcium channels (Amedee et al, 1987; Blanks et al, 2007).
Calcium is not only an important second messenger in the genera-
tion of force via calcium-calmodulin-dependent myosin light chain
kinase, but also depolarizes the plasma membrane, allowing for
activation of other voltage-dependent ion channels (Word et al,
1994; Brainard et al, 2007). This voltage-mediated control of uterine
excitability is modulated in a gestation-dependent manner in all
mammalian species. In particular, mid-gestation is characterized by
a hyperpolarized membrane potential close to the reversal potential
for potassium Ek (Casteels & Kuriyama, 1965). As pregnancy
progresses towards term, the myometrium becomes increasingly
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depolarized, to approximately 45 mV at parturition (Casteels &
Kuriyama, 1965; Parkington et al, 1999). The mechanism underpin-
ning this crucial, evolutionarily conserved process remains
unknown.
A number of potassium channels have been demonstrated to
play a role in shaping the myometrial action potential and modulat-
ing myometrial contractility (Brainard et al, 2007). The putative
roles for the different channels are diverse and depend on the physi-
ological environment. These roles range from voltage-dependent
modulation of the action potential waveform (Knock et al, 1999), to
modulating responses to intracellular calcium release through BKca
and SK3 (Khan et al, 1993; Pierce et al, 2008), intracellular ATP
concentration through KATP (Khan et al, 1998) and uterine stretch
through tandem pore channels (Tichenor et al, 2005).
Within the potassium channel super-family, inwardly rectifying
potassium channels represents good candidates for the regulation of
resting membrane potential. Kir7.1 is a member of the inwardly
rectifying potassium channel sub-family and is only 38% identical
to its closest relative, Kir4.2 (Doring et al, 1998; Krapivinsky et al,
1998; Partiseti et al, 1998). Kir7.1 is expressed in visceral tissues
and some neurones within the CNS (Krapivinsky et al, 1998;
Nakamura et al, 1999; Ookata et al, 2000; Shimura et al, 2001),
although little is known about its functional role. Studies in retinal
pigment epithelial cells indicate that the channel may play an inte-
gral role in setting resting membrane potential and modulating K+
recycling (Shimura et al, 2001). A rare genetic mutation in Kir7.1
causes autosomal-dominant snowflake vitreoretinal degeneration
characterized by congenital degeneration of ocular tissues including
the vitreous (Hejtmancik et al, 2008). Kir7.1 has also been linked to
developmental pathways. For example, the jaguar/obelix mutation
in zebra fish renders the Kir7.1 homologue non-functional. As a
result, melanophores fail to respond appropriately to external cues,
leading to melanosome aggregation and the phenotype of a broader
striping pattern (Iwashita et al, 2006). Kir7.1 may also be involved
in palate formation in mice. Kcnj13 was identified as one of 8 genes
whose mis-expression correlates with formation of cleft palate in
TGF3beta knockouts, though the precise role of the channel remains
to be described (Ozturk et al, 2013).
In this study, we demonstrate the crucial importance of Kir7.1
in modulating uterine contractility in mice and humans. We show
that the physiological function of Kir7.1 is to maintain a hyperpo-
larized membrane potential during uterine quiescence and that
removal of this hyperpolarizing drive renders the uterus more
excitable. Furthermore, we show that Kir7.1 also modulates the
action potential waveform, modifying the excitation-contraction
cycle by participating in key stages of repolarization. Pharmaco-
logical manipulation of this normal physiological process could be
an alternative strategy to treat an atonic uterus and obstetric
haemorrhage.
Results
The aim of our study was to identify a potassium channel with the
appropriate biophysical attributes to regulate the myometrial resting
membrane potential during gestation. To identify candidates, we
undertook a genome-wide qRT-PCR screen of all known K+
channels and associated subunits in cDNA pools generated from
laser-capture micro-dissected MSM and whole myometrial tissue. Of
seven transcripts enriched in MSM (Supplementary Table S1), only
KCNJ13 coded for a K+ channel (Kir7.1) with appropriate biophysi-
cal attributes. Kcnj13 transcript levels increased markedly in the
pregnant mouse uterus during mid-gestation, peaking on gestational
day (GD) 15, and followed by a sharp decline towards term (C57BL/
6J mice deliver in the morning of GD19; Fig 1A). KCNJ13 transcript
levels (Fig 1B) were also significantly lower (P < 0.05) in samples
taken from pregnant women in labour at term than in samples from
women not in labour. Immunoblot of myometrial lysates from both
labour and non-labour samples demonstrated a single immuno-
reactive band at ~42 kDa. As positive and negative controls, we also
tested human eye and adipose cell lysate, respectively (Fig 1C and
Supplementary Fig S1). Furthermore, Kir7.1 immuno-reactivity was
expressed in MSMs and was absent in the vasculature in both
human and mouse myometrial samples (Fig 1D), supporting the
specificity of the laser-capture screen.
To determine the functional significance of this K+ channel in
the uterus, we first investigated its electrophysiological properties in
freshly dissociated mouse MSMs. Under voltage-clamp conditions,
an inwardly rectifying potassium current (Fig 2A,B) was inhibited
by VU590, a known Kir7.1 inhibitor (Lewis et al, 2009). Consistent
with the finding that Kir7.1 expression was higher at GD15 than
GD18, the VU590 sensitive current density at -150 mV was signifi-
cantly greater (P < 0.05) on GD15 when compared to GD18
(Fig 2C).
To understand the function of Kir7.1 in the generation of the
myometrial action potential, we modelled the potential impact of
changes in Kir7.1 channel density on myometrial electrogenesis
using a Hodgkin-Huxley type current summing model. In free-
running simulations of membrane potential, increasing Kir7.1 chan-
nel density (within the range measured in our experimental data)
hyperpolarized resting membrane potential and decreased calcium
entry during the action potential (Fig 3). Furthermore, simulations
predicted that overall membrane conductance during the excited
phase of the action potential is so finely balanced that small changes
in Kir7.1 current density exerted large effects on membrane poten-
tial. Given its expression profile and biophysical properties, we
hypothesized that Kir7.1 is a key regulator of myometrial membrane
potential during gestation.
To assess the role of Kir7.1 in regulating uterine contractility
experimentally, we used lentiviral vectors expressing miRNA target-
ing Kcnj13 or the human Kir7.1 channel to inhibit and over-express
the channel in murine MSM, both in vitro and in vivo. Knockdown
of Kir7.1, in vitro, significantly increased the contractile activity inte-
gral (2.5-fold) (area under the time-force curve), duration (2.2-fold)
and maximum force (1.3-fold) of phasic contractions when
compared to scrambled miRNA control (Fig 4 and Supplementary
Fig S2). Conversely, over-expression of Kir7.1 significantly
decreased all three parameters. To determine whether these altera-
tions in contractility were due to electrogenic effects, we used sharp
microelectrodes to measure membrane potentials in the treated
myometrial strips. Knockdown of Kir7.1 depolarized resting
membrane potential with extended excited periods (Fig 5A,B),
whereas over-expression of Kir7.1 hyperpolarized resting membrane
potential and suppressed excitability (Fig 5C). Mean resting
membrane potentials differed significantly between the two
treatment groups (Fig 5D).
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Figure 1. Kir7.1 is expressed in uterine myocytes and is regulated in pregnancy in mice and humans.
A mRNA expression of Kcnj13 in mice (n = 5; mean  SD, per GD) normalized to GD13. *P < 0.05, Student’s t-test.
B mRNA expression of KCNJ13 (plotted as arbitrary units relative to 18s rRNA) in human myometrial samples from women at term not in labour (NIL) and at term in
labour (LAB) (n = 8; mean  SD, per group). *P < 0.05, Student’s t-test.
C Immunoblot of pooled lysates from eye, adipose tissue, NIL and LAB myometrium (n = 4) probed with antibody to human Kir7.1 (full blot available in Supplementary
Fig S1).
D Immunohistochemistry for Kir7.1 in human NIL myometrium (left panel), GD13 murine myometrium (centre panel) and GD15 murine myometrium (right panel).
Arrow indicates absence of staining in blood vessel. Inset panels show tissue treated with pre-absorbed primary antibody control counterstained with haematoxylin.
Scale bar = 100 lm.
A B C
Figure 2. Kir7.1 current in uterine myocytes decreases from mid-pregnancy to term.
A Measurement of inwardly rectifying, VU590-sensitive current in freshly dissociated GD15 murine myometrial cells. Shown are voltage-clamp recordings in the
presence and absence of 10 lM VU590.
B Current-voltage relation (n = 5; mean  SD, per data point) of current density [VU590 subtracted from control (vehicle alone)].
C Current density (pA/pF) at 150 mV and 500 ms in freshly dissociated murine myometrial cells from GD15 and GD18 (n = 5 mean  SD, per GD). *P < 0.05, Student’s
t-test.
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Ion channel function in vivo may differ to that observed
in vitro, because of either effects of the sample preparation, or
influence of in vivo factors not captured in vitro. To account for
these potential experimental confounders and to assess the pheno-
type of targeting Kir7.1 during pregnancy, we injected mice uteri
on GD9 with anti-Kir7.1 miRNA or scrambled miRNA control. To
record uterine activity, we surgically implanted a pressure
catheter with remote telemeter into the injected horn of both
knockdown and control mice. Intra-uterine pressure was recorded
continuously, and the animals were monitored by video. Mice in
which Kir7.1 was knocked down had significantly increased intra-
uterine pressure when compared to control mice (Fig 6 and
Supplementary Fig S3). Consistent with our findings that Kir7.1
expression and channel activity were higher at GD15 than GD18,
the effect on intrauterine pressure was more pronounced in mid-
gestation.
Figure 3. A free-running simulation of the effect on the myometrial action potential waveform of increasing densities of Kir7.1.
Time-dependent effect of increasing Kir7.1 channel densities on Vm (mV, left) and [Ca]i (nM, right). Increasing density of Kir7.1 within experimentally determined values
hyperpolarizes resting membrane potential, whereas decreasing membrane excitability during depolarizing excursions in Vm leading to decreased calcium entry.
A B C
D E F
Figure 4. Knockdown of Kir7.1 in vitro increases myometrial activity and promotes tonic contractions.
A–C Representative time-force recordings of phasic contractions demonstrating (A) the effect of scrambled miRNA compared to (B) knockdown (Anti-Kir7.1) and (C)
overexpression (+Kir7.1) of Kir7.1 on contractility in murine GD15 myometrial strips.
D–F Mean data are summarized (n = 8; mean  SD, per group of experiments) as activity integral (area under the time-force curve) (D), contraction duration (E) and
maximum force (F). *P < 0.05, compared to scrambled control by ANOVA with Tukey’s post hoc test.
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The increased contractility associated with Kir7.1 knockdown
raised the possibility that pharmacological targeting of this ion
channel could be of clinical value, for example in the management
of severe post-partum haemorrhage. To assess this possibility,
we first performed current clamp microelectrode recordings of
spontaneous action potentials in isolated murine myometrial strips.
We observed slow, inter-contraction, depolarization of resting
membrane potential followed by transient complex action poten-
tials (Fig 7). Administration of 10 lM VU590 rapidly depolarized
resting membrane potential to threshold (Fig 7Ai), followed by a
sustained plateau potential that was reversible on wash out
(Fig 7Aii and Aiii). In myometrial strips from women, application
of VU590 increased the activity integral, largely due to an increase
in contraction duration (Fig 7B), with contractions lasting several
hours observed.
To assess the potential therapeutic benefit of inhibiting Kir7.1,
we compared the effect of VU590 with oxytocin, the established
front-line treatment for post-partum haemorrhage. The effect of
VU590 on contractile force in samples taken from GD15 and
GD18 mice was dependent on dose and gestation (Fig 8A) and
when used in combination with oxytocin, increased activity inte-
gral by 172  14 fold and 90  42 fold on GD15 and GD18,
respectively, as compared to 4  2 fold and 8  3 fold for OXT
treatment alone (Fig 8B). The effect of VU590 was similar in
human term myometrium, which was also dose-dependent, with
the observed increase in activity integral, largely due to an
increase in contraction duration (Fig 8C,D). Importantly, sufficient
channels remain at term to generate a significant phenotypic
effect, underscoring the potential post-partum benefit of pharma-
cological intervention.
A B
C D
Figure 5. Knockdown of Kir7.1 in vitro depolarizes resting membrane potential.
A–C Representative membrane potential recordings in current clamp configuration from murine myometrial strips (A) treated with scrambled control miRNA (B) treated
with Kir7.1 knockdown (Anti-Kir7.1) and (C) overexpressing Kir7.1 (+Kir7.1).
D Resting membrane potential in current clamp configuration from murine myometrial strips (n = 6; mean  SD) from experiments depicted in (5A–C). *P < 0.05 by
Student’s t-test.
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To expand the pharmacological tools for Kir7.1 inhibition, we
used population patch-clamp technology to screen a library of
known ion channel inhibitors in a Chinese Hamster Ovary cell line
expressing Kir7.1 (Supplementary Fig S4 and Supplementary Meth-
ods). We identified compounds with different structures than
VU590 to assess whether the phenotype of Kir7.1 inhibition was
similar (Fig 9A). We also manufactured a control compound 1,3-Bis
(5-nitro-1H-benzo[d]imidazol-2-yl)propane (BNBI), which is known
to inhibit the structurally related Kir1.1 (Renal outer medulla potas-
sium channel) but does not inhibit Kir7.1 (Bhave et al, 2011).
Administration of 100 lM BNBI had no detectable effect on uterine
contractility in the GD15 mouse (Fig 9B), suggesting that loss of effi-
cacy for Kir7.1 inhibition is associated with loss of pro-contractile
activity. Finally, administration of 10 lM MRT2000769, a potent
Kir7.1 inhibitor that is structurally unrelated to VU590, induced
long-lasting contractions similar to those observed with VU590
(Fig 9C). The effectiveness of MRT2000769 further supported the
correlation between effective Kir7.1 inhibition and the phenotype of
long-lasting contractions (Supplementary Fig S5).
Discussion
Inwardly rectifying potassium channels are known to regulate
diverse but important physiological processes such as insulin secre-
tion in the pancreas, regulation of the cardiac action potential, para-
sympathetic stimulation and potassium reuptake in the kidney
(Hibino et al, 2010). In most cases, the channels act to hyperpolar-
ize resting membrane potential by remaining persistently open,
allowing the efflux of potassium. In excitable tissues, this dampens
electrical activity, while in epithelial cells, the potassium gradient
created in combination with energy-dependent ion pumps is used to
transport other ions. In secretory cells, inhibition of the current
causes depolarization and calcium entry leading to a secretion event
(Liu et al, 2001; Ashcroft, 2005; Hebert et al, 2005). The important
physiological roles of Kir channels are underscored by the many
diseases that are associated with Kir channel malfunction, such as
Bartter’s syndrome, Anderson syndrome, short Q-T syndrome and
neonatal diabetes (Derst et al, 1997; Andelfinger et al, 2002; Edghill
et al, 2004; Priori et al, 2005; Ellard et al, 2007).
Here we present the novel finding that Kir7.1 is a crucial regula-
tor of membrane potential in uterine myocytes during pregnancy in
both mice and humans. In mid-gestation, high expression of Kir7.1
keeps the resting membrane potential close to the reversal potential
for potassium, increasing the depolarizing drive required to initiate
an action potential, calcium entry and subsequent contraction. At
term, this damping of excitability is lost by reduction, but not
complete loss, of Kir7.1. Our results also indicate that inhibition of
Kir7.1 when combined with oxytocin administration is synergistic, a
mechanism that may be related to the sensitivity of Kir7.1 to intra-
cellular phosphatidylinositol 4,5-bisphosphate depletion (Pattnaik &
Hughes, 2009). Such a mechanism, when acting in conjunction with
a decreased gap junction density and decreased receptors to stimula-
tory ligands, could provide a robust means of maintaining uterine
quiescence during gestation (Garfield et al, 1977; Fuchs et al, 1982;
Smith, 2007).
Within the Kir superfamily, Kir7.1 displays several unique prop-
erties such as low sensitivity to Ba2+ and Cs+, low single channel
conductance, no internal block by Mg2+ ions, and a relative insensi-
tivity to external K+ concentration, tetraethylammonium
(IC50 > 10 mM) or 4-aminopyridine (IC50 ~10 mM) (Krapivinsky
et al, 1998). In in vitro expression systems, Kir7.1 exhibits rapid
Figure 6. Knockdown of Kir7.1 in vivo significantly increases intrauterine pressure.
Mice in which Kir7.1 was knocked down (Anti-Kir7.1) had significantly increased intrauterine pressure when compared to mice injected with scrambled miRNA lentivirus
(scrambled) from GD13 to GD18 (Fig 6 and Supplementary Fig S3). (n = 6 per time point). *P < 0.05; see methods for statistical model.
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activation kinetics and is essentially non-inactivating at potentials
negative to 40 mV with a small single channel conductance in both
recombinant and native cells (Doring et al, 1998; Krapivinsky et al,
1998; Shimura et al, 2001). Since the channel has a low conduc-
tance and little voltage or time dependence in physiological ranges,
high expression of this channel gives rise to a stable and hyperpolar-
ized resting membrane potential. Thus, the biophysics of Kir7.1 is
ideally suited to regulating myometrial smooth muscle cells during
mid-gestation quiescence.
Transgenic mouse models have demonstrated the critical nature
of control of myometrial membrane potential during parturition. For
example, mice overexpressing the small conductance potassium
channel SK3 suffer acute uterine dystocia, and both mother and
pups die during delivery (Bond et al, 2000). Similarly, mice
harbouring a smooth muscle specific deletion of the important uter-
ine gap junction protein connexin43 demonstrate a significant delay
in delivery and increased mortality of pups (Doring et al, 2006).
These data, in conjunction with our in vivo observations demon-
strating a significant increase in intrauterine pressure in the absence
of endocrine changes, underline the importance of the development
of uterine excitability during gestation to the overall delivery
process. It is notable that the decrease in Kir7.1 expression precedes
progesterone withdrawal in the mouse suggesting that modulation
of excitability is, at least in part, independent of progesterone. These
biophysical factors act in addition to, and in concert with, other
endocrine/paracrine changes that alter uterine stimulants (Cha et al,
2013) and lead to uterine disorders such as preterm labour or
dysfunctional labour. The overall role of membrane potential in the
control of parturition in the context of other controlling factors is
summarized in Fig 10.
In addition to a clear effect on resting membrane potential, our
computer modelling predicted that increasing Kir7.1 activity
A
B
i
i
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i
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Figure 7. Pharmacological inhibition of Kir7.1 in vitro in human and murine myometrium induces membrane depolarization and long-lasting contractions.
A Representative membrane potential recording in current clamp configuration from a murine GD15 myometrial strip. (i) Addition of 10 lM VU590 depolarizes resting
membrane potential (note slope change from resting potentials of preceding phasic bursts) and leads to a sustained plateau potential. (ii) Upon washout, spike
potentials recover as plateau potential hyperpolarizes. (iii) On complete washout, phasic bursting resumes.
B Addition of 1 nM oxytocin and 10 lM VU590 to human myometrial strips stimulates long-lasting contractions. (i) Initial component of the response is phasic,
followed by establishment of a tonic contraction.
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modulates calcium entry during the plateau phase of the complex
action potential, resulting in a decrease in contractile force and inef-
ficient contractions. Decreasing Kir7.1 has the effect of stressing the
repolarizing drive such that increased contributions from other K+
channels are required to ensure action potential repolarization
(Supplementary Fig S6) (Fink et al, 2006; Greenwood et al, 2009;
McCallum et al, 2011). These effects explain the longer action
potentials observed during pharmacological inhibition and experi-
mentally induced reduction in the expression of Kir7.1 protein.
When Kir7.1 current density is reduced to very low levels, the
myometrial smooth muscle effectively loses phasic behaviour and
manifests a new tonic-like tone. The greatly increased contraction
length induced by Kir7.1 inhibition may be useful for reducing
blood loss in an atonic uterus. As a treatment for post-partum haem-
orrhage, Kir7.1 block would have the advantage of being more
potent than current first line treatments. The mechanism of action
also circumvents the agonist pathways (Fig 10) targeted by current
treatments that are prone to desensitization during failed labour
inductions.
Materials and Methods
Ethical approval
All procedures involving women were conducted within the guide-
lines of The Declaration of Helsinki and were subject to local ethical
approval (REC-05/Q2802/107). Prior to surgery, informed written
consent for sample collection was obtained.
All animal procedures complied with the guidelines for the
care and use of animals set forth by the National Institutes of
Health. The Animal Studies Committee at Washington University
in St. Louis approved all protocols (protocol number 20110138 to
Sarah K. England). Adult C57BL/6J (Jackson Laboratory) female
mice were mated at 8 weeks of age until 6 months of age. Mice
were mated for 2-h time periods, and the presence of a copula-
tory plug was marked 0 days postcoitum (dpc). Animals were
housed in Washington University School of Medicine vivarium in
the BJCIH building, which is an AAALAC (Association for Assess-
ment and Accreditation of Laboratory Animal Care International)
A B
C D
Figure 8. Pharmacological inhibition of Kir7.1 in vitro in human and murine myometrium stimulates longer-lasting contractions than oxytocin.
A Dose- and gestation-dependent effect of VU590 on murine myometrial contractility [n = 5, activity integral expressed as a fold-change of pre-treatment contractions
(mean  SD, per GD)]. *P < 0.05 GD18 vs GD15 per dose by ANOVA with Tukey’s post hoc test.
B As in (A) but comparing the effect of 1 nM oxytocin with 1 nM oxytocin + 10 lM VU590. *P < 0.05 OT vs OT = VU590 per GD by Student’s t-test.
C Dose-dependent effect of VU590 (Black Bars) and VU590 + 1 nM oxytocin (grey bars) on human myometrial contractility (n = 8; activity integral expressed as
fold-change over pre-treatment contractions, mean  SD). *P < 0.05 compared to control by ANOVA with Tukey’s post hoc test.
D Dose-dependent effect of VU590 on contraction duration in human myometrial strips taken at term (n = 8, mean  SD). *P < 0.05 compared to control by ANOVA
with Tukey’s post hoc test.
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approved animal care facility. For in vivo intrauterine pressure
measurements, eight pregnant mice were injected with scrambled
miRNA and eight pregnant mice were injected with Kir7.1
miRNA.
Subject criteria and selection
Subjects were recruited into two groups, spontaneous labour (LAB)
and elective caesarean section not in labour (NIL) between 38 and
40 weeks gestation. The LAB group was undergoing caesarean
section for reasons of undiagnosed breech. LAB was defined as
regular contractions (< 3 min apart), membrane rupture and cervi-
cal dilatation (> 2 cm) with no augmentation.
Sample collection
At caesarean section, samples were collected before syntocin admin-
istration by knife biopsy from the lower uterine segment incision.
Samples were washed briefly in saline and flash-frozen in liquid
nitrogen for mRNA, immunoblot or immunohistochemistry
analyses. Samples for cell isolation or contractility experiments were
placed in ice-cold modified Krebs–Henseleit (m-KHS) solution and
used the same day.
Laser capture screen
mRNA was extracted from 100 mg of frozen human myometrium
using Trizol reagent (Invitrogen), and further column purified by
RNeasy kit (Qiagen) according to the manufacturer’s instructions.
Total RNA was quantified by spectrophotometer and further tested
for quality and purity by bioanalyser (Agilent Technologies) accord-
ing to the manufacturer’s instructions. cDNA was generated from
100 ng of mRNA using Superscript III (Invitrogen) according to the
manufacturer’s instructions and stored at 80°C until qRT-PCR
analysis.
Laser Capture Microdissection (LCM): All slides, LCM caps,
Haematoxylin and Eosin (H&E) Staining Kit for LCM and solutions
were obtained from Molecular Machines & Industries. Briefly,
cryomold-mounted myometrial samples were transferred from
70°C and equilibrated in a pre-cooled cryostat (30°C) for
10 min. Sections (8 lM) were cut and H&E stained according to
A
B C
Figure 9. Stimulation of uterine contractions correlates with Kir7.1 inhibitory potency.
A The structures of the three compounds tested in this study. BNBI, a potent Kir1.1 inhibitor does not inhibit Kir7.1. MRT2000769 is structurally unrelated to VU590
and was identified as inhibiting Kir7.1 in a high throughput electrophysiology screen. VU590 is the first described inhibitor of Kir7.1.
B, C Effects of BNBI (B) and MRT2000769 (C) on murine GD15 myometrial contractility.
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the manufacturer’s instructions. Slides were dehydrated in graded
alcohols and xylene and placed in a desiccator until laser capture.
At least 50,000 lm2 of human uterine myocytes was captured for
each gene. mRNA was extracted from each isolation by using the
Picopure RNA isolation kit (Arcturus) according to the manufac-
turer’s instructions. Reverse transcription was as previously
described. PCR primer design and qRT-PCR are described in the
Supplementary Methods.
Immunohistochemistry
Frozen sections (8 lM) were fixed in ice-cold acetone for 5 min
prior to incubation in phosphate-buffered saline (PBS). Endogenous
peroxidase activity was blocked by immersing the slides for 30 min
in freshly prepared 0.3% hydrogen peroxide in PBS. Slides were
pre-incubated in 1.5% non-immune goat serum in PBS for 30 min at
room temperature and then in primary anti-Kir7.1 antibody (1:100;
Alomone) overnight at 4°C in a humidified chamber. Primary
Figure 10. Model of the role of Kir7.1 in maintenance of uterine quiescence.
In normal labour in the human myometrium, changes take place over a number of weeks that increase both the intrinsic electrical excitability of the cell (blue box) and, by
altering cellular receptors and contractile machinery, the susceptibility to stimulation. Alterations in stimulation either by infection or gene-environment interaction can
precipitate preterm labour (Cha et al, 2013); however, changes in control of the myometrial membrane potential or interference with functional gap junctions can affect
labour even under normal endocrine conditions (Bond et al, 2000; Doring et al, 2006). In this study, we demonstrate that alteration of the function of a single potassium
channel profoundly alters uterine contractility. Loss of Kir7.1 function depolarizes the plasmamembrane and promotes voltage-gated calcium entry. In addition, the duration
of the depolarization is extended, preventing the normal phasic contractions. In this way, the process of excitation-contraction coupling in uterine myocytes overrides
pharmaco-contraction coupling. This effect could be used for therapeutic benefit. (Key: CPI-17 = C-kinase potentiated protein phosphatase-1 inhibitor. CX26 = Connexin 26.
CX43 = Connexin 43. CX45 = Connexin 45. GEFs = Guanine nucleotide exchange factors. GPCR = G-protein coupled receptors. IP3 = inositol 1,4,5-trisphosphate.
IP3R = inositol 1,4,5-trisphosphate receptor. MLC = Myosin light chain. MLCp = Phosphorylated myosin light chain. PIP2 = Phosphatidylinositol 4,5-bisphosphate. PLC
b = Phospholipase C. RHOgtp = Ras homologue gene family, member A. RHO-K = Rho-associated, coiled-coil containing protein kinase 1.)
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antibody pre-absorbed for 24 h with recombinant antigen served as
negative control. Staining was visualized using the Vectastain Elite
ABC rabbit IgG kit (Vector Laboratories) according to the manufac-
turer’s instructions.
Immunoblot
After tissue was suspended in RIPA lysis buffer containing protease
inhibitor cocktail tablets, mechanically homogenized and cleared by
centrifugation, the supernatant was aliquoted and frozen. Whole
tissue and protein lysates from adult human eye, adult mouse
adipose and adult mouse brain were purchased from Novus Biologi-
cals (Cambridge, UK) at a stock concentration of 5 mg/ml. All
protein concentrations were confirmed with the BioRad assay (Bio-
Rad laboratories, Hemel Hempstead, UK). A total of 40 lg of
protein per sample (pooled from 4 biopsies each for NIL and LAB
samples) was subjected to SDS-PAGE according to standard proto-
cols. The membrane was blocked in 5% milk protein solution
(Marvel, Lincs, UK) for 1 h at room temperature, incubated with
primary rabbit polyclonal anti Kir7.1 antibody (1:200; Alomone
Labs, Jerusalem) overnight at 4°C in blocking buffer and then incu-
bated with polyclonal goat anti-rabbit HRP secondary antibody
(1:100; Dako, Ely, UK). ECL Plus (GE Healthcare LTD, Amersham
place, UK) was used to detect signal. To confirm equal loading, the
blot was treated with Restore western blot stripping buffer (Thermo
Fisher Scientific, Hemel Hempstead, UK) for 15 min at room
temperature, washed, blocked and re-probed with an antibody to
human b-actin.
Electrophysiology
Cell isolation
Strips of myometrium from the longitudinal layer (2 × 2 × 20 mm)
of time-mated C57BL/6J mice were isolated and washed in Ca2+
and Mg2+ free Hank’s balanced salt solution (HBSS) at 37°C for 10,
20 and 30 min, respectively, followed by 45 min incubations in
digestion solution (Roche Blendzyme 3) at 37°C according to the
manufacturer’s instructions. Digestion was terminated by several
dilutions with fresh HBSS. Cells were dispersed by slow trituration
through a wide-bore fire-polished glass pipette in HBSS. Single
myometrial cells were filtered through a 200-lM gauze and stored
in HBSS for use within six hours.
Voltage clamp
A drop of myometrial cell suspension was placed in a glass-
bottomed Petri dish and mounted on the stage of an inverted
microscope (IX51, Olympus). After settling (~ 10 min), cells were
perfused with bath solution at a rate of 1–2 ml/min at 37°C. Patch
pipettes were fabricated (Model P-87; Sutter Instruments, Novato,
CA, USA) from 1.5-mm glass capillaries and had a resistance of
2.0–4.0 MΩ when filled with pipette solution (containing in mM:
KCL 140; EGTA 1.1; CaCl2 0.06; Hepes 10; MgCl2 2; adjusted to
pH 7.2 at 25°C with 5 m NaOH). Liquid junction potential was
zeroed prior to seal formation. Transmembrane currents were
recorded with an amplifier (Axopatch 700b; Axon Instruments)
using the perforated patch configuration of the whole cell patch-
clamp technique (Rae et al, 1991). The antibiotic amphotericin B
(720 lg/ml) was used to perforate the cell membrane. Series resis-
tance was compensated after membrane perforation. Currents were
elicited by stepping to a range of potentials between 150 mV and
+80mV from a holding potential of 60 mV. To isolate currents
that were sensitive to inhibition by drug application, difference
currents were obtained by electronic subtraction of traces.
Currents were filtered at 10 kHz and sampled at 5 kHz. Voltage
protocols were delivered via a Digidata 1440a computer interface
using pCLAMP 9.0 software (Molecular Devices, Sunnyvale, CA,
USA).
Current clamp
Strips (5 × 10 mm) of murine myometrium from the longitudinal
layer were pinned out on a sylgard base and perfused with m-KHS
containing (in mM: NaCl, 133; KCl, 4.7; Tes, 10; glucose, 11.1;
MgSO4, 1.2; KH2 PO4, 1.2; CaCl2, 2.5; adjusted to pH 7.4 at 25°C
with NaOH) at 37°C on an upright microscope (MVX10, Olympus).
Tissue was incubated with 5 lM wortmannin (Sigma) to prevent
spontaneous contractions from dislodging impalements. Smooth
muscle cells were impaled with glass microelectrodes filled with
2 M KCl of resistance 80–120 MΩ. Transmembrane potentials were
recorded with an amplifier (Axopatch 700b; Axon Instruments)
and a Digidata 1440a computer interface running pCLAMP 9.0
software.
In vitro knockdown and contractility
Strips of GD15 or GD18 myometrium from the longitudinal layer
(2 × 2 × 20 mm) were washed in sterile Ca2+ and Mg2+ free HBSS
DMEM/F-12. Strips were placed (in triplicate) under 1.5× slack
length tension in media containing 2% dextran-coated charcoal-
treated foetal bovine serum with 0.5 mM 8-bromo-cAMP (Sigma),
106 M medroxyprogesterone acetate (Sigma) and pLenti6-cppt-
CMV-mCherry-mouse 543A miRNA (Anti-Kir7.1), pLenti6-cppt-
CMV-mCherry-neg miRNA (Scrambled), or pLenti6-cppt-CMV/TO-
humKir7.1-IRES-mCherry-opre (+Kir7.1). Construction of lentiviral
vectors is detailed in the Supplementary Methods.
On day five, strips were placed under 2mN tension in a four
channel flatbed organ bath (DMT) in m-KHS solution. Isometric
force was recorded on ADI Instruments LABCHART software. Activ-
ity integral was measured as the area under the time-force curve
(mN/s) over a 20-min period. Contraction duration was determined
as the mean duration (rise and fall to baseline) of contractions
within a 20-min period. Maximum force was determined as the peak
force measurement within a 20-min period. All measurements were
made over the same time period for all strips.
In vivo intrauterine pressure measurements
C57BL/6J time-mated mice were anesthetized on GD8 to GD10 by
intraperitoneal injection of ketamine (100 mg/kg) plus xylazine
(10 mg/kg, IP), and a PhysioTel PA-C10 transmitter (Data Sciences
International) was implanted in one horn of the pregnant uterus
between the uterine wall and foetal sacs. At this time, 3.7 × 105
particles/ml of pLenti6-cppt-CMV-mCherry-Neg miRNA (scrambled)
or pLenti6-cppt-CMV-mCherry-miRNA mouse Kir7.1 (Anti-Kir7.1)
were injected into the uterine muscle of the implanted horn. Five
days later, uterine pressures were continuously measured every
10 s at 500 Hz with Dataquest A.R.T. data acquisition system
version 4.31 (DSI) for 4–8 days.
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Data analysis and statistics for telemetry studies
Longitudinal changes in intrauterine pressure after infection with
pLenti6-cppt-CMV-mCherry-Neg miRNA (scrambled) or pLenti6-
cppt-CMV-mCherry-miRNA mouse Kir7.1 (Anti-Kir7.1) were analy-
sed by using a linear-mixed effect (LME) model implemented by
PROC MIXED in SAS 9.3. Before analysis, data were first temporally
aligned according to gestational days. The dependent (response)
variable was taken as the hourly average intrauterine pressure.
Fixed effects were treatment group (scrambled vs miRNA), gestation
day and their interaction. Random intercepts were also used to
incorporate mouse-specific effects. In addition, a first-order autore-
gressive correlation structure was used to account for the repeated
measurements over time, which implies that the temporal correla-
tion among repeated measures decays as a power function of the
time lag. Residuals from initial LME analysis displayed a skewed
distribution, and a square-root transformation of the response vari-
able was found to be effective to correct the non-normality in the
residuals. A few mice had negative hourly average pressures in
certain hours, and 58 such observations (around 3% of the entire
data set and split equally between the scrambled and miRNA group)
were excluded from the analysis.
Compound screening
Cell line generation, cell culture, and Kir7.1 automated electrophysi-
ology assay and data analysis are all described in the Supplementary
Methods. The MRCT ion channel focused compound file was
selected in collaboration with the Dundee Hit Finding Unit and
consisting of ~ 4,000 compounds. The set covered 119 bioactive
templates from nine categories of ion channel targets and molecular
weights of the screening compounds ranged between 150 and 450.
Computational simulations
Computational simulations are described in detail the Supplemen-
tary data.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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